{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "name": "Query_Basics.ipynb",
      "provenance": [],
      "authorship_tag": "ABX9TyNvY1nZfxHkbA1THFi9Dak4",
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/bcgsc/pori/blob/feature%2Fcolab-notebooks/docs/graphkb/scripting/Query_Basics.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "qiwjGCPxU27G"
      },
      "source": [
        "# Query Basics"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "oQqCn1YLU5TT"
      },
      "source": [
        "Documentation for the API can be seen via its OpenAPI specification at [`/api/spec`](https://pori-demo.bcgsc.ca/graphkb-api/api/spec). Here we will cover just the query endpoint which is the most commonly used endpoint as it is used for all searches. The `/query` endpoint accepts a JSON body in a POST request. This is how the user passes filters and other search-related parameters. We will defined a few of the important fields and concepts that are used below.\n",
        "\n",
        "All the running examples below use the python GraphKB adapter. This assumes the user has aready initialized the connector and logged in as shown below (using the demo database and credentials).\n",
        "\n",
        "First install the adapter"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "y-5SkyOEU72X",
        "outputId": "4a6b1985-d63d-45ac-8e39-74639b237609"
      },
      "source": [
        "!pip install graphkb"
      ],
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "text": [
            "Collecting graphkb\n",
            "  Downloading graphkb-1.5.4-py3-none-any.whl (33 kB)\n",
            "Requirement already satisfied: requests<3,>=2.22.0 in /usr/local/lib/python3.7/dist-packages (from graphkb) (2.23.0)\n",
            "Requirement already satisfied: typing-extensions<4,>=3.7.4.2 in /usr/local/lib/python3.7/dist-packages (from graphkb) (3.7.4.3)\n",
            "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3,>=2.22.0->graphkb) (1.24.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3,>=2.22.0->graphkb) (2021.5.30)\n",
            "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3,>=2.22.0->graphkb) (3.0.4)\n",
            "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3,>=2.22.0->graphkb) (2.10)\n",
            "Installing collected packages: graphkb\n",
            "Successfully installed graphkb-1.5.4\n"
          ],
          "name": "stdout"
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "XCh97olfU9h0"
      },
      "source": [
        "Then set up the connector "
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "GS0iBsyOVGZu"
      },
      "source": [
        "from graphkb import GraphKBConnection\n",
        "\n",
        "GKB_API_URL = 'https://pori-demo.bcgsc.ca/graphkb-api/api'\n",
        "GKB_USER = 'colab_demo'\n",
        "GKB_PASSWORD = 'colab_demo'\n",
        "\n",
        "graphkb_conn = GraphKBConnection(GKB_API_URL)\n",
        "\n",
        "graphkb_conn.login(GKB_USER, GKB_PASSWORD)"
      ],
      "execution_count": 2,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "wR2wT51dVOoo"
      },
      "source": [
        "## Important Fields and Concepts\n",
        "\n",
        "### Query Target\n",
        "\n",
        "The target is the class/table that the users wishes to query. If it is at the top level of the request body then it is also the type of record which will be returned. For example to get a list of all publications in GraphKB. We limit this to the first 10 publications for the purposes of this demo"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ILh3Gu6DVot7",
        "outputId": "af6dc12b-c9ce-47c4-c107-95a961b0f66f"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Publication'\n",
        "}, paginate=False, limit=10)"
      ],
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'@class': 'Publication',\n",
              "  '@rid': '#38:0',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612980878029,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25500544',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'the landscape and therapeutic relevance of cancer-associated transcript fusions.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25500544',\n",
              "  'updatedAt': 1612980878029,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25500544',\n",
              "  'uuid': '1294db97-ee26-4bd4-9b50-d122436905be',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981149054,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16081687',\n",
              "  'journalName': 'blood',\n",
              "  'name': 'the jak2v617f activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16081687',\n",
              "  'updatedAt': 1612981149054,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16081687',\n",
              "  'uuid': '52e0d70f-07f8-48b9-b59d-b0258d60b9ae',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981150038,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15146165',\n",
              "  'journalName': 'laboratory investigation; a journal of technical methods and pathology',\n",
              "  'name': 'a great majority of gists with pdgfra mutations represent gastric tumors of low or no malignant potential.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15146165',\n",
              "  'updatedAt': 1612981150038,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15146165',\n",
              "  'uuid': '9e600c55-3247-4e24-bcd8-4a20bb0fb794',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:3',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981150922,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22081665',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'do aml patients with dnmt3a exon 23 mutations benefit from idarubicin as compared to daunorubicin? a single center experience.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22081665',\n",
              "  'updatedAt': 1612981150922,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22081665',\n",
              "  'uuid': '6c8fb887-9dee-467c-997e-6c320dde874b',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:4',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981151489,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22490330',\n",
              "  'journalName': 'blood',\n",
              "  'name': 'mutant dnmt3a: a marker of poor prognosis in acute myeloid leukemia.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22490330',\n",
              "  'updatedAt': 1612981151489,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22490330',\n",
              "  'uuid': '837d374c-b6c5-4a4e-a078-0d8733eeea09',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:5',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981152037,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19287384',\n",
              "  'journalName': 'nature genetics',\n",
              "  'name': 'a germline jak2 snp is associated with predisposition to the development of jak2(v617f)-positive myeloproliferative neoplasms.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19287384',\n",
              "  'updatedAt': 1612981152037,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19287384',\n",
              "  'uuid': '4b7541fa-0544-4c5b-af7e-b8c1babe88a7',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:6',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981152898,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24571676',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'ras mutations in early age leukaemia modulated by nqo1 rs1800566 (c609t) are associated with second-hand smoking exposures.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24571676',\n",
              "  'updatedAt': 1612981152898,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24571676',\n",
              "  'uuid': 'f1655881-97c5-4f48-851e-0b564c433a28',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:7',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981153755,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23861977',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'nras and braf mutations in melanoma-associated nevi and uninvolved nevi.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23861977',\n",
              "  'updatedAt': 1612981153755,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23861977',\n",
              "  'uuid': 'c483b540-2f87-4071-925c-354caeb5fef1',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:8',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981154659,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19915144',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'mek1 mutations confer resistance to mek and b-raf inhibition.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19915144',\n",
              "  'updatedAt': 1612981154659,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19915144',\n",
              "  'uuid': 'ed5a9c65-6b1f-4593-85be-2624a73dc8b0',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:9',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981155387,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23569304',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23569304',\n",
              "  'updatedAt': 1612981155387,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23569304',\n",
              "  'uuid': '1762a178-6206-4043-a65c-c547a825e585',\n",
              "  'year': 2013}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 4
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "BqQcpn4YXAM_"
      },
      "source": [
        "### Filters\n",
        "\n",
        "Any field that is accessible with the current users permissions level can be queried via this endpoint. Most commonly users want to filter on this like a records name or source ID (ID in the external database it was imported from). Continuing our example from above let's search for publications with the word \"cancer\"  in them.\n",
        "\n",
        "**Note**: The current full text index only searches on word and word prefixes. Future iterations will support a full lucene index."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "MpWbHi5QXU3b",
        "outputId": "55e58833-08a9-4379-a87d-930813fd88c5"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Publication',\n",
        "    'filters': {'name': 'cancer', 'operator': 'CONTAINSTEXT'}\n",
        "})"
      ],
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'@class': 'Publication',\n",
              "  '@rid': '#38:0',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612980878029,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25500544',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'the landscape and therapeutic relevance of cancer-associated transcript fusions.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25500544',\n",
              "  'updatedAt': 1612980878029,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25500544',\n",
              "  'uuid': '1294db97-ee26-4bd4-9b50-d122436905be',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:19',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981162739,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24666267',\n",
              "  'journalName': 'acta oncologica (stockholm, sweden)',\n",
              "  'name': 'the predictive value of kras, nras, braf, pik3ca and pten for anti-egfr treatment in metastatic colorectal cancer: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24666267',\n",
              "  'updatedAt': 1612981162739,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24666267',\n",
              "  'uuid': '06981f31-59d0-439e-b5cd-71f503f9c50e',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:22',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981164833,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21030459',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'the neuroblastoma-associated f1174l alk mutation causes resistance to an alk kinase inhibitor in alk-translocated cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21030459',\n",
              "  'updatedAt': 1612981164833,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21030459',\n",
              "  'uuid': '4f088978-1736-4e3e-83fb-6d2c70e88873',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:25',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981166942,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20619739',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'effects of kras, braf, nras, and pik3ca mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20619739',\n",
              "  'updatedAt': 1612981166942,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20619739',\n",
              "  'uuid': '6345dc8f-a6b3-4241-87c6-4fb37409b402',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:36',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981175007,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18073307',\n",
              "  'journalName': 'the journal of clinical endocrinology and metabolism',\n",
              "  'name': 'prognostic significance of somatic ret oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18073307',\n",
              "  'updatedAt': 1612981175007,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18073307',\n",
              "  'uuid': '82456543-4b7c-412c-b151-b323146165ce',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:37',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981175518,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21422803',\n",
              "  'journalName': 'journal of endocrinological investigation',\n",
              "  'name': 'anti-tumor activity of motesanib in a medullary thyroid cancer model.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21422803',\n",
              "  'updatedAt': 1612981175518,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21422803',\n",
              "  'uuid': 'bcd12a07-967f-471b-9c32-852af8e6b29d',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:38',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981176064,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23056499',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'azd1480 blocks growth and tumorigenesis of ret- activated thyroid cancer cell lines.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23056499',\n",
              "  'updatedAt': 1612981176064,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23056499',\n",
              "  'uuid': 'eb10c823-5433-4212-9a48-20cc23bbb352',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:40',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981177589,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21594703',\n",
              "  'journalName': 'annals of surgical oncology',\n",
              "  'name': 'both braf v600e mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21594703',\n",
              "  'updatedAt': 1612981177589,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21594703',\n",
              "  'uuid': 'a556bb4e-8479-4e0d-8826-1a31ab2826da',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:41',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981178109,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24570209',\n",
              "  'journalName': 'hormone and metabolic research = hormon- und stoffwechselforschung = hormones et metabolisme',\n",
              "  'name': 'immunohistochemistry for braf(v600e) antibody ve1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24570209',\n",
              "  'updatedAt': 1612981178109,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24570209',\n",
              "  'uuid': '6749cac6-a325-4f26-a86b-06cd0a0c9c08',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:42',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981178679,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23325582',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase iii study of metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23325582',\n",
              "  'updatedAt': 1612981178679,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23325582',\n",
              "  'uuid': '8e26adff-eff5-4c68-9d63-9c626ab73bce',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:43',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981179299,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19001320',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'wild-type braf is required for response to panitumumab or cetuximab in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19001320',\n",
              "  'updatedAt': 1612981179299,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19001320',\n",
              "  'uuid': '714a1332-a0ea-4c4f-86a7-028a518a0c1c',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:45',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981180103,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23524406',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'molecular characterization of acquired resistance to the braf inhibitor dabrafenib in a patient with braf-mutant non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23524406',\n",
              "  'updatedAt': 1612981180103,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23524406',\n",
              "  'uuid': '92269f30-42a6-421c-aee4-87efaa8db031',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:46',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981180725,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21098728',\n",
              "  'journalName': 'science signaling',\n",
              "  'name': 'braf gene amplification can promote acquired resistance to mek inhibitors in cancer cells harboring the braf v600e mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21098728',\n",
              "  'updatedAt': 1612981180725,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21098728',\n",
              "  'uuid': '04df00f9-c607-4a4c-a5e1-a34dcb2b0d41',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:50',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981182953,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22180495',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'antitumor activity of braf inhibitor vemurafenib in preclinical models of braf-mutant colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22180495',\n",
              "  'updatedAt': 1612981182953,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22180495',\n",
              "  'uuid': '39b2de94-9dbf-4819-b5b8-e0efeb698fe9',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:51',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981183393,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24594804',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'brafv600e mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24594804',\n",
              "  'updatedAt': 1612981183393,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24594804',\n",
              "  'uuid': '4bb232fd-d4f9-4ad9-8f17-70c64865f2f7',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:62',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981189624,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18202412',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'kras mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18202412',\n",
              "  'updatedAt': 1612981189624,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18202412',\n",
              "  'uuid': '74b42cac-3bbe-40c8-b09c-d2a87767712b',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:63',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981190144,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20978259',\n",
              "  'journalName': 'jama',\n",
              "  'name': 'association of kras p.g13d mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20978259',\n",
              "  'updatedAt': 1612981190144,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20978259',\n",
              "  'uuid': '39db9b04-151d-4907-807e-cf17ab9f69ec',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:68',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981196440,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19966866',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'tsc1 loss synergizes with kras activation in lung cancer development in the mouse and confers rapamycin sensitivity.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19966866',\n",
              "  'updatedAt': 1612981196440,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19966866',\n",
              "  'uuid': 'a826fbea-f835-44e0-8704-7cad209b7b94',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:77',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981201438,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20026798',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'favorable prognostic impact of npm1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microrna-expression signatures: a cancer and leukemia group b study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20026798',\n",
              "  'updatedAt': 1612981201438,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20026798',\n",
              "  'uuid': '7dd1c4f3-fdb8-4a8b-88d8-a2acf24324e4',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:85',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981205502,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18559874',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': \"wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group b study.\",\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18559874',\n",
              "  'updatedAt': 1612981205502,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18559874',\n",
              "  'uuid': '880caa85-11fc-4082-90e5-73f2771c7299',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:86',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981206633,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23346317',\n",
              "  'journalName': 'journal of gynecologic oncology',\n",
              "  'name': 'advanced ovarian cancer: what should be the standard of care?',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23346317',\n",
              "  'updatedAt': 1612981206633,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23346317',\n",
              "  'uuid': '1399961d-cf6e-4a32-af06-58d3d951df89',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:89',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981210456,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15961768',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'cyclin d1 in breast cancer pathogenesis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15961768',\n",
              "  'updatedAt': 1612981210457,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15961768',\n",
              "  'uuid': '435bd53f-0ad0-4811-9399-eb4fd991bf68',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:94',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981213142,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23014527',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'molecular epidemiology of egfr and kras mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related kras-mutant cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23014527',\n",
              "  'updatedAt': 1612981213142,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23014527',\n",
              "  'uuid': '004f3896-7dee-4fd0-8a7b-59db60519c93',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:95',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981214053,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24736073',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24736073',\n",
              "  'updatedAt': 1612981214053,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24736073',\n",
              "  'uuid': 'cf6b40e2-a158-44e5-ada2-587befbb555c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:98',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981215655,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20979473',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'eml4-alk mutations in lung cancer that confer resistance to alk inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20979473',\n",
              "  'updatedAt': 1612981215655,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20979473',\n",
              "  'uuid': '9093f0a6-1aa1-4382-a0e7-6499f233fdd6',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:100',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981216514,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15728811',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'egfr mutation and resistance of non-small-cell lung cancer to gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15728811',\n",
              "  'updatedAt': 1612981216514,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15728811',\n",
              "  'uuid': 'd6eccc87-6667-478d-8c6e-285787335c57',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:101',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981217028,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21430269',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'genotypic and histological evolution of lung cancers acquiring resistance to egfr inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21430269',\n",
              "  'updatedAt': 1612981217028,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21430269',\n",
              "  'uuid': 'b0fa6ba4-7831-4c7c-a244-65edc569c10b',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:102',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981217893,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23220880',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'activating her2 mutations in her2 gene amplification negative breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23220880',\n",
              "  'updatedAt': 1612981217893,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23220880',\n",
              "  'uuid': '35f31b17-b451-425f-a1ac-c35af6d94b0a',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:103',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981218958,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24185512',\n",
              "  'journalName': 'nature genetics',\n",
              "  'name': 'esr1 ligand-binding domain mutations in hormone-resistant breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24185512',\n",
              "  'updatedAt': 1612981218958,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24185512',\n",
              "  'uuid': '28e0c25c-b731-4135-ad0d-353573a31201',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:106',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981221242,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16618717',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'kras mutation status is predictive of response to cetuximab therapy in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16618717',\n",
              "  'updatedAt': 1612981221242,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16618717',\n",
              "  'uuid': '41e9898b-9432-4589-8325-e45dbb7f6d27',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:107',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981221674,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19794967',\n",
              "  'journalName': 'neoplasia (new york, n.y.)',\n",
              "  'name': 'clinical implications of kras mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19794967',\n",
              "  'updatedAt': 1612981221674,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19794967',\n",
              "  'uuid': '01a0ff56-711a-48f2-847f-896ce061e2b5',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:109',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981223546,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25002028',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'cdk 4/6 inhibitors sensitize pik3ca mutant breast cancer to pi3k inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25002028',\n",
              "  'updatedAt': 1612981223546,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25002028',\n",
              "  'uuid': '2f94169f-8829-47a9-8950-d38d9350e61f',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:110',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981224359,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22328973',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'mutations in the ddr2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22328973',\n",
              "  'updatedAt': 1612981224359,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22328973',\n",
              "  'uuid': 'fa69ceb6-235e-4116-9310-6300750159fd',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:112',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981225891,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15118125',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'egfr mutations in lung cancer: correlation with clinical response to gefitinib therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15118125',\n",
              "  'updatedAt': 1612981225891,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15118125',\n",
              "  'uuid': 'b52691a0-4d22-476a-a3e7-897ee797f6c6',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:113',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981226291,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24457318',\n",
              "  'journalName': 'oncology',\n",
              "  'name': 'clinical predictors of response to egfr tyrosine kinase inhibitors in patients with egfr-mutant non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24457318',\n",
              "  'updatedAt': 1612981226291,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24457318',\n",
              "  'uuid': 'f8f5375c-0bf3-45af-b5c8-e042ac625d5b',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:115',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981227498,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24658966',\n",
              "  'journalName': 'amino acids',\n",
              "  'name': 'a systematic profile of clinical inhibitors responsive to egfr somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24658966',\n",
              "  'updatedAt': 1612981227498,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24658966',\n",
              "  'uuid': '76b63f4d-d39b-4cb6-b2e3-4d5683d77885',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:116',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981229062,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24185510',\n",
              "  'journalName': 'nature genetics',\n",
              "  'name': 'activating esr1 mutations in hormone-resistant metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24185510',\n",
              "  'updatedAt': 1612981229062,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24185510',\n",
              "  'uuid': '64acde96-79fd-4066-aec6-cd017ab11ce9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:120',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981234134,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22541434',\n",
              "  'journalName': 'cell',\n",
              "  'name': 'the gata2 transcriptional network is requisite for ras oncogene-driven non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22541434',\n",
              "  'updatedAt': 1612981234134,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22541434',\n",
              "  'uuid': '0451f8d8-d01e-4504-af75-0604cc76abdc',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:124',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981235879,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19029981',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'effective use of pi3k and mek inhibitors to treat mutant kras g12d and pik3ca h1047r murine lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19029981',\n",
              "  'updatedAt': 1612981235879,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19029981',\n",
              "  'uuid': '26cad4c1-3a4b-464e-917e-6eef71cf75fe',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:126',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981237035,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21558396',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'the selective class i pi3k inhibitor ch5132799 targets human cancers harboring oncogenic pik3ca mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21558396',\n",
              "  'updatedAt': 1612981237035,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21558396',\n",
              "  'uuid': 'ca43babe-e5c3-4581-909d-771f2d760d8a',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:127',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981237441,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15647370',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15647370',\n",
              "  'updatedAt': 1612981237441,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15647370',\n",
              "  'uuid': 'cf21810d-9987-455b-994f-a5e038667c1c',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:129',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981239786,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20085938',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'the pi3k pathway as drug target in human cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20085938',\n",
              "  'updatedAt': 1612981239786,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20085938',\n",
              "  'uuid': '8b281fad-f8fc-4bdc-87d5-a813823bef56',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:130',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981240554,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22698404',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22698404',\n",
              "  'updatedAt': 1612981240554,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22698404',\n",
              "  'uuid': '2ed1bd16-6f12-4c3d-9fb9-20a1a82314fa',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:131',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981240997,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24662454',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'relationship between egfr expression, egfr mutation status, and the efficacy of chemotherapy plus cetuximab in flex study patients with advanced non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24662454',\n",
              "  'updatedAt': 1612981240997,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24662454',\n",
              "  'uuid': 'e1ca6498-e607-4701-9d7c-187a7bb5fd29',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:136',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981244669,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17070615',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'cyclin d1 in non-small cell lung cancer: a key driver of malignant transformation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17070615',\n",
              "  'updatedAt': 1612981244669,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17070615',\n",
              "  'uuid': 'ddaebfee-a08b-4384-961b-180e8841ac2c',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:139',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981246048,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:10547574',\n",
              "  'journalName': 'the journal of pathology',\n",
              "  'name': 'cyclin d2, but not cyclin d1, overexpression closely correlates with gastric cancer progression and prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '10547574',\n",
              "  'updatedAt': 1612981246048,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/10547574',\n",
              "  'uuid': '68473ef3-758a-4d75-b458-9c72b62b97be',\n",
              "  'year': 1999},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:140',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981246915,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12432043',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'cyclin e and survival in patients with breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12432043',\n",
              "  'updatedAt': 1612981246915,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12432043',\n",
              "  'uuid': '2657758e-2920-48ca-91b4-00292d7aef89',\n",
              "  'year': 2002},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:141',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981247313,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:10224221',\n",
              "  'journalName': 'faseb journal : official publication of the federation of american societies for experimental biology',\n",
              "  'name': 'cyclin e in human cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '10224221',\n",
              "  'updatedAt': 1612981247313,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/10224221',\n",
              "  'uuid': '7e98c0bd-8f83-4bbd-952b-6aabc2ffd3e4',\n",
              "  'year': 1999},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:142',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981248093,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23111194',\n",
              "  'journalName': 'diagnostic molecular pathology : the american journal of surgical pathology, part b',\n",
              "  'name': 'cdkn2a (p16) promoter hypermethylation influences the outcome in young lung cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23111194',\n",
              "  'updatedAt': 1612981248093,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23111194',\n",
              "  'uuid': '65d2c856-58ef-4349-8511-6b41eb5cfc24',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:143',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981248495,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24623981',\n",
              "  'journalName': 'oncotargets and therapy',\n",
              "  'name': 'the predictive role of pretreatment epidermal growth factor receptor t790m mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24623981',\n",
              "  'updatedAt': 1612981248495,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24623981',\n",
              "  'uuid': '98454bf7-6167-4dea-96d7-d39760d1f546',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:144',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981248894,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24729716',\n",
              "  'journalName': 'oncotargets and therapy',\n",
              "  'name': 'primary concomitant egfr t790m mutation predicted worse prognosis in non-small cell lung cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24729716',\n",
              "  'updatedAt': 1612981248894,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24729716',\n",
              "  'uuid': 'a6b9ad7d-f2cc-41f3-a5f7-8e1a6b9978ae',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:145',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981249441,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11585760',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of flt3: a cancer and leukemia group b study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11585760',\n",
              "  'updatedAt': 1612981249441,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11585760',\n",
              "  'uuid': '26f90613-af62-4a4a-b36f-f596afd72b7b',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:149',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981251254,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15597105',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'the role of ras oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15597105',\n",
              "  'updatedAt': 1612981251254,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15597105',\n",
              "  'uuid': '1101faf8-cbaa-4b67-bf4d-6fe7859bba06',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:150',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981252091,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20007775',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'alterations of the notch pathway in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20007775',\n",
              "  'updatedAt': 1612981252091,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20007775',\n",
              "  'uuid': 'c3f467e4-386d-418d-9e1c-84ac4c761243',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:151',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981252764,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19223544',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'pik3ca mutations in colorectal cancer are associated with clinical resistance to egfr-targeted monoclonal antibodies.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19223544',\n",
              "  'updatedAt': 1612981252764,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19223544',\n",
              "  'uuid': '3b0af8a8-e8cc-4d3f-87b4-5cadebbd2f6e',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:152',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981253374,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16489069',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'the clinical value of somatic tp53 gene mutations in 1,794 patients with breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16489069',\n",
              "  'updatedAt': 1612981253374,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16489069',\n",
              "  'uuid': 'dfba08c1-c3b9-47e8-832d-81aaa8493bd3',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:153',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981253870,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:9569050',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'mutations in residues of tp53 that directly contact dna predict poor outcome in human primary breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '9569050',\n",
              "  'updatedAt': 1612981253870,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/9569050',\n",
              "  'uuid': '1d61a660-d669-45b0-9a37-4acf23b348b8',\n",
              "  'year': 1998},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:160',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981262635,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16818686',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16818686',\n",
              "  'updatedAt': 1612981262635,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16818686',\n",
              "  'uuid': 'ac370478-0724-42fe-a30a-98156eeafb4d',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:161',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981263400,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25670080',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'a targetable gata2-igf2 axis confers aggressiveness in lethal prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25670080',\n",
              "  'updatedAt': 1612981263400,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25670080',\n",
              "  'uuid': '50575ac0-ac22-4713-ae13-3bec84e0cbf8',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:168',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981267772,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21343549',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'tet2 mutations improve the new european leukemianet risk classification of acute myeloid leukemia: a cancer and leukemia group b study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21343549',\n",
              "  'updatedAt': 1612981267772,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21343549',\n",
              "  'uuid': '6f9fc819-a2b0-4cc2-b622-1d5929a9e05e',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:174',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981272136,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22277784',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'mechanisms of acquired crizotinib resistance in alk-rearranged lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22277784',\n",
              "  'updatedAt': 1612981272136,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22277784',\n",
              "  'uuid': '210311e7-81eb-4742-8709-a7f8864549de',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:186',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981280659,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15630448',\n",
              "  'journalName': 'the journal of clinical investigation',\n",
              "  'name': 'oncogenic akap9-braf fusion is a novel mechanism of mapk pathway activation in thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15630448',\n",
              "  'updatedAt': 1612981280659,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15630448',\n",
              "  'uuid': '7f7e47cb-9504-4b0e-a23a-325a647a5614',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:188',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981281899,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22274685',\n",
              "  'journalName': 'jama',\n",
              "  'name': 'association between brca1 and brca2 mutations and survival in women with invasive epithelial ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22274685',\n",
              "  'updatedAt': 1612981281899,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22274685',\n",
              "  'uuid': '01562a29-0e33-439a-8ce0-dbcaa08a5107',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:189',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981282393,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20336784',\n",
              "  'journalName': 'cancer',\n",
              "  'name': 'gene amplification ccne1 is related to poor survival and potential therapeutic target in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20336784',\n",
              "  'updatedAt': 1612981282393,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20336784',\n",
              "  'uuid': 'b31279d3-e49a-41a9-8402-1d5cb8fca975',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:195',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981284992,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17538160',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17538160',\n",
              "  'updatedAt': 1612981284992,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17538160',\n",
              "  'uuid': '27ca8edd-c429-4e63-8ed4-2a3b04c745c5',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:199',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981288913,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16254181',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'recurrent fusion of tmprss2 and ets transcription factor genes in prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16254181',\n",
              "  'updatedAt': 1612981288913,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16254181',\n",
              "  'uuid': '37cdae4f-0885-496e-9c50-bf9079785db3',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:200',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981289261,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20542753',\n",
              "  'journalName': 'cancer epidemiology',\n",
              "  'name': 'fgfr3 mutational status and protein expression in patients with bladder cancer in a jordanian population.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20542753',\n",
              "  'updatedAt': 1612981289261,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20542753',\n",
              "  'uuid': '6629c698-88bf-4365-b665-98ff77b0264d',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:206',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981293637,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23322234',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'prognostic relevance of aib1 (ncoa3) amplification and overexpression in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23322234',\n",
              "  'updatedAt': 1612981293637,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23322234',\n",
              "  'uuid': 'bc046a15-fa21-4977-bb87-8e6701f8b7a9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:211',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981297810,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16497822',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, egf receptor and her2 status.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16497822',\n",
              "  'updatedAt': 1612981297810,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16497822',\n",
              "  'uuid': '958768ae-0f18-46e6-a7bc-75db423bab55',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:213',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981298667,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22292935',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'highly frequent pik3ca amplification is associated with poor prognosis in gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22292935',\n",
              "  'updatedAt': 1612981298667,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22292935',\n",
              "  'uuid': 'eb43089f-a0bc-4687-bdf6-cd82a9d3b66b',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:214',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981299097,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17700571',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'fish analysis of 107 prostate cancers shows that pten genomic deletion is associated with poor clinical outcome.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17700571',\n",
              "  'updatedAt': 1612981299097,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17700571',\n",
              "  'uuid': 'c471e5ab-bea8-442c-9ffb-d159021555dc',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:215',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981299527,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21163703',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'kras, braf, pik3ca, and pten mutations: implications for targeted therapies in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21163703',\n",
              "  'updatedAt': 1612981299527,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21163703',\n",
              "  'uuid': '2ed8f43c-b043-475f-945e-65cd12cd942b',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:219',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981301610,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19584151',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'smad4 gene mutations are associated with poor prognosis in pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19584151',\n",
              "  'updatedAt': 1612981301610,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19584151',\n",
              "  'uuid': 'b66159d2-fce4-4b64-b8d4-0f3d7a921b46',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:224',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981304654,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22090360',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'tp53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22090360',\n",
              "  'updatedAt': 1612981304654,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22090360',\n",
              "  'uuid': '8eeb146b-420a-4921-b149-00627d7a656c',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:230',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981307084,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11248153',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11248153',\n",
              "  'updatedAt': 1612981307084,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11248153',\n",
              "  'uuid': 'eb5d6cde-f86a-48b4-b564-cd587e8fb067',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:231',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981307458,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15911866',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized phase ii trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the m77001 study group.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15911866',\n",
              "  'updatedAt': 1612981307458,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15911866',\n",
              "  'uuid': '4aa3168a-aae7-4789-ac63-0f05251c5805',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:248',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981316305,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23989949',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'pten deficiency is associated with reduced sensitivity to mtor inhibitor in human bladder cancer through the unhampered feedback loop driving pi3k/akt activation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23989949',\n",
              "  'updatedAt': 1612981316305,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23989949',\n",
              "  'uuid': '43604d95-dc61-4c58-b1e9-c40516c1d163',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:249',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981316753,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24387334',\n",
              "  'journalName': 'current drug targets',\n",
              "  'name': 'therapeutic targeting of cancers with loss of pten function.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24387334',\n",
              "  'updatedAt': 1612981316753,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24387334',\n",
              "  'uuid': '07b9c312-5c28-4c85-9bb2-56b8e6bad874',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:250',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981317185,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25923550',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'rociletinib in egfr-mutated non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25923550',\n",
              "  'updatedAt': 1612981317185,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25923550',\n",
              "  'uuid': '888ddfec-4388-4736-9ff9-a6188cc9b93e',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:251',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981317636,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26510020',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'dna-repair defects and olaparib in metastatic prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26510020',\n",
              "  'updatedAt': 1612981317636,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26510020',\n",
              "  'uuid': '13c4c855-b4db-4950-9c49-2c15630a8ecb',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:255',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981320293,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25024077',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'braf v600e and tert promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25024077',\n",
              "  'updatedAt': 1612981320293,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25024077',\n",
              "  'uuid': '094eb6b6-aded-41e0-9542-4840c0ba88d2',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:256',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981320799,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23766237',\n",
              "  'journalName': 'endocrine-related cancer',\n",
              "  'name': 'highly prevalent tert promoter mutations in aggressive thyroid cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23766237',\n",
              "  'updatedAt': 1612981320799,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23766237',\n",
              "  'uuid': '3a9941fa-aad8-4d72-bed1-6a84f761c685',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:257',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981321542,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19157633',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'polymorphisms in xrcc1 and xpg and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19157633',\n",
              "  'updatedAt': 1612981321542,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19157633',\n",
              "  'uuid': '691f3c1f-5b38-44fb-8be4-30d105d586cf',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:259',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981323254,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23188704',\n",
              "  'journalName': 'tumour biology : the journal of the international society for oncodevelopmental biology and medicine',\n",
              "  'name': 'upregulation of the antiapoptotic factor livin contributes to cisplatin resistance in colon cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23188704',\n",
              "  'updatedAt': 1612981323254,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23188704',\n",
              "  'uuid': '52b9d478-7bc6-4b16-8f13-e97de03ecf7d',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:260',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981323711,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23764753',\n",
              "  'journalName': 'carcinogenesis',\n",
              "  'name': 'exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23764753',\n",
              "  'updatedAt': 1612981323711,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23764753',\n",
              "  'uuid': '7bcff1fd-e995-4a93-886d-c5d72fa994b6',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:261',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981324566,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22139083',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'a kras variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22139083',\n",
              "  'updatedAt': 1612981324566,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22139083',\n",
              "  'uuid': 'e9c84cdc-b67a-4c4a-bcd8-48a05a09a6b0',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:263',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981327990,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21926398',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'an ezh2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21926398',\n",
              "  'updatedAt': 1612981327990,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21926398',\n",
              "  'uuid': '320a7281-237d-416c-9de4-435bb733ce1e',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:264',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981328816,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18704422',\n",
              "  'journalName': 'cancer chemotherapy and pharmacology',\n",
              "  'name': 'the polymorphisms of ts and mthfr predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in chinese population.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18704422',\n",
              "  'updatedAt': 1612981328816,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18704422',\n",
              "  'uuid': 'cbda5e82-1b57-450c-b551-c4ad49593852',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:266',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981330006,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22112610',\n",
              "  'journalName': 'gynecologic oncology',\n",
              "  'name': 'common variants in abcb1, abcc2 and abcg2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a gynecologic oncology group study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22112610',\n",
              "  'updatedAt': 1612981330006,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22112610',\n",
              "  'uuid': 'cc359e32-d5e6-4492-944c-d30836898631',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:267',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981330421,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22551904',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'genetic polymorphism of xrcc1 arg399gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22551904',\n",
              "  'updatedAt': 1612981330421,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22551904',\n",
              "  'uuid': 'b2ae18d7-af56-40ca-9079-0b91a72c049f',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:268',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981330847,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16875718',\n",
              "  'journalName': 'gynecologic oncology',\n",
              "  'name': 'xrcc1 r399q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16875718',\n",
              "  'updatedAt': 1612981330847,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16875718',\n",
              "  'uuid': '4fb2132d-280c-4d9d-bace-a36d126d50bd',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:269',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981331632,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16467099',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: g2677t/a correlates with response to paclitaxel chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16467099',\n",
              "  'updatedAt': 1612981331632,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16467099',\n",
              "  'uuid': 'de7eb6a1-d02f-4043-acbe-54062c1427da',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:270',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981332072,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22296372',\n",
              "  'journalName': 'asian pacific journal of cancer prevention : apjcp',\n",
              "  'name': 'influence of mdr1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22296372',\n",
              "  'updatedAt': 1612981332072,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22296372',\n",
              "  'uuid': '1ac3d0e6-b351-4bfd-ab3d-2c9408b85cdb',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:272',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981333558,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19470925',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'japanese-us common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19470925',\n",
              "  'updatedAt': 1612981333558,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19470925',\n",
              "  'uuid': '027fff4c-b901-4b9f-ba50-1e853e9d6e3b',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:273',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981334659,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22896685',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'lrp1b deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22896685',\n",
              "  'updatedAt': 1612981334659,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22896685',\n",
              "  'uuid': 'eaf3a3be-8911-46bd-a40f-be8ac206be94',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:274',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981335569,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24771645',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'fgfr1 mrna and protein expression, not gene copy number, predict fgfr tki sensitivity across all lung cancer histologies.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24771645',\n",
              "  'updatedAt': 1612981335569,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24771645',\n",
              "  'uuid': '90191de6-ff3c-4d2e-80ce-856b3d372783',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:275',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981335988,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23182986',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23182986',\n",
              "  'updatedAt': 1612981335988,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23182986',\n",
              "  'uuid': 'fa63f844-6edc-4b4f-bdba-48065526414f',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:276',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981336328,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25086725',\n",
              "  'journalName': 'virchows archiv : an international journal of pathology',\n",
              "  'name': 'fgfr1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25086725',\n",
              "  'updatedAt': 1612981336328,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25086725',\n",
              "  'uuid': '042e239b-a513-48d2-a19a-927b7eb5ef93',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:277',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981336730,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23806793',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'fibroblast growth factor receptor 1 (fgfr1) copy number is an independent prognostic factor in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23806793',\n",
              "  'updatedAt': 1612981336730,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23806793',\n",
              "  'uuid': '27cf8b2a-0c0a-46bb-ba43-61951005cc08',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:278',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981337130,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25171497',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'prognostic value of fgfr gene amplification in patients with different types of cancer: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25171497',\n",
              "  'updatedAt': 1612981337130,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25171497',\n",
              "  'uuid': 'ce01f78f-a38a-4f17-8f44-508895054620',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:279',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981337885,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25264305',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'crizotinib in ros1-rearranged non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25264305',\n",
              "  'updatedAt': 1612981337885,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25264305',\n",
              "  'uuid': 'd46dc595-91b1-4dca-a485-86ca9bc7d05a',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:280',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981338677,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22389872',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'durable complete response of metastatic gastric cancer with anti-met therapy followed by resistance at recurrence.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22389872',\n",
              "  'updatedAt': 1612981338677,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22389872',\n",
              "  'uuid': '587850a7-513c-4785-af99-cbc2742d19d5',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:281',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981339404,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19470935',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'atr mutation in endometrioid endometrial cancer is associated with poor clinical outcomes.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19470935',\n",
              "  'updatedAt': 1612981339404,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19470935',\n",
              "  'uuid': '8ef4137f-e314-4bad-93b3-8a9652ca25a1',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:282',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981339851,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22056021',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'egfr expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 flex study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22056021',\n",
              "  'updatedAt': 1612981339851,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22056021',\n",
              "  'uuid': 'c198c897-8784-4a0b-ad82-eb0bcafc9026',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:284',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981342168,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26561417',\n",
              "  'journalName': 'international journal of colorectal disease',\n",
              "  'name': 'hras g13d, a new mutation implicated in the resistance to anti-egfr therapies in colorectal cancer, a case report.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26561417',\n",
              "  'updatedAt': 1612981342168,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26561417',\n",
              "  'uuid': 'c68e9ef7-2787-4380-b340-e659985d281d',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:287',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981344124,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26625204',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'prognostic impact of programmed cell death-1 (pd-1) and pd-ligand 1 (pd-l1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26625204',\n",
              "  'updatedAt': 1612981344124,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26625204',\n",
              "  'uuid': '3907a126-a0ac-4a81-a6bc-300bb6a10975',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:288',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981344567,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26086854',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'differential activity of nivolumab, pembrolizumab and mpdl3280a according to the tumor expression of programmed death-ligand-1 (pd-l1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26086854',\n",
              "  'updatedAt': 1612981344567,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26086854',\n",
              "  'uuid': '899479a2-ed22-4fe7-aead-69adf188ef21',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:290',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981346648,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22842582',\n",
              "  'journalName': 'international journal of oncology',\n",
              "  'name': 'akt expression and compartmentalization in prediction of clinical outcome in her2-positive metastatic breast cancer patients treated with trastuzumab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22842582',\n",
              "  'updatedAt': 1612981346648,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22842582',\n",
              "  'uuid': '4d8eea4e-5530-48a7-b006-f68220379e82',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:293',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981347974,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23888070',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pik3ca and akt1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23888070',\n",
              "  'updatedAt': 1612981347974,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23888070',\n",
              "  'uuid': '942b3ed3-9fbe-40f2-b6f2-0b0d53d8d8e8',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:297',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981350522,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25878190',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25878190',\n",
              "  'updatedAt': 1612981350522,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25878190',\n",
              "  'uuid': 'a63ac657-d4ef-499d-8347-89c200345ebb',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:299',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981351467,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22270724',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22270724',\n",
              "  'updatedAt': 1612981351467,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22270724',\n",
              "  'uuid': '50c1094e-a4f7-46f1-8604-35fec93e63ea',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:300',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981352265,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26508446',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'prediction of response to anti-egfr antibody-based therapies by multigene sequencing in colorectal cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26508446',\n",
              "  'updatedAt': 1612981352265,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26508446',\n",
              "  'uuid': 'db0a115a-d548-435e-804d-4262c0fececc',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:305',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981358055,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25520391',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from calgb 80203 (alliance).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25520391',\n",
              "  'updatedAt': 1612981358055,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25520391',\n",
              "  'uuid': 'd2c5f2fa-fab4-4857-92df-fd5b581a847c',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:306',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981358896,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26683709',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'prognostic value of high ezh2 expression in patients with different types of cancer: a systematic review with meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26683709',\n",
              "  'updatedAt': 1612981358896,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26683709',\n",
              "  'uuid': '7cd1a53d-83d5-4244-9fcd-127e85759f87',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:307',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981359586,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17463250',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'met amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17463250',\n",
              "  'updatedAt': 1612981359586,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17463250',\n",
              "  'uuid': '2f034f3c-5f62-4f62-83ed-798c4c0c5a88',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:308',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981360378,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26596839',\n",
              "  'journalName': 'tumour biology : the journal of the international society for oncodevelopmental biology and medicine',\n",
              "  'name': 'increased expression of myd88 and association with paclitaxel resistance in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26596839',\n",
              "  'updatedAt': 1612981360378,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26596839',\n",
              "  'uuid': 'e6977ed6-9da1-4bf7-bba9-42a466873ce9',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:309',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981360788,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21623265',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'activity of crizotinib (pf02341066), a dual mesenchymal-epithelial transition (met) and anaplastic lymphoma kinase (alk) inhibitor, in a non-small cell lung cancer patient with de novo met amplification.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21623265',\n",
              "  'updatedAt': 1612981360788,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21623265',\n",
              "  'uuid': '1a94e6f2-7807-4f88-a556-3e48395bd7cc',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:310',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981361214,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26439803',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'low egfr/met ratio is associated with resistance to egfr inhibitors in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26439803',\n",
              "  'updatedAt': 1612981361214,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26439803',\n",
              "  'uuid': '5334403d-0ad5-4276-8737-8997e902df96',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:313',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981362642,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26686064',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26686064',\n",
              "  'updatedAt': 1612981362642,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26686064',\n",
              "  'uuid': 'c0ac69b4-8ba3-40cd-bf3f-d5a03a6569a1',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:314',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981363445,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26617739',\n",
              "  'journalName': 'international journal of clinical and experimental pathology',\n",
              "  'name': 'elevated expression of rit1 correlates with poor prognosis in endometrial cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26617739',\n",
              "  'updatedAt': 1612981363445,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26617739',\n",
              "  'uuid': '95f93601-6203-414e-a580-6e9460fcf340',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:321',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981370790,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26625312',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'different prognostic impact of stk11 mutations in non-squamous non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26625312',\n",
              "  'updatedAt': 1612981370790,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26625312',\n",
              "  'uuid': 'b0e42e62-4fe9-47cd-b7b0-5ceb841bc312',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:322',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981372252,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26096845',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26096845',\n",
              "  'updatedAt': 1612981372252,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26096845',\n",
              "  'uuid': '22d3031c-2c45-492b-aca9-fbff95423394',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:325',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981374112,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20142587',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'neratinib, an irreversible erbb receptor tyrosine kinase inhibitor, in patients with advanced erbb2-positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20142587',\n",
              "  'updatedAt': 1612981374112,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20142587',\n",
              "  'uuid': 'd3eafaaa-f3c7-49e6-a52c-b8b422323e21',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:328',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981376278,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22235099',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'mechanisms of resistance to crizotinib in patients with alk gene rearranged non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22235099',\n",
              "  'updatedAt': 1612981376278,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22235099',\n",
              "  'uuid': '96fdf818-2328-4db5-8d04-5f8b4ab88652',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:329',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981376696,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23344087',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'heterogeneity of genetic changes associated with acquired crizotinib resistance in alk-rearranged lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23344087',\n",
              "  'updatedAt': 1612981376696,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23344087',\n",
              "  'uuid': '30d4c0ae-4234-4733-bab5-1133fc9e4220',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:331',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981378013,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25242168',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'potent antitumor activity of cabozantinib, a c-met and vegfr2 inhibitor, in a colorectal cancer patient-derived tumor explant model.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25242168',\n",
              "  'updatedAt': 1612981378013,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25242168',\n",
              "  'uuid': 'ce41335a-e4d2-4962-b6aa-5c23cbda600b',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:334',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981380345,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21840482',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'neuregulin-1-mediated autocrine signaling underlies sensitivity to her2 kinase inhibitors in a subset of human cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21840482',\n",
              "  'updatedAt': 1612981380345,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21840482',\n",
              "  'uuid': '66e9681e-92e2-4dee-bedd-a635111e34fc',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:336',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981381211,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20227043',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'an activated erbb3/nrg1 autocrine loop supports in vivo proliferation in ovarian cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20227043',\n",
              "  'updatedAt': 1612981381211,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20227043',\n",
              "  'uuid': 'e0a56b64-3ebd-4050-aacf-bd2db3792af6',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:337',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981381657,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23390248',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'blocking nrg1 and other ligand-mediated her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23390248',\n",
              "  'updatedAt': 1612981381657,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23390248',\n",
              "  'uuid': 'a13dfe37-a49c-4c5d-884c-2e23d4da453c',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:340',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981384148,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24894453',\n",
              "  'journalName': 'molecular cancer',\n",
              "  'name': 'colon cancer-derived oncogenic egfr g724s mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24894453',\n",
              "  'updatedAt': 1612981384148,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24894453',\n",
              "  'uuid': '5fd0aaa1-8b4a-42ad-abe5-4e8360da88fd',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:341',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981385137,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23374602',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of egfr ligand expression with ras/raf, pik3ca genotypes.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23374602',\n",
              "  'updatedAt': 1612981385137,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23374602',\n",
              "  'uuid': 'c807e95d-72c4-414d-ae55-04ab5f7b0565',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:343',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981386823,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26673008',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'fgfr1 is an adverse outcome indicator for luminal a breast cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26673008',\n",
              "  'updatedAt': 1612981386823,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26673008',\n",
              "  'uuid': '95d25a8a-fe18-44fd-89e0-f1d6aa6d53df',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:344',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981387286,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24836576',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24836576',\n",
              "  'updatedAt': 1612981387286,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24836576',\n",
              "  'uuid': '962ac5f0-ee0a-4416-869b-c36eba3ac28d',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:347',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981388706,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26015511',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'fgfr1 expression levels predict bgj398 sensitivity of fgfr1-dependent head and neck squamous cell cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26015511',\n",
              "  'updatedAt': 1612981388706,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26015511',\n",
              "  'uuid': '4347bd08-bbbf-46db-b2f9-26144a5be958',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:348',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981389149,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26637881',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'targeting fibroblast growth factor receptor (fgfr) with bgj398 in a gastric cancer model.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26637881',\n",
              "  'updatedAt': 1612981389149,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26637881',\n",
              "  'uuid': '9b69d5fe-779d-48bf-b698-57745ab8aa9b',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:351',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981392545,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26261420',\n",
              "  'journalName': 'oncotargets and therapy',\n",
              "  'name': 'whole blood defensin mrna expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26261420',\n",
              "  'updatedAt': 1612981392545,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26261420',\n",
              "  'uuid': 'b7743d04-889e-481b-9937-f5c8f809c179',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:353',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981393804,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26152787',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'a notch1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a notch1 targeting antibody in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26152787',\n",
              "  'updatedAt': 1612981393804,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26152787',\n",
              "  'uuid': 'dafdd2ed-1f07-4fbe-9ad6-1c1bce82b5ab',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:354',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981394241,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26137564',\n",
              "  'journalName': 'ebiomedicine',\n",
              "  'name': 'clinical translation and validation of a predictive biomarker for patritumab, an anti-human epidermal growth factor receptor 3 (her3) monoclonal antibody, in patients with advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26137564',\n",
              "  'updatedAt': 1612981394241,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26137564',\n",
              "  'uuid': '75fdc000-7829-443d-81f7-00c9076cdf83',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:355',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981395415,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26057002',\n",
              "  'journalName': 'scientific reports',\n",
              "  'name': 'wee1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26057002',\n",
              "  'updatedAt': 1612981395415,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26057002',\n",
              "  'uuid': '7b97d895-62a8-4f15-be73-364cec864fdd',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:356',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981396450,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26033044',\n",
              "  'journalName': 'british journal of clinical pharmacology',\n",
              "  'name': 'the fntb promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26033044',\n",
              "  'updatedAt': 1612981396450,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26033044',\n",
              "  'uuid': '9f4d4f49-ec4e-48de-8bd2-a2474fb3bbf1',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:357',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981398238,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25968887',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'kras genomic status predicts the sensitivity of ovarian cancer cells to decitabine.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25968887',\n",
              "  'updatedAt': 1612981398238,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25968887',\n",
              "  'uuid': '5a14ad60-1d93-42c4-8b2e-8d95eb066706',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:360',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981402587,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25900183',\n",
              "  'journalName': 'endocrine-related cancer',\n",
              "  'name': 'tff3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25900183',\n",
              "  'updatedAt': 1612981402587,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25900183',\n",
              "  'uuid': 'be800be1-e869-4ec3-9cea-4cf2c8c0cb56',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:361',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981403645,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25788273',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'nuclear dickkopf-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25788273',\n",
              "  'updatedAt': 1612981403645,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25788273',\n",
              "  'uuid': '5891c42c-43e2-4aae-b6c3-c54a62dee25e',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:362',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981404831,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25677871',\n",
              "  'journalName': 'journal of oral pathology & medicine : official publication of the international association of oral pathologists and the american academy of oral pathology',\n",
              "  'name': 'epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25677871',\n",
              "  'updatedAt': 1612981404831,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25677871',\n",
              "  'uuid': 'faaa5c17-405b-4277-8fca-f3b2b0df1a5e',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:365',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981407371,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26311741',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26311741',\n",
              "  'updatedAt': 1612981407371,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26311741',\n",
              "  'uuid': '4a49929a-3cbf-4a70-8fe3-d1428cbe6874',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:367',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981408792,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26502926',\n",
              "  'journalName': 'bmc pulmonary medicine',\n",
              "  'name': 'thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26502926',\n",
              "  'updatedAt': 1612981408792,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26502926',\n",
              "  'uuid': '5bcaae41-f90f-4d77-85a4-81ec824dc5ac',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:368',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981409609,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26745678',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'topk promotes lung cancer resistance to egfr tyrosine kinase inhibitors by phosphorylating and activating c-jun.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26745678',\n",
              "  'updatedAt': 1612981409609,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26745678',\n",
              "  'uuid': '5c520598-4a68-4c80-b33a-11f9d988b162',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:370',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981411412,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26671993',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'smarca4/brg1 is a novel prognostic biomarker predictive of cisplatin-based chemotherapy outcomes in resected non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26671993',\n",
              "  'updatedAt': 1612981411412,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26671993',\n",
              "  'uuid': '21bb84d2-a0d3-4122-a1ac-d74ef74fa68b',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:374',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981415533,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24740294',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24740294',\n",
              "  'updatedAt': 1612981415533,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24740294',\n",
              "  'uuid': 'db175c72-c910-4ca1-99d5-cf3902aec15e',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:375',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981416387,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24708484',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'p21 and cd166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24708484',\n",
              "  'updatedAt': 1612981416387,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24708484',\n",
              "  'uuid': '3ec9468d-0c43-4e44-b328-5e2746f1153e',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:376',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981417273,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24653627',\n",
              "  'journalName': 'chinese journal of cancer research = chung-kuo yen cheng yen chiu',\n",
              "  'name': 'egfr gene copy number as a predictive biomarker for resistance to anti-egfr monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24653627',\n",
              "  'updatedAt': 1612981417273,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24653627',\n",
              "  'uuid': 'fdd00d9b-b6e6-43f5-9f61-b41a7a2d7778',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:377',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981418223,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24587245',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24587245',\n",
              "  'updatedAt': 1612981418223,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24587245',\n",
              "  'uuid': 'cd03aab9-f5c4-48d1-8b72-de3973a60816',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:378',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981418634,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15138475',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'cyclin d1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15138475',\n",
              "  'updatedAt': 1612981418634,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15138475',\n",
              "  'uuid': '81a496f3-4cdf-4df9-a45f-34f7fd453f43',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:382',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981423210,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25300346',\n",
              "  'journalName': 'oncology',\n",
              "  'name': 'pten deficiency as a predictive biomarker of resistance to her2-targeted therapy in advanced gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25300346',\n",
              "  'updatedAt': 1612981423210,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25300346',\n",
              "  'uuid': 'ef0d26d1-9012-43cd-831a-d89898b3eb7f',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:383',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981424343,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25210794',\n",
              "  'journalName': 'cell death & disease',\n",
              "  'name': 'udp glucuronosyltransferase 1a expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25210794',\n",
              "  'updatedAt': 1612981424343,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25210794',\n",
              "  'uuid': '09e7f115-eff5-40b6-9e76-c51d6abc23f2',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:384',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981424832,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25153719',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'nuclear her4 mediates acquired resistance to trastuzumab and is associated with poor outcome in her2 positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25153719',\n",
              "  'updatedAt': 1612981424832,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25153719',\n",
              "  'uuid': 'af61b536-ef69-468d-90cb-8fe84f227e16',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:385',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981425251,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25590338',\n",
              "  'journalName': 'cell cycle (georgetown, tex.)',\n",
              "  'name': 'receptor tyrosine kinase erbb4 mediates acquired resistance to erbb2 inhibitors in breast cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25590338',\n",
              "  'updatedAt': 1612981425251,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25590338',\n",
              "  'uuid': 'b2e3ac46-b9bf-495a-a261-10780e3b07ad',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:387',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981426685,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25082261',\n",
              "  'journalName': 'journal of translational medicine',\n",
              "  'name': 'aurora-a contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25082261',\n",
              "  'updatedAt': 1612981426685,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25082261',\n",
              "  'uuid': 'de4d9876-bfd2-45c0-8e39-7d8b1d1982ee',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:390',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981428759,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24961465',\n",
              "  'journalName': 'medical oncology (northwood, london, england)',\n",
              "  'name': 'nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24961465',\n",
              "  'updatedAt': 1612981428759,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24961465',\n",
              "  'uuid': '9360f828-2033-411d-89e7-de5e25aa048f',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:391',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981429240,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24957073',\n",
              "  'journalName': 'journal of the national cancer institute',\n",
              "  'name': 'tp53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the expert-c trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24957073',\n",
              "  'updatedAt': 1612981429240,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24957073',\n",
              "  'uuid': '437925c2-670d-43cd-a60d-66dcdf141951',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:392',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981430090,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24927325',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'effect of mre11 loss on parp-inhibitor sensitivity in endometrial cancer in vitro.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24927325',\n",
              "  'updatedAt': 1612981430090,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24927325',\n",
              "  'uuid': 'e316cdf4-2483-445f-a77d-8f3d1f3d8332',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:393',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981430498,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24841718',\n",
              "  'journalName': 'cell cycle (georgetown, tex.)',\n",
              "  'name': 'low atm protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24841718',\n",
              "  'updatedAt': 1612981430498,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24841718',\n",
              "  'uuid': 'ce24c2e9-34c3-46b6-aef3-6b891ee5d5e4',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:395',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981431377,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25862853',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'afatinib is especially effective against non-small cell lung cancer carrying an egfr exon 19 deletion.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25862853',\n",
              "  'updatedAt': 1612981431377,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25862853',\n",
              "  'uuid': 'ae74f0e2-5bf3-4766-ad0a-1a32508251ee',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:397',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981432160,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22285168',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced egfr mutation-positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22285168',\n",
              "  'updatedAt': 1612981432160,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22285168',\n",
              "  'uuid': '53591f8d-5f1c-4e4e-9523-d59881c8fad8',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:398',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981432610,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25268372',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'afatinib demonstrates remarkable activity against her2-amplified uterine serous endometrial cancer in vitro and in vivo.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25268372',\n",
              "  'updatedAt': 1612981432610,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25268372',\n",
              "  'uuid': 'b2d22c64-e5a8-49e3-a579-79d4364474b6',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:399',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981433029,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25537159',\n",
              "  'journalName': 'clinical breast cancer',\n",
              "  'name': 'a neoadjuvant, randomized, open-label phase ii trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced her2-positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25537159',\n",
              "  'updatedAt': 1612981433029,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25537159',\n",
              "  'uuid': '080d3788-6b32-4a36-a04b-9f2b9e51cbd1',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:400',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981433974,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24256029',\n",
              "  'journalName': 'scandinavian journal of gastroenterology',\n",
              "  'name': 'assessment of the topoisomerase i gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24256029',\n",
              "  'updatedAt': 1612981433974,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24256029',\n",
              "  'uuid': '3b09e793-328f-43b8-aa30-95b0e23df162',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:403',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981435850,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24167368',\n",
              "  'journalName': 'disease markers',\n",
              "  'name': 'agr2 predicts tamoxifen resistance in postmenopausal breast cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24167368',\n",
              "  'updatedAt': 1612981435850,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24167368',\n",
              "  'uuid': '2330f4d3-c56f-4eba-8cc0-d5b473f5de4f',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:404',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981436441,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24135816',\n",
              "  'journalName': 'digestion',\n",
              "  'name': 'fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24135816',\n",
              "  'updatedAt': 1612981436441,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24135816',\n",
              "  'uuid': '96adfd0d-fb6c-4249-b003-2bac4adb4911',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:406',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981438839,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23881388',\n",
              "  'journalName': 'tumour biology : the journal of the international society for oncodevelopmental biology and medicine',\n",
              "  'name': 'timp1 overexpression mediates resistance of mcf-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23881388',\n",
              "  'updatedAt': 1612981438839,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23881388',\n",
              "  'uuid': '5392f682-324c-4e09-a5f8-47cc9aa84b2d',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:407',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981439646,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23867504',\n",
              "  'journalName': 'the journal of clinical investigation',\n",
              "  'name': 'metastasis-associated prl-3 induces egfr activation and addiction in cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23867504',\n",
              "  'updatedAt': 1612981439646,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23867504',\n",
              "  'uuid': '5f1aa114-ac0a-40b6-bfc6-d763291ccfe1',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:409',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981440930,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23619944',\n",
              "  'journalName': 'cellular oncology (dordrecht)',\n",
              "  'name': 'insulin-like growth factor-1 receptor (igf-1r) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23619944',\n",
              "  'updatedAt': 1612981440930,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23619944',\n",
              "  'uuid': 'a2cece8a-c5ac-4432-8000-c942e35c7710',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:410',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981441644,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23579861',\n",
              "  'journalName': 'medical oncology (northwood, london, england)',\n",
              "  'name': 'gene expression profiling identifies ephb4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23579861',\n",
              "  'updatedAt': 1612981441644,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23579861',\n",
              "  'uuid': 'fe7993a2-6fa3-47b9-a1e4-da558703d5a7',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:411',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981442049,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23515910',\n",
              "  'journalName': 'annals of surgical oncology',\n",
              "  'name': 'correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23515910',\n",
              "  'updatedAt': 1612981442049,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23515910',\n",
              "  'uuid': '9fbb4863-f6a0-4863-a888-c484ba52eb63',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:414',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981443810,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15486187',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'topoisomerase-ii alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15486187',\n",
              "  'updatedAt': 1612981443810,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15486187',\n",
              "  'uuid': '8f2f3ad1-467a-4061-a9ba-f5c68b17f0b9',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:416',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981444719,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18794099',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'clinical usefulness of egfr gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18794099',\n",
              "  'updatedAt': 1612981444719,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18794099',\n",
              "  'uuid': 'da53a531-22e3-4e6a-a1fa-858ccbe0b728',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:417',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981445184,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19775480',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'topoisomerase i but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19775480',\n",
              "  'updatedAt': 1612981445184,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19775480',\n",
              "  'uuid': 'f1a2ec05-64a3-492a-b60b-2f23ae5c6044',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:418',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981446506,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23456958',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'the unfolded protein response regulator grp78 is a novel predictive biomarker in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23456958',\n",
              "  'updatedAt': 1612981446506,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23456958',\n",
              "  'uuid': '5b47e46d-dcb3-4eb7-b2e2-3184feab09d9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:419',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981446947,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23435830',\n",
              "  'journalName': 'journal of cancer research and clinical oncology',\n",
              "  'name': 'pik3ca mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-egfr monoclonal antibody therapy: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23435830',\n",
              "  'updatedAt': 1612981446947,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23435830',\n",
              "  'uuid': 'b6a62fba-d9e4-45f0-9b92-a0ac47fb23b0',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:420',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981447348,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23435671',\n",
              "  'journalName': 'journal of gastroenterology',\n",
              "  'name': 'kras mutation status is not predictive for objective response to anti-egfr treatment with erlotinib in patients with advanced pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23435671',\n",
              "  'updatedAt': 1612981447348,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23435671',\n",
              "  'uuid': 'e4f1c902-f6f6-4801-851b-ee3cd92cb411',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:421',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981448507,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23340172',\n",
              "  'journalName': 'cancer letters',\n",
              "  'name': 'phosphorylation of 4e-bp1 predicts sensitivity to everolimus in gastric cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23340172',\n",
              "  'updatedAt': 1612981448507,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23340172',\n",
              "  'uuid': '910302fc-d479-4f9e-890f-f766570205af',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:424',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981450194,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23218766',\n",
              "  'journalName': 'clinical breast cancer',\n",
              "  'name': 'high expression of class iii β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23218766',\n",
              "  'updatedAt': 1612981450194,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23218766',\n",
              "  'uuid': 'bd5673b5-66f8-48df-9f00-250cc438a3ac',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:425',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981450613,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23060591',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'association between expression of thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23060591',\n",
              "  'updatedAt': 1612981450613,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23060591',\n",
              "  'uuid': '5cf9c8b5-e4d8-4aea-9920-80fd9d3aab8d',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:427',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981452010,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22623731',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'elevation of c-flip in castrate-resistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22623731',\n",
              "  'updatedAt': 1612981452010,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22623731',\n",
              "  'uuid': 'fcbc9cc2-8c68-4008-9376-ee93c7f03bd2',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:429',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981453201,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22544540',\n",
              "  'journalName': 'medical oncology (northwood, london, england)',\n",
              "  'name': 'high expression of timp-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22544540',\n",
              "  'updatedAt': 1612981453201,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22544540',\n",
              "  'uuid': '09428433-49c4-4863-a397-eec2fc413090',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:430',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981454002,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22431701',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'foxp3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase iii unicancer-pacs 01 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22431701',\n",
              "  'updatedAt': 1612981454002,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22431701',\n",
              "  'uuid': '1e286661-dbe8-4c12-afb2-176a28b3b2d8',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:431',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981454445,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22422354',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'thymidylate synthase mrna levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22422354',\n",
              "  'updatedAt': 1612981454445,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22422354',\n",
              "  'uuid': '6f125ed7-d24b-4e64-85df-0d18ea7006a4',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:432',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981455254,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22343617',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'phase ii study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22343617',\n",
              "  'updatedAt': 1612981455254,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22343617',\n",
              "  'uuid': '81c7ae82-5ad1-4a77-8261-6a863fae5e6e',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:433',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981456089,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22333600',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'enzastaurin has anti-tumour effects in lung cancers with overexpressed jak pathway molecules.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22333600',\n",
              "  'updatedAt': 1612981456089,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22333600',\n",
              "  'uuid': '823b92c0-fece-46e5-9077-dc1a113c0d5e',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:434',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981457114,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22262166',\n",
              "  'journalName': 'cell cycle (georgetown, tex.)',\n",
              "  'name': 'mtor-independent 4e-bp1 phosphorylation is associated with cancer resistance to mtor kinase inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22262166',\n",
              "  'updatedAt': 1612981457114,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22262166',\n",
              "  'uuid': '854aa838-10eb-430d-884b-eea1fca8d8da',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:440',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981461322,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21920589',\n",
              "  'journalName': 'gynecologic oncology',\n",
              "  'name': 'brca1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21920589',\n",
              "  'updatedAt': 1612981461322,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21920589',\n",
              "  'uuid': 'e1566cc6-d343-444f-bd3b-344b24c5c0e5',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:441',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981461776,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21883677',\n",
              "  'journalName': 'respirology (carlton, vic.)',\n",
              "  'name': 'atp-binding cassette b1 gene polymorphisms, mrna expression and chemosensitivity to paclitaxel in non-small cell lung cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21883677',\n",
              "  'updatedAt': 1612981461776,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21883677',\n",
              "  'uuid': 'ed372598-207d-4fc7-a930-7cf4fd24fe78',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:442',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981462192,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21642865',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21642865',\n",
              "  'updatedAt': 1612981462192,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21642865',\n",
              "  'uuid': '65bda5e4-b7b9-468c-b724-8d22c4f95719',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:443',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981462598,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21458988',\n",
              "  'journalName': 'european journal of cancer (oxford, england : 1990)',\n",
              "  'name': 'dna methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21458988',\n",
              "  'updatedAt': 1612981462598,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21458988',\n",
              "  'uuid': 'da6a9e0e-7d9b-44eb-8677-c206bb310edb',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:445',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981463456,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20826716',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'egfr gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20826716',\n",
              "  'updatedAt': 1612981463456,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20826716',\n",
              "  'uuid': 'acd508b2-5598-4ba4-8d08-c86bb592553c',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:446',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981464202,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20651371',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'cxcr4, a potential predictive marker for docetaxel sensitivity in gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20651371',\n",
              "  'updatedAt': 1612981464202,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20651371',\n",
              "  'uuid': '23d1b427-4f48-454e-aa44-4ef7ca7b1377',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:448',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981465910,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18593940',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'functional genomics identifies abcc3 as a mediator of taxane resistance in her2-amplified breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18593940',\n",
              "  'updatedAt': 1612981465910,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18593940',\n",
              "  'uuid': 'a2da443b-819b-45b9-a307-130e9b27db5b',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:449',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981466735,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18445659',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'mrp7/abcc10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18445659',\n",
              "  'updatedAt': 1612981466735,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18445659',\n",
              "  'uuid': 'c796ddce-8f85-4452-b5fc-0afde258830f',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:450',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981467533,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17088436',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17088436',\n",
              "  'updatedAt': 1612981467533,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17088436',\n",
              "  'uuid': 'd87050d9-e1bd-4003-acb7-6ee9157397cf',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:451',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981467961,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16707605',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'epidermal growth factor receptor messenger rna expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16707605',\n",
              "  'updatedAt': 1612981467961,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16707605',\n",
              "  'uuid': '1d68f835-eaeb-45ce-87f3-fc36fd3b5b86',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:452',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981468298,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16404430',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'pten activity could be a predictive marker of trastuzumab efficacy in the treatment of erbb2-overexpressing breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16404430',\n",
              "  'updatedAt': 1612981468298,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16404430',\n",
              "  'uuid': 'c2645fde-7fb2-4f60-a223-d409768fbe90',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:453',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981469081,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26789870',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'cdx2 as a prognostic biomarker in stage ii and stage iii colon cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26789870',\n",
              "  'updatedAt': 1612981469081,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26789870',\n",
              "  'uuid': 'e31d716a-0e7f-4311-ae74-9971a17ea02a',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:455',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981471762,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26398480',\n",
              "  'journalName': 'oncology reports',\n",
              "  'name': 'oct4b1 promotes cell growth, migration and invasion suppressing sensitivity to οxaliplatin in colon cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26398480',\n",
              "  'updatedAt': 1612981471762,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26398480',\n",
              "  'uuid': '1e461d0e-25ca-41ce-bf10-976f37b20655',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:458',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981473171,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22418700',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'a phase ii study of afatinib (bibw 2992), an irreversible erbb family blocker, in patients with her2-positive metastatic breast cancer progressing after trastuzumab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22418700',\n",
              "  'updatedAt': 1612981473171,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22418700',\n",
              "  'uuid': 'bb981ee2-40c6-4523-ba68-20fb4d0201dc',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:459',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981473639,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26668065',\n",
              "  'journalName': 'targeted oncology',\n",
              "  'name': 'afatinib, an irreversible egfr family inhibitor, shows activity toward pancreatic cancer cells, alone and in combination with radiotherapy, independent of kras status.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26668065',\n",
              "  'updatedAt': 1612981473639,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26668065',\n",
              "  'uuid': 'f2766395-8424-4d0b-8d26-10fb33b82d20',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:460',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981474147,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24893891',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'azd9291, an irreversible egfr tki, overcomes t790m-mediated resistance to egfr inhibitors in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24893891',\n",
              "  'updatedAt': 1612981474147,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24893891',\n",
              "  'uuid': 'ae1445fb-426d-42a4-9616-eed1302666be',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:461',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981474569,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25939061',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'acquired egfr c797s mutation mediates resistance to azd9291 in non-small cell lung cancer harboring egfr t790m.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25939061',\n",
              "  'updatedAt': 1612981474569,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25939061',\n",
              "  'uuid': 'c4597c65-d711-4b3c-8bc7-9c14a7eaa10f',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:462',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981475047,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25923549',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'azd9291 in egfr inhibitor-resistant non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25923549',\n",
              "  'updatedAt': 1612981475047,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25923549',\n",
              "  'uuid': 'c516c692-54d4-460b-8dd6-1eaca32f73ad',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:464',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981475815,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26515464',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'in vitro modeling to determine mutation specificity of egfr tyrosine kinase inhibitors against clinically relevant egfr mutants in non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26515464',\n",
              "  'updatedAt': 1612981475815,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26515464',\n",
              "  'uuid': '805edfed-1c22-41b0-b92e-0e11c77fe5da',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:466',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981477169,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26807188',\n",
              "  'journalName': 'american journal of translational research',\n",
              "  'name': 'low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26807188',\n",
              "  'updatedAt': 1612981477169,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26807188',\n",
              "  'uuid': 'a2225fa1-0ab6-4001-a934-b96ac767daaf',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:467',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981477646,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26771872',\n",
              "  'journalName': 'european journal of cancer (oxford, england : 1990)',\n",
              "  'name': 'predictive relevance of pd-l1 expression combined with cd8+ til density in stage iii non-small cell lung cancer patients receiving concurrent chemoradiotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26771872',\n",
              "  'updatedAt': 1612981477646,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26771872',\n",
              "  'uuid': '278186d3-06fd-4a45-b446-078aa342f8f6',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:469',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981478785,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26716414',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'ntrk1 fusions for the therapeutic intervention of korean patients with colon cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26716414',\n",
              "  'updatedAt': 1612981478785,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26716414',\n",
              "  'uuid': 'e8f7f2e0-e583-415b-9bab-1c725af378f2',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:470',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981479654,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24439929',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung cancer harbouring egfr mutations (lux-lung 6): an open-label, randomised phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24439929',\n",
              "  'updatedAt': 1612981479654,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24439929',\n",
              "  'uuid': '3ef152a4-fcd1-4217-9cdd-d03234ca46df',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:472',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981480818,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26838030',\n",
              "  'journalName': 'tumour biology : the journal of the international society for oncodevelopmental biology and medicine',\n",
              "  'name': 'complete loss of stag2 expression is an indicator of good prognosis in patients with bladder cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26838030',\n",
              "  'updatedAt': 1612981480818,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26838030',\n",
              "  'uuid': 'd2493f2c-82e7-46e7-a241-515c002512da',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:476',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981483407,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25199829',\n",
              "  'journalName': 'cell reports',\n",
              "  'name': 'raf suppression synergizes with mek inhibition in kras mutant cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25199829',\n",
              "  'updatedAt': 1612981483407,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25199829',\n",
              "  'uuid': '524e6baa-768d-4aad-82e3-0381345c33a2',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:477',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981483870,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24685132',\n",
              "  'journalName': 'cell reports',\n",
              "  'name': 'intrinsic resistance to mek inhibition in kras mutant lung and colon cancer through transcriptional induction of erbb3.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24685132',\n",
              "  'updatedAt': 1612981483870,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24685132',\n",
              "  'uuid': '48fd35f2-b7c5-4a6a-a5f4-1480fbfacd28',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:478',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981484370,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18946061',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'k-ras mutations and benefit from cetuximab in advanced colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18946061',\n",
              "  'updatedAt': 1612981484370,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18946061',\n",
              "  'uuid': '707cc87a-ba83-45b9-9331-805ed38330c3',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:479',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981484806,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23200175',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'selumetinib plus docetaxel for kras-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23200175',\n",
              "  'updatedAt': 1612981484806,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23200175',\n",
              "  'uuid': '61ba5cef-e3a8-443d-8a16-cdc7a32a2411',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:480',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981485213,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23434733',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'multicenter phase i trial of the mitogen-activated protein kinase 1/2 inhibitor bay 86-9766 in patients with advanced cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23434733',\n",
              "  'updatedAt': 1612981485213,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23434733',\n",
              "  'uuid': 'defdabdc-e659-456e-b1a6-1f8209b0e356',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:482',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981486325,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21985784',\n",
              "  'journalName': 'the journal of clinical investigation',\n",
              "  'name': 'receptor tyrosine kinases exert dominant control over pi3k signaling in human kras mutant colorectal cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21985784',\n",
              "  'updatedAt': 1612981486325,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21985784',\n",
              "  'uuid': '6eb80e0a-bd82-4ac9-bc4b-da195b5a858a',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:484',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981487282,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16091755',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'combining lapatinib (gw572016), a small molecule inhibitor of erbb1 and erbb2 tyrosine kinases, with therapeutic anti-erbb2 antibodies enhances apoptosis of erbb2-overexpressing breast cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16091755',\n",
              "  'updatedAt': 1612981487282,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16091755',\n",
              "  'uuid': 'dd185764-9df1-408d-a6a6-f8402c182a08',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:485',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981487747,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22493419',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase ii cher-lob study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22493419',\n",
              "  'updatedAt': 1612981487747,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22493419',\n",
              "  'uuid': 'ee44572b-bd65-48eb-b908-1f20fc86a23c',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:486',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981488232,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20124187',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized study of lapatinib alone or in combination with trastuzumab in women with erbb2-positive, trastuzumab-refractory metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20124187',\n",
              "  'updatedAt': 1612981488232,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20124187',\n",
              "  'uuid': '12809b0b-8009-4a1a-ab18-a85bb9e8c7da',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:487',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981488678,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26596672',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': \"afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for her2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (lux-breast 3): a randomised, open-label, multicentre, phase 2 trial.\",\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26596672',\n",
              "  'updatedAt': 1612981488678,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26596672',\n",
              "  'uuid': '8b50f9be-aab2-4c20-bda9-a7319db2c399',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:488',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981489152,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25370464',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'phase i study to assess the combination of afatinib with trastuzumab in patients with advanced or metastatic her2-positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25370464',\n",
              "  'updatedAt': 1612981489152,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25370464',\n",
              "  'uuid': '6a6b4c6d-cb4e-4789-b005-d9a5ba096d94',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:492',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981490862,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24162815',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'oncogenic and drug-sensitive ntrk1 rearrangements in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24162815',\n",
              "  'updatedAt': 1612981490862,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24162815',\n",
              "  'uuid': '550e5675-32ea-4bbc-9ca7-4cbfdc20e129',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:493',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981491357,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26867820',\n",
              "  'journalName': 'jama oncology',\n",
              "  'name': 'combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with ras wild-type advanced colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26867820',\n",
              "  'updatedAt': 1612981491357,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26867820',\n",
              "  'uuid': '099df82d-b093-48c8-8bd7-5561b6887244',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:494',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981491942,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20728210',\n",
              "  'journalName': 'lancet (london, england)',\n",
              "  'name': 'trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20728210',\n",
              "  'updatedAt': 1612981491942,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20728210',\n",
              "  'uuid': '4467daa6-95f0-46cc-878d-a99f66bc72c3',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:495',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981492366,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24868024',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of her2-amplified advanced gastric cancer in asian populations: tytan--a randomized, phase iii study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24868024',\n",
              "  'updatedAt': 1612981492366,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24868024',\n",
              "  'uuid': '67a39b6d-ce6c-424d-b886-5e4ccf686a09',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:501',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981496737,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20363910',\n",
              "  'journalName': 'the american journal of pathology',\n",
              "  'name': 'hif1a overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20363910',\n",
              "  'updatedAt': 1612981496737,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20363910',\n",
              "  'uuid': 'd14b581a-c83b-4f77-b55f-5af04b2fdb8f',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:503',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981497582,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16341243',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'hypoxia-inducible factor determines sensitivity to inhibitors of mtor in kidney cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16341243',\n",
              "  'updatedAt': 1612981497582,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16341243',\n",
              "  'uuid': '6fead3bd-92f9-4a62-b5c5-17f4883f05d7',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:506',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981499143,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26598547',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'lung cancer patients with her2 mutations treated with chemotherapy and her2-targeted drugs: results from the european euher2 cohort.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26598547',\n",
              "  'updatedAt': 1612981499143,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26598547',\n",
              "  'uuid': 'e6f9abc6-6f3b-4669-8390-18f03618c395',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:507',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981500070,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25601188',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'favorable response to trastuzumab plus irinotecan combination therapy in two patients with her2-positive relapsed small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25601188',\n",
              "  'updatedAt': 1612981500070,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25601188',\n",
              "  'uuid': '684049cb-b501-4d56-9a19-6049f7fe1a20',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:508',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981501454,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26559459',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'her2 insertion yvma mutant lung cancer: long natural history and response to afatinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26559459',\n",
              "  'updatedAt': 1612981501454,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26559459',\n",
              "  'uuid': 'c36051ed-da32-4a44-a98e-a947bcf30e95',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:510',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981502858,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26894977',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'psmb8 and pbk as potential gastric cancer subtype-specific biomarkers associated with prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26894977',\n",
              "  'updatedAt': 1612981502858,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26894977',\n",
              "  'uuid': '335f3bce-e36c-4e0a-8820-b00b072542b2',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:513',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981505157,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26888827',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'the first-in-class anti-egfr antibody mixture sym004 overcomes cetuximab resistance mediated by egfr extracellular domain mutations in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26888827',\n",
              "  'updatedAt': 1612981505157,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26888827',\n",
              "  'uuid': 'b54d9404-2ede-4d7b-88ba-f60f30d27587',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:515',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981508150,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26893365',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'a genetic variation in microrna target site of ets2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26893365',\n",
              "  'updatedAt': 1612981508150,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26893365',\n",
              "  'uuid': '3c593284-819f-491d-9ae3-db59d738e847',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:516',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981508956,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26892177',\n",
              "  'journalName': 'international journal of oncology',\n",
              "  'name': 'downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26892177',\n",
              "  'updatedAt': 1612981508956,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26892177',\n",
              "  'uuid': 'f71f8bd4-c4e5-4518-a902-66b5d81bb515',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:517',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981509774,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26891277',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26891277',\n",
              "  'updatedAt': 1612981509774,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26891277',\n",
              "  'uuid': '27cf428d-fd1c-463f-b1dc-49ac99b06185',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:524',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981515902,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22906996',\n",
              "  'journalName': 'oncology',\n",
              "  'name': 'abcb1, fcgr2a, and fcgr3a polymorphisms in patients with her2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22906996',\n",
              "  'updatedAt': 1612981515902,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22906996',\n",
              "  'uuid': 'f83f98a7-1095-42d4-a4cd-467acebf0af3',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:525',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981516465,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25693012',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'pertuzumab, trastuzumab, and docetaxel in her2-positive metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25693012',\n",
              "  'updatedAt': 1612981516465,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25693012',\n",
              "  'uuid': 'f066d7df-d4b2-4f18-8c2f-c4362e63942a',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:526',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981517696,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24989892',\n",
              "  'journalName': 'cancer immunology research',\n",
              "  'name': 'association studies of fcγ receptor polymorphisms with outcome in her2+ breast cancer patients treated with trastuzumab in ncctg (alliance) trial n9831.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24989892',\n",
              "  'updatedAt': 1612981517696,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24989892',\n",
              "  'uuid': 'b2e38708-772c-41dc-bbdc-fd4f1b7dd8d7',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:532',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981520670,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26729443',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'met exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent met genomic amplification and c-met overexpression.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26729443',\n",
              "  'updatedAt': 1612981520670,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26729443',\n",
              "  'uuid': '7ae48507-122d-4812-b6bc-f196ae49d415',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:533',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981521150,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15746676',\n",
              "  'journalName': 'american journal of obstetrics and gynecology',\n",
              "  'name': 'racial differences in the overexpression of epidermal growth factor type ii receptor (her2/neu): a major prognostic indicator in uterine serous papillary cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15746676',\n",
              "  'updatedAt': 1612981521150,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15746676',\n",
              "  'uuid': '8358df00-299e-42fd-ab03-6dd77a81d2f8',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:537',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981523568,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25351743',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'cabozantinib overcomes crizotinib resistance in ros1 fusion-positive cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25351743',\n",
              "  'updatedAt': 1612981523568,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25351743',\n",
              "  'uuid': '9b7537b3-98c4-4c0e-b3ff-fad11e186b6e',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:540',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981526060,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20179196',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'fgfr1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20179196',\n",
              "  'updatedAt': 1612981526060,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20179196',\n",
              "  'uuid': 'd11e568e-6e05-4b38-9c6c-2798deafe1e3',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:542',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981527767,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25295501',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'response and acquired resistance to everolimus in anaplastic thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25295501',\n",
              "  'updatedAt': 1612981527767,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25295501',\n",
              "  'uuid': '0309aa1c-8d05-4664-8ddd-cee85546f305',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:545',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981529181,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26874901',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'neratinib after trastuzumab-based adjuvant therapy in patients with her2-positive breast cancer (extenet): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26874901',\n",
              "  'updatedAt': 1612981529181,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26874901',\n",
              "  'uuid': '69512545-7a9f-4665-9fb7-0258f42550b1',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:548',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981531255,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26894380',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'cip2a down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26894380',\n",
              "  'updatedAt': 1612981531255,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26894380',\n",
              "  'uuid': '52fbb4b7-1278-44e2-87c0-de490c73cda3',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:549',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981532188,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26442524',\n",
              "  'journalName': 'carcinogenesis',\n",
              "  'name': 'microrna-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting birc5.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26442524',\n",
              "  'updatedAt': 1612981532188,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26442524',\n",
              "  'uuid': '1cee9962-32a4-49f9-90ed-971975ca2322',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:551',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981533018,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16236737',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'trastuzumab after adjuvant chemotherapy in her2-positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16236737',\n",
              "  'updatedAt': 1612981533018,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16236737',\n",
              "  'uuid': '7d54f469-ecaa-4fc2-a366-16176d6807e8',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:552',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981533899,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24137399',\n",
              "  'journalName': 'oncology letters',\n",
              "  'name': 'a novel <i>brca1</i> mutation in a patient with breast and ovarian cancer: a case report.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24137399',\n",
              "  'updatedAt': 1612981533899,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24137399',\n",
              "  'uuid': '74c482b5-c623-42d6-84e0-58f77ffe5605',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:553',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981534413,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25789838',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'rapid response to trastuzumab emtansine in a patient with her2-driven lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25789838',\n",
              "  'updatedAt': 1612981534413,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25789838',\n",
              "  'uuid': '81a973c4-245b-4ec2-b3ad-044144c8da7c',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:555',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981535384,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19661358',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'a novel k-ras mutation in colorectal cancer. a case report and literature review.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19661358',\n",
              "  'updatedAt': 1612981535384,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19661358',\n",
              "  'uuid': '2b304ce2-2eec-4542-a562-0c1b1d358784',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:556',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981535760,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17192538',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'lapatinib plus capecitabine for her2-positive advanced breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17192538',\n",
              "  'updatedAt': 1612981535760,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17192538',\n",
              "  'uuid': '59e0f645-afb0-4510-b700-266b74a82125',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:557',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981536189,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19289619',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19289619',\n",
              "  'updatedAt': 1612981536189,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19289619',\n",
              "  'uuid': 'dd6b2d7a-8fe4-4301-89a6-b030a6091068',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:560',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981540552,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23828442',\n",
              "  'journalName': 'medical oncology (northwood, london, england)',\n",
              "  'name': 'kras as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23828442',\n",
              "  'updatedAt': 1612981540552,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23828442',\n",
              "  'uuid': 'c9a69320-fc17-4e20-9066-1af0c5627034',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:561',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981541018,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23934108',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'mechanism of mek inhibition determines efficacy in mutant kras- versus braf-driven cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23934108',\n",
              "  'updatedAt': 1612981541018,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23934108',\n",
              "  'uuid': '58c4add1-fae4-4639-97f5-0802958e1dcb',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:562',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981541472,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26125448',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'impact of kras codon subtypes from a randomised phase ii trial of selumetinib plus docetaxel in kras mutant advanced non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26125448',\n",
              "  'updatedAt': 1612981541472,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26125448',\n",
              "  'uuid': 'a0eb1fe8-1b58-423e-b1aa-43dc885ae359',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:563',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981542015,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22425996',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'a murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22425996',\n",
              "  'updatedAt': 1612981542015,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22425996',\n",
              "  'uuid': 'd791a6d8-0c7b-4654-8b05-695b5fa0f18f',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:564',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981542596,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26899019',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'prognostic and predictive effect of tp53 mutations in patients with non-small cell lung cancer from adjuvant cisplatin-based therapy randomized trials: a lace-bio pooled analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26899019',\n",
              "  'updatedAt': 1612981542596,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26899019',\n",
              "  'uuid': '0e16de76-4590-4172-a892-0fecdc3d6327',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:566',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981545066,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24793816',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': \"trastuzumab emtansine versus treatment of physician's choice for pretreated her2-positive advanced breast cancer (th3resa): a randomised, open-label, phase 3 trial.\",\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24793816',\n",
              "  'updatedAt': 1612981545066,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24793816',\n",
              "  'uuid': 'aef8f317-cae1-4069-9f0d-047373f26128',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:567',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981546344,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23020162',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'trastuzumab emtansine for her2-positive advanced breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23020162',\n",
              "  'updatedAt': 1612981546344,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23020162',\n",
              "  'uuid': '4f3caecc-6105-40f4-8e9c-d0e53a07e10b',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:569',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981548016,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26943774',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26943774',\n",
              "  'updatedAt': 1612981548016,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26943774',\n",
              "  'uuid': '119f679e-e85b-49e5-9e72-52e07ff3449d',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:573',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981550322,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16906227',\n",
              "  'journalName': 'the journal of clinical investigation',\n",
              "  'name': 'allelic dilution obscures detection of a biologically significant resistance mutation in egfr-amplified lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16906227',\n",
              "  'updatedAt': 1612981550322,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16906227',\n",
              "  'uuid': '50bc9a77-8c62-4dbf-a61b-ee4da5ec0a48',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:574',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981550748,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26970723',\n",
              "  'journalName': 'lancet (london, england)',\n",
              "  'name': 'atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (poplar): a multicentre, open-label, phase 2 randomised controlled trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26970723',\n",
              "  'updatedAt': 1612981550748,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26970723',\n",
              "  'uuid': '20f61975-3720-4e4d-846d-7da1f7e4e18a',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:575',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981551282,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26243863',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'her2 activating mutations are targets for colorectal cancer treatment.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26243863',\n",
              "  'updatedAt': 1612981551282,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26243863',\n",
              "  'uuid': 'fecd6007-f94e-40f2-b110-e0d84d558b0a',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:576',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981551682,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26973324',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'activity and safety of ceritinib in patients with alk-rearranged non-small-cell lung cancer (ascend-1): updated results from the multicentre, open-label, phase 1 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26973324',\n",
              "  'updatedAt': 1612981551682,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26973324',\n",
              "  'uuid': '43c6ef3e-d4a5-4278-9524-1f283650ceeb',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:577',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981552898,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26371285',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'phase ii study of single-agent cetuximab in kras g13d mutant metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26371285',\n",
              "  'updatedAt': 1612981552898,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26371285',\n",
              "  'uuid': 'fd58ee77-43c3-4234-a032-6deba60501a8',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:578',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981553300,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26812186',\n",
              "  'journalName': 'european journal of cancer (oxford, england : 1990)',\n",
              "  'name': 'meta-analysis comparing the efficacy of anti-egfr monoclonal antibody therapy between kras g13d and other kras mutant metastatic colorectal cancer tumours.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26812186',\n",
              "  'updatedAt': 1612981553300,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26812186',\n",
              "  'uuid': '2f471dca-0b13-458d-b7d9-532471810133',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:579',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981554242,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26709701',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'kras genotype correlates with proteasome inhibitor ixazomib activity in preclinical in vivo models of colon and non-small cell lung cancer: potential role of tumor metabolism.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26709701',\n",
              "  'updatedAt': 1612981554242,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26709701',\n",
              "  'uuid': '1262c3e9-0fc7-45d2-94cc-a8e7d1686fb7',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:580',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981555869,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26662432',\n",
              "  'journalName': 'genetics and molecular research : gmr',\n",
              "  'name': 'reduced mirna-218 expression in pancreatic cancer patients as a predictor of poor prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26662432',\n",
              "  'updatedAt': 1612981555869,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26662432',\n",
              "  'uuid': '5975b31c-ee7c-4864-8c5d-f74652a2a24b',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:581',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981556372,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20979469',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20979469',\n",
              "  'updatedAt': 1612981556372,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20979469',\n",
              "  'uuid': '685e6785-7e8c-40ff-adfe-6ac2f673442b',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:582',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981556895,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27004155',\n",
              "  'journalName': 'cureus',\n",
              "  'name': 'kdr mutation as a novel predictive biomarker of exceptional response to regorafenib in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27004155',\n",
              "  'updatedAt': 1612981556895,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27004155',\n",
              "  'uuid': '04d8a2cd-b1db-4537-bc65-027b1f3f226e',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:583',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981557342,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23724913',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'crizotinib versus chemotherapy in advanced alk-positive lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23724913',\n",
              "  'updatedAt': 1612981557342,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23724913',\n",
              "  'uuid': '9d14a7b8-c7fd-4955-a941-c9c4ae436831',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:584',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981557753,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25470694',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'first-line crizotinib versus chemotherapy in alk-positive lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25470694',\n",
              "  'updatedAt': 1612981557753,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25470694',\n",
              "  'uuid': '4b81ec87-96a7-42ea-9734-3a966a57a41b',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:586',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981558654,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27022118',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'intracranial efficacy of crizotinib versus chemotherapy in patients with advanced alk-positive non-small-cell lung cancer: results from profile 1014.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27022118',\n",
              "  'updatedAt': 1612981558654,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27022118',\n",
              "  'uuid': 'aff1b74f-6e62-4665-8fe6-b346d5007b75',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:587',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981559071,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20940188',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'activity of ipi-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20940188',\n",
              "  'updatedAt': 1612981559071,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20940188',\n",
              "  'uuid': 'f4cec9a4-97df-4a15-bc0b-69ef98429043',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:590',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981560454,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27037411',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'nanofluidic digital pcr and extended genotyping of ras and braf for improved selection of metastatic colorectal cancer patients for anti-egfr therapies.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27037411',\n",
              "  'updatedAt': 1612981560454,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27037411',\n",
              "  'uuid': 'b37e3b52-6f7c-409b-b7b1-48103c9742ec',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:594',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981563975,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22948721',\n",
              "  'journalName': 'oncology',\n",
              "  'name': 'impact of the specific mutation in kras codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22948721',\n",
              "  'updatedAt': 1612981563975,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22948721',\n",
              "  'uuid': 'bc56d420-a952-470f-ad1f-f75e36086d1f',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:595',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981564395,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23313110',\n",
              "  'journalName': 'cancer genetics',\n",
              "  'name': 'the dominant role of g12c over other kras mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23313110',\n",
              "  'updatedAt': 1612981564395,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23313110',\n",
              "  'uuid': '87349768-9eab-48c2-b379-953a177c4ec2',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:597',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981565222,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21862683',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'impact of kras mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21862683',\n",
              "  'updatedAt': 1612981565222,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21862683',\n",
              "  'uuid': '9cd1147c-7a77-476a-a85f-0c1e6a041886',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:606',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981569310,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25504439',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'metformin and trametinib have synergistic effects on cell viability and tumor growth in nras mutant cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25504439',\n",
              "  'updatedAt': 1612981569310,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25504439',\n",
              "  'uuid': 'edf0828b-f947-4034-963d-0de7c7b27e14',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:607',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981569716,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23582881',\n",
              "  'journalName': 'european urology',\n",
              "  'name': 'phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (sakk 08/08).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23582881',\n",
              "  'updatedAt': 1612981569716,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23582881',\n",
              "  'uuid': 'a7670587-f972-4e55-8f39-eed37a466f09',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:610',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981571260,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26574622',\n",
              "  'journalName': 'cancer biology & therapy',\n",
              "  'name': 'antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating fgfr2 mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26574622',\n",
              "  'updatedAt': 1612981571260,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26574622',\n",
              "  'uuid': '83c42f06-8736-4e6e-b194-3bbbb8f0d9c2',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:611',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981571747,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24670165',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'ceritinib in alk-rearranged non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24670165',\n",
              "  'updatedAt': 1612981571747,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24670165',\n",
              "  'uuid': '276f3523-332c-4106-97bb-1296e861efeb',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:618',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981576643,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26917690',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'clinical activity of ceritinib in ros1-rearranged non-small cell lung cancer: bench to bedside report.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26917690',\n",
              "  'updatedAt': 1612981576643,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26917690',\n",
              "  'uuid': 'f2a14599-baf8-4e68-bfc0-38810b928b03',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:621',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981578204,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25688157',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'molecular changes associated with acquired resistance to crizotinib in ros1-rearranged non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25688157',\n",
              "  'updatedAt': 1612981578204,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25688157',\n",
              "  'uuid': '0d9662e7-41a4-4ad9-aecc-c808b7395381',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:627',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981582456,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23639470',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'ch5424802 (ro5424802) for patients with alk-rearranged advanced non-small-cell lung cancer (af-001jp study): a single-arm, open-label, phase 1-2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23639470',\n",
              "  'updatedAt': 1612981582456,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23639470',\n",
              "  'uuid': '49a4446b-2fde-40c5-af61-41cd4ab5bfa8',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:628',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981582816,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26938871',\n",
              "  'journalName': 'anti-cancer drugs',\n",
              "  'name': 'rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26938871',\n",
              "  'updatedAt': 1612981582816,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26938871',\n",
              "  'uuid': '9583eb53-f997-43ed-bc9d-75a3c9ff3776',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:629',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981583215,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27086918',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27086918',\n",
              "  'updatedAt': 1612981583215,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27086918',\n",
              "  'uuid': 'e74352ee-ae8b-4ef7-9c87-58ef122c5f09',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:630',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981583821,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27009855',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'pd-l1 is an independent prognostic predictor in gastric cancer of western patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27009855',\n",
              "  'updatedAt': 1612981583821,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27009855',\n",
              "  'uuid': 'd4096c23-08b3-4c5a-82c9-d828ad9c45f9',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:633',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981585721,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25153538',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant alk-rearranged non-small-cell lung cancer (af-002jg): results from the dose-finding portion of a phase 1/2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25153538',\n",
              "  'updatedAt': 1612981585721,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25153538',\n",
              "  'uuid': '32944632-01a7-4440-98ee-28ac530f59f5',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:634',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981586516,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22426421',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'a common bim deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22426421',\n",
              "  'updatedAt': 1612981586516,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22426421',\n",
              "  'uuid': 'eff8cbc0-ba00-4b8f-9d8c-5ed3c4dd6423',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:635',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981586897,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26708155',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'alectinib in alk-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26708155',\n",
              "  'updatedAt': 1612981586897,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26708155',\n",
              "  'uuid': '79a82ce0-2c98-4b20-9d1f-8990b78da772',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:640',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981590076,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27091708',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from bolero-1 and bolero-3.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27091708',\n",
              "  'updatedAt': 1612981590076,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27091708',\n",
              "  'uuid': '3cfb9b7b-fdd4-4f5a-8268-33c9c7e0b73b',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:641',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981590653,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22983505',\n",
              "  'journalName': 'journal of gastroenterology',\n",
              "  'name': 'prognostic value of k-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22983505',\n",
              "  'updatedAt': 1612981590653,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22983505',\n",
              "  'uuid': '484b7407-a9ab-4a1c-89c3-9c307b7b46ef',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:643',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981591426,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24296758',\n",
              "  'journalName': 'molecular cancer research : mcr',\n",
              "  'name': 'ros1 and alk fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24296758',\n",
              "  'updatedAt': 1612981591426,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24296758',\n",
              "  'uuid': '794d0fcd-e572-42f7-91f8-a5b9561e7f45',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:644',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981592321,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21135251',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'personalizing cancer treatment in the age of global genomic analyses: palb2 gene mutations and the response to dna damaging agents in pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21135251',\n",
              "  'updatedAt': 1612981592321,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21135251',\n",
              "  'uuid': '5ac0fea3-ac33-46fb-8128-2dfb6e976fbd',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:649',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981597121,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22619677',\n",
              "  'journalName': 'journal of oncology',\n",
              "  'name': 'altered p16(ink4) and rb1 expressions are associated with poor prognosis in patients with nonsmall cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22619677',\n",
              "  'updatedAt': 1612981597121,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22619677',\n",
              "  'uuid': '79b522db-cc17-4918-899c-3d305b6e76c5',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:650',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981597948,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24748501',\n",
              "  'journalName': 'gastric cancer : official journal of the international gastric cancer association and the japanese gastric cancer association',\n",
              "  'name': 'predictive value of chfr and mlh1 methylation in human gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24748501',\n",
              "  'updatedAt': 1612981597948,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24748501',\n",
              "  'uuid': 'f9988ac1-70dd-4b4a-872f-00eabde74a7d',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:651',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981598724,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24297342',\n",
              "  'journalName': 'international journal of oncology',\n",
              "  'name': 'shp2 promotes laryngeal cancer growth through the ras/raf/mek/erk pathway and serves as a prognostic indicator for laryngeal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24297342',\n",
              "  'updatedAt': 1612981598724,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24297342',\n",
              "  'uuid': '00c232f5-e244-4bc6-b2aa-b051b8f5c695',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:654',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981600550,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24631838',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'a diverse array of cancer-associated mtor mutations are hyperactivating and can predict rapamycin sensitivity.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24631838',\n",
              "  'updatedAt': 1612981600550,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24631838',\n",
              "  'uuid': '4d70ad63-71f2-4829-9c56-6377c0eee287',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:656',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981604354,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27177629',\n",
              "  'journalName': 'journal of cancer research and clinical oncology',\n",
              "  'name': 'feasibility of novel ppp1r15a and proposed anxa11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27177629',\n",
              "  'updatedAt': 1612981604354,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27177629',\n",
              "  'uuid': '88c01a9e-a7f7-4d36-b237-428c6d2da242',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:657',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981604906,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25322874',\n",
              "  'journalName': 'cancer chemotherapy and pharmacology',\n",
              "  'name': 'phase ii study of selumetinib (azd6244, arry-142886) plus irinotecan as second-line therapy in patients with k-ras mutated colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25322874',\n",
              "  'updatedAt': 1612981604906,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25322874',\n",
              "  'uuid': '6200d3e6-993a-4d83-bd0c-7376378d8f4f',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:660',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981606318,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19737969',\n",
              "  'journalName': 'molecular cancer research : mcr',\n",
              "  'name': 'exon array profiling detects eml4-alk fusion in breast, colorectal, and non-small cell lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19737969',\n",
              "  'updatedAt': 1612981606318,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19737969',\n",
              "  'uuid': '87dd0362-3f2a-4070-9bd7-f04bb98fc955',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:663',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981607738,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24675041',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'the alk inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24675041',\n",
              "  'updatedAt': 1612981607738,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24675041',\n",
              "  'uuid': 'f8730648-1099-4aa9-aa71-84da6ff65021',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:665',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981609354,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23619167',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'frequent mutation of the pi3k pathway in head and neck cancer defines predictive biomarkers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23619167',\n",
              "  'updatedAt': 1612981609354,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23619167',\n",
              "  'uuid': 'c474c640-cfed-43a4-a567-eaab785fb940',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:667',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981610327,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20368568',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii clinical trial of sorafenib in metastatic medullary thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20368568',\n",
              "  'updatedAt': 1612981610327,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20368568',\n",
              "  'uuid': '8275382a-b628-4cd5-948d-16d3ccfcedfb',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:674',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981613716,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21278246',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'expression of p16 and retinoblastoma determines response to cdk4/6 inhibition in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21278246',\n",
              "  'updatedAt': 1612981613716,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21278246',\n",
              "  'uuid': '2a53be46-7a28-4a70-a11a-7ba7478ddeb8',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:678',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981615812,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17936563',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'a functional genetic approach identifies the pi3k pathway as a major determinant of trastuzumab resistance in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17936563',\n",
              "  'updatedAt': 1612981615812,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17936563',\n",
              "  'uuid': '5110fd1d-a71d-4c91-ae12-335f29b5a5b1',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:679',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981616258,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20813970',\n",
              "  'journalName': 'the american journal of pathology',\n",
              "  'name': 'pten, pik3ca, p-akt, and p-p70s6k status: association with trastuzumab response and survival in patients with her2-positive metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20813970',\n",
              "  'updatedAt': 1612981616258,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20813970',\n",
              "  'uuid': 'f5b5ba7b-56db-4774-af54-117c1866700a',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:682',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981618875,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23470965',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'analysis of tumor specimens at the time of acquired resistance to egfr-tki therapy in 155 patients with egfr-mutant lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23470965',\n",
              "  'updatedAt': 1612981618875,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23470965',\n",
              "  'uuid': 'c4f70b98-b2e2-46ba-9a0c-911e13c32ccf',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:684',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981620096,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20522446',\n",
              "  'journalName': 'japanese journal of clinical oncology',\n",
              "  'name': 'good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 agc &gt; atc in exon 20 (s768i).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20522446',\n",
              "  'updatedAt': 1612981620096,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20522446',\n",
              "  'uuid': 'f1b16f54-0b92-4be5-a7e6-655f0aee2ec3',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:685',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981621073,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26181354',\n",
              "  'journalName': 'jama oncology',\n",
              "  'name': 'acquired resistance of egfr-mutant lung cancer to a t790m-specific egfr inhibitor: emergence of a third mutation (c797s) in the egfr tyrosine kinase domain.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26181354',\n",
              "  'updatedAt': 1612981621073,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26181354',\n",
              "  'uuid': 'ae48f054-27fd-4435-8df9-c76ac29d23ba',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:688',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981622523,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25550549',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'in vitro anticancer activity of pi3k alpha selective inhibitor byl719 in head and neck cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25550549',\n",
              "  'updatedAt': 1612981622523,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25550549',\n",
              "  'uuid': 'aeb0c57a-baeb-4e34-85bd-670cdc1c9ef1',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:691',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981623806,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22281684',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'unresponsiveness of colon cancer to braf(v600e) inhibition through feedback activation of egfr.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22281684',\n",
              "  'updatedAt': 1612981623806,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22281684',\n",
              "  'uuid': '427cbe7f-de6a-4c38-bdf2-52c84c816ad2',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:695',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981625516,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19273710',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'dpc4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19273710',\n",
              "  'updatedAt': 1612981625516,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19273710',\n",
              "  'uuid': '7d652716-8138-4594-a35a-93c9d03ca049',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:697',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981626389,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26392102',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'combined braf and mek inhibition with dabrafenib and trametinib in braf v600-mutant colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26392102',\n",
              "  'updatedAt': 1612981626389,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26392102',\n",
              "  'uuid': 'bfd629b2-e556-4c4a-aa5f-732e369ddaee',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:698',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981627156,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21933749',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring alk gene rearrangement: a retrospective analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21933749',\n",
              "  'updatedAt': 1612981627156,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21933749',\n",
              "  'uuid': '73eaba6f-bda7-4eaf-ab4f-2890f8860d11',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:699',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981627985,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27028764',\n",
              "  'journalName': 'plos genetics',\n",
              "  'name': 'the mkk7 p.glu116lys rare variant serves as a predictor for lung cancer risk and prognosis in chinese.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27028764',\n",
              "  'updatedAt': 1612981627985,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27028764',\n",
              "  'uuid': 'b9ccdf61-a568-406f-802b-73ece636c4ab',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:706',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981631342,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23382472',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23382472',\n",
              "  'updatedAt': 1612981631342,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23382472',\n",
              "  'uuid': '6ee7aecf-71ad-4590-96ce-85684afb0ba9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:707',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981632807,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22149875',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22149875',\n",
              "  'updatedAt': 1612981632807,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22149875',\n",
              "  'uuid': '24156370-1069-4ff4-9a6d-1645a7c2cc02',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:708',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981633445,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22257673',\n",
              "  'journalName': 'lancet (london, england)',\n",
              "  'name': 'lapatinib with trastuzumab for her2-positive early breast cancer (neoaltto): a randomised, open-label, multicentre, phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22257673',\n",
              "  'updatedAt': 1612981633445,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22257673',\n",
              "  'uuid': '461b2f9b-22b0-4737-b849-b3285d9f6c70',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:709',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981634254,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26370156',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'rictor amplification defines a novel subset of patients with lung cancer who may benefit from treatment with mtorc1/2 inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26370156',\n",
              "  'updatedAt': 1612981634254,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26370156',\n",
              "  'uuid': '47818ea9-4e2b-4fd5-bdd8-dd7dc5f5b9c5',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:711',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981635968,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22215748',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'ros1 rearrangements define a unique molecular class of lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22215748',\n",
              "  'updatedAt': 1612981635968,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22215748',\n",
              "  'uuid': '50a4dafd-1646-4019-8de6-3c234c64c8af',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:718',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981640773,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18829560',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'nvp-bez235, a dual pi3k/mtor inhibitor, prevents pi3k signaling and inhibits the growth of cancer cells with activating pi3k mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18829560',\n",
              "  'updatedAt': 1612981640773,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18829560',\n",
              "  'uuid': 'b35954e3-c43e-4c27-8929-14545c652080',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:725',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981645706,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18390968',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase i pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor azd6244 (arry-142886) in patients with advanced cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18390968',\n",
              "  'updatedAt': 1612981645706,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18390968',\n",
              "  'uuid': '3d363dd8-e5f8-4e38-8a14-5eee2032f9f9',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:732',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981649926,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25393796',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'identification of a novel hip1-alk fusion variant in non-small-cell lung cancer (nsclc) and discovery of alk i1171 (i1171n/s) mutations in two alk-rearranged nsclc patients with resistance to alectinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25393796',\n",
              "  'updatedAt': 1612981649926,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25393796',\n",
              "  'uuid': '0f62b34d-a8a5-4764-ab1f-bac74d3ad2d5',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:735',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981651899,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15790433',\n",
              "  'journalName': 'gynecologic oncology',\n",
              "  'name': 'activation of pi3k/akt pathway by pten reduction and pik3ca mrna amplification contributes to cisplatin resistance in an ovarian cancer cell line.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15790433',\n",
              "  'updatedAt': 1612981651899,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15790433',\n",
              "  'uuid': 'f3bed1df-df85-4701-8086-634948b32462',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:736',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981652355,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15900596',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'akt phosphorylation associates with loh of pten and leads to chemoresistance for gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15900596',\n",
              "  'updatedAt': 1612981652355,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15900596',\n",
              "  'uuid': '5772c66d-0e19-4fcc-9b99-8b7393da60e4',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:739',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981654426,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24088382',\n",
              "  'journalName': 'journal of translational medicine',\n",
              "  'name': 'the akt inhibitor azd5363 is selectively active in pi3kca mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with pten loss to taxotere.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24088382',\n",
              "  'updatedAt': 1612981654426,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24088382',\n",
              "  'uuid': 'e16c7b2b-2de6-4fbd-ad52-c250fc40d617',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:745',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981657996,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22658127',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'safety, activity, and immune correlates of anti-pd-1 antibody in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22658127',\n",
              "  'updatedAt': 1612981657996,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22658127',\n",
              "  'uuid': '32e84ad2-413a-4149-90db-f86b4e1504f2',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:749',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981661029,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26000489',\n",
              "  'journalName': 'cell',\n",
              "  'name': 'integrative clinical genomics of advanced prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26000489',\n",
              "  'updatedAt': 1612981661029,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26000489',\n",
              "  'uuid': '7ce79283-c909-4d5c-a25d-b6762217537c',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:751',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981661992,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23569316',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'germline brca mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23569316',\n",
              "  'updatedAt': 1612981661992,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23569316',\n",
              "  'uuid': '7d4b8f1b-547b-4832-9f47-73da78f617d9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:752',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981662505,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24277854',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'targeting wnt-driven cancer through the inhibition of porcupine by lgk974.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24277854',\n",
              "  'updatedAt': 1612981662505,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24277854',\n",
              "  'uuid': 'ce94a875-8b97-494f-98f7-f7c145f64b7f',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:753',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981663595,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27252418',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'high cdk6 protects cells from fulvestrant-mediated apoptosis and is a predictor of resistance to fulvestrant in estrogen receptor-positive metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27252418',\n",
              "  'updatedAt': 1612981663595,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27252418',\n",
              "  'uuid': '9be5b5c7-6763-456d-90eb-e94db66d80eb',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:757',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981665770,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20473330',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'therapeutic cdk4/6 inhibition in breast cancer: key mechanisms of response and failure.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20473330',\n",
              "  'updatedAt': 1612981665770,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20473330',\n",
              "  'uuid': 'b191c16b-621c-4e81-b6b2-1b312ec37e6e',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:758',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981666542,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25524798',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, her2-negative, advanced breast cancer (paloma-1/trio-18): a randomised phase 2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25524798',\n",
              "  'updatedAt': 1612981666542,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25524798',\n",
              "  'uuid': 'd895e0ee-477c-4eaf-9918-55ac69c3cd45',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:761',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981668007,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27404270',\n",
              "  'journalName': 'oncology',\n",
              "  'name': 'colorectal cancer with braf d594g mutation is not associated with microsatellite instability or poor prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27404270',\n",
              "  'updatedAt': 1612981668007,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27404270',\n",
              "  'uuid': 'cea2c864-724f-4055-9f2c-775379b64b8d',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:764',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981669656,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19874578',\n",
              "  'journalName': 'breast cancer research : bcr',\n",
              "  'name': 'pd 0332991, a selective cyclin d kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19874578',\n",
              "  'updatedAt': 1612981669656,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19874578',\n",
              "  'uuid': 'a45720ba-5fdc-4967-8549-110801eebcb4',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:768',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981671425,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21716144',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'met tyrosine kinase inhibitor crizotinib (pf-02341066) shows differential antitumor effects in non-small cell lung cancer according to met alterations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21716144',\n",
              "  'updatedAt': 1612981671425,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21716144',\n",
              "  'uuid': 'f8cfad02-984a-4df1-9d54-543441fd3c81',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:771',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981674709,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18003960',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'cetuximab for the treatment of colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18003960',\n",
              "  'updatedAt': 1612981674709,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18003960',\n",
              "  'uuid': '96c230d5-d547-404d-b179-b1971e6810a5',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:772',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981675179,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26287849',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'vemurafenib in multiple nonmelanoma cancers with braf v600 mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26287849',\n",
              "  'updatedAt': 1612981675179,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26287849',\n",
              "  'uuid': '1862c14e-627a-4267-b6f3-736b679f5023',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:773',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981675621,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26466010',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'crizotinib versus chemotherapy in advanced alk-positive lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26466010',\n",
              "  'updatedAt': 1612981675621,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26466010',\n",
              "  'uuid': '1c871231-e5e6-49fe-8fd7-582e1682f228',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:779',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981678644,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27325282',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'met-driven resistance to dual egfr and braf blockade may be overcome by switching from egfr to met inhibition in braf-mutated colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27325282',\n",
              "  'updatedAt': 1612981678644,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27325282',\n",
              "  'uuid': '894ebce8-cc02-4e09-8f08-47aeacf8829a',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:781',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981679964,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27460442',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'vemurafenib in patients with braf(v600e)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27460442',\n",
              "  'updatedAt': 1612981679964,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27460442',\n",
              "  'uuid': 'ddd3ce1e-1b5b-4506-8db3-ac34223aee09',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:783',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981681169,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26341751',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'prognostic value of different cut-off levels of ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26341751',\n",
              "  'updatedAt': 1612981681169,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26341751',\n",
              "  'uuid': '0dc40cd3-e815-4cee-ad2d-6c7d0502a186',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:784',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981681605,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23329234',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'prognostic value of ki-67 for prostate cancer death in a conservatively managed cohort.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23329234',\n",
              "  'updatedAt': 1612981681605,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23329234',\n",
              "  'uuid': '21c715d6-a14f-4462-a0e6-9fe0f855997d',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:788',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981684594,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26787234',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26787234',\n",
              "  'updatedAt': 1612981684594,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26787234',\n",
              "  'uuid': '78ed7c65-4f0d-49e3-adc2-4dad775d3403',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:791',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981685910,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23658459',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'targeting fgfr with dovitinib (tki258): preclinical and clinical data in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23658459',\n",
              "  'updatedAt': 1612981685910,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23658459',\n",
              "  'uuid': '974d11e7-1439-4713-be81-4eac152a9c9a',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:793',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981687648,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21358673',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'pik3ca mutation, but not pten loss of function, determines the sensitivity of breast cancer cells to mtor inhibitory drugs.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21358673',\n",
              "  'updatedAt': 1612981687648,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21358673',\n",
              "  'uuid': '179f3552-ecf2-4202-8182-32924e57013c',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:794',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981688632,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23674493',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pi3k pathway dependencies in endometrioid endometrial cancer cell lines.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23674493',\n",
              "  'updatedAt': 1612981688632,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23674493',\n",
              "  'uuid': '2964c99a-d08e-49fe-839d-11712156fabc',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:795',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981689183,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21189378',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'mtor inhibitor treatment of pancreatic cancer in a patient with peutz-jeghers syndrome.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21189378',\n",
              "  'updatedAt': 1612981689183,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21189378',\n",
              "  'uuid': '6d5166ad-73e1-4d75-8902-39767fa24873',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:798',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981690486,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25982012',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'systemic and cns activity of the ret inhibitor vandetanib combined with the mtor inhibitor everolimus in kif5b-ret re-arranged non-small cell lung cancer with brain metastases.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25982012',\n",
              "  'updatedAt': 1612981690486,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25982012',\n",
              "  'uuid': '0c500d59-9219-4a7c-94a0-6bd54a062fbb',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:799',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981691046,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27445490',\n",
              "  'journalName': 'oncotargets and therapy',\n",
              "  'name': 'combined treatment with everolimus and fulvestrant reversed anti-her2 resistance in a patient with refractory advanced breast cancer: a case report.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27445490',\n",
              "  'updatedAt': 1612981691046,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27445490',\n",
              "  'uuid': '0bd9525e-9c97-43ee-a04a-ccdbaa26f78c',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:800',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981691535,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19706758',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'genetic alterations in the phosphoinositide 3-kinase/akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of akt and mammalian target of rapamycin.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19706758',\n",
              "  'updatedAt': 1612981691535,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19706758',\n",
              "  'uuid': '33dcd6a1-f531-419d-b54f-077296086c5b',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:802',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981692559,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27020857',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'early adaptation and acquired resistance to cdk4/6 inhibition in estrogen receptor-positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27020857',\n",
              "  'updatedAt': 1612981692559,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27020857',\n",
              "  'uuid': '2d383108-c9d0-414f-92e4-2151dcef33cb',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:803',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981693049,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24586741',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'fbxw7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mtor inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24586741',\n",
              "  'updatedAt': 1612981693049,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24586741',\n",
              "  'uuid': '51135386-51c7-40a8-9979-7b039614c5ae',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:805',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981694240,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27022066',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27022066',\n",
              "  'updatedAt': 1612981694240,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27022066',\n",
              "  'uuid': '416bfb73-45ee-45e6-9046-8b160e93d05a',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:807',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981698189,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26732495',\n",
              "  'journalName': 'clinical lung cancer',\n",
              "  'name': 'single nucleotide polymorphisms in cblb, a regulator of t-cell response, predict radiation pneumonitis and outcomes after definitive radiotherapy for non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26732495',\n",
              "  'updatedAt': 1612981698189,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26732495',\n",
              "  'uuid': 'be3aa0a2-dfc3-4ff5-8826-e7e656143691',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:812',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981701245,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12237773',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'smad4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12237773',\n",
              "  'updatedAt': 1612981701245,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12237773',\n",
              "  'uuid': '0ba194de-b969-4701-a37d-2e8f6ed06b82',\n",
              "  'year': 2002},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:822',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981706966,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27153245',\n",
              "  'journalName': 'journal of cellular biochemistry',\n",
              "  'name': 'growth arrest-specific 6 (gas6) promotes prostate cancer survival by g<sub>1</sub> arrest/s phase delay and inhibition of apoptosis during chemotherapy in bone marrow.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27153245',\n",
              "  'updatedAt': 1612981706966,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27153245',\n",
              "  'uuid': '53ea9d13-e523-42f8-a7ab-ad3f0221d3af',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:824',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981708244,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25544710',\n",
              "  'journalName': 'tumour biology : the journal of the international society for oncodevelopmental biology and medicine',\n",
              "  'name': 'overexpression of etv4 is associated with poor prognosis in prostate cancer: involvement of upa/upar and mmps.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25544710',\n",
              "  'updatedAt': 1612981708244,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25544710',\n",
              "  'uuid': '78781716-068e-4ddf-91f0-a860f03d9a42',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:826',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981709521,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26324360',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26324360',\n",
              "  'updatedAt': 1612981709521,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26324360',\n",
              "  'uuid': '0c3d53e5-3459-476a-80ad-07233bab6418',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:829',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981712583,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18509184',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'specific egfr mutations predict treatment outcome of stage iiib/iv patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18509184',\n",
              "  'updatedAt': 1612981712583,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18509184',\n",
              "  'uuid': '8edbe735-e35e-40a2-91e0-7d5e025009b0',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:833',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981714697,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26740259',\n",
              "  'journalName': 'gynecologic oncology',\n",
              "  'name': 'brca1/2 mutations associated with progression-free survival in ovarian cancer patients in the ago-ovar 16 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26740259',\n",
              "  'updatedAt': 1612981714697,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26740259',\n",
              "  'uuid': '0c91b1ba-579c-4d3f-8e53-41b43c10f2cf',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:834',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981715169,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25218906',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25218906',\n",
              "  'updatedAt': 1612981715169,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25218906',\n",
              "  'uuid': '66580038-c7d7-47c1-8dd1-fa2a2c93a45c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:836',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981717935,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25847936',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'tbcrc009: a multicenter phase ii clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25847936',\n",
              "  'updatedAt': 1612981717935,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25847936',\n",
              "  'uuid': '8a9c6256-570b-4954-b7f3-e800be934524',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:837',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981718498,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22586653',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'a molecularly annotated platform of patient-derived xenografts (\"xenopatients\") identifies her2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22586653',\n",
              "  'updatedAt': 1612981718498,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22586653',\n",
              "  'uuid': '274851cf-3711-41cf-85fb-7d0d7dad54f9',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:838',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981718961,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23348520',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'her2 gene copy number status may influence clinical efficacy to anti-egfr monoclonal antibodies in metastatic colorectal cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23348520',\n",
              "  'updatedAt': 1612981718961,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23348520',\n",
              "  'uuid': 'de3a19a1-58ca-4034-9e51-8e5afb5eadab',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:839',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981719464,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27108243',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, kras codon 12/13 wild-type, her2-positive metastatic colorectal cancer (heracles): a proof-of-concept, multicentre, open-label, phase 2 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27108243',\n",
              "  'updatedAt': 1612981719464,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27108243',\n",
              "  'uuid': '6e4cc3d4-e4d2-4790-a319-ffcee7c0805c',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:842',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981720836,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25636205',\n",
              "  'journalName': 'european urology',\n",
              "  'name': 'erbb2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25636205',\n",
              "  'updatedAt': 1612981720836,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25636205',\n",
              "  'uuid': '05028938-1f2f-4cde-b503-8bb35d1dcc43',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:850',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981726682,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17470858',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17470858',\n",
              "  'updatedAt': 1612981726682,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17470858',\n",
              "  'uuid': 'ea9a137a-966d-4c17-9fe8-92b6b780a74b',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:851',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981727034,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:14993230',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '14993230',\n",
              "  'updatedAt': 1612981727034,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/14993230',\n",
              "  'uuid': 'd5570f3e-58d2-4d48-a095-42d12c8b8db0',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:855',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981729883,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27664533',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'responses to crizotinib can occur in high-level met-amplified non-small cell lung cancer independent of met exon 14 alterations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27664533',\n",
              "  'updatedAt': 1612981729883,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27664533',\n",
              "  'uuid': 'adc62f08-8db9-494a-8ded-cda0769e7f85',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:860',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981732602,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27083334',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'afatinib versus gefitinib as first-line treatment of patients with egfr mutation-positive non-small-cell lung cancer (lux-lung 7): a phase 2b, open-label, randomised controlled trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27083334',\n",
              "  'updatedAt': 1612981732602,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27083334',\n",
              "  'uuid': 'a85d0da0-7936-44d5-b6db-1f629cacbe2f',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:862',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981734032,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27718847',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'pembrolizumab versus chemotherapy for pd-l1-positive non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27718847',\n",
              "  'updatedAt': 1612981734032,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27718847',\n",
              "  'uuid': 'bb77e1ce-0bb9-4725-9acd-6fd60598ac26',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:864',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981734918,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27663592',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'selective targeting of cyclin e1-amplified high-grade serous ovarian cancer by cyclin-dependent kinase 2 and akt inhibition.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27663592',\n",
              "  'updatedAt': 1612981734918,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27663592',\n",
              "  'uuid': '7023ae46-d049-4bb5-a1df-2545c01acd96',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:865',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981735323,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26124334',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'effectiveness of tyrosine kinase inhibitors in japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results from a multicenter retrospective study (hanshin oncology group 0212).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26124334',\n",
              "  'updatedAt': 1612981735323,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26124334',\n",
              "  'uuid': '62447c41-a8bd-4f59-bead-0be37127c4e4',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:866',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981735824,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12865922',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'further observations on lkb1/stk11 status and cancer risk in peutz-jeghers syndrome.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12865922',\n",
              "  'updatedAt': 1612981735824,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12865922',\n",
              "  'uuid': 'ada0b6d8-2915-4981-9973-2ee191e3ed5d',\n",
              "  'year': 2003},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:869',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981737936,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27470558',\n",
              "  'journalName': 'biomedicine & pharmacotherapy = biomedecine & pharmacotherapie',\n",
              "  'name': 'the association of phosphatase and tensin homolog (pten) deletion and prostate cancer risk: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27470558',\n",
              "  'updatedAt': 1612981737936,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27470558',\n",
              "  'uuid': 'a46f0fe1-3e20-4a8d-9125-31c5ecd14ee4',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:870',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981738376,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26359368',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'nf2 loss promotes oncogenic ras-induced thyroid cancers via yap-dependent transactivation of ras proteins and sensitizes them to mek inhibition.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26359368',\n",
              "  'updatedAt': 1612981738376,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26359368',\n",
              "  'uuid': 'be649878-4449-49f5-9fca-2e2a87e4fa59',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:871',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981740676,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26621817',\n",
              "  'journalName': 'scientific reports',\n",
              "  'name': 'meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near sh2b3 and tshz1.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26621817',\n",
              "  'updatedAt': 1612981740676,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26621817',\n",
              "  'uuid': 'a2b172b6-edeb-4dfd-a16b-310ad0ab421b',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:876',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981744157,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26422378',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'the gadd45a (1506t&gt;c) polymorphism is associated with ovarian cancer susceptibility and prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26422378',\n",
              "  'updatedAt': 1612981744157,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26422378',\n",
              "  'uuid': '1c48b260-2f56-4c67-8824-6a22362868ac',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:880',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981746219,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27819322',\n",
              "  'journalName': 'scientific reports',\n",
              "  'name': 'mthfr c.677c&gt;t inhibits cell proliferation and decreases prostate cancer susceptibility in the han chinese population in shanghai.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27819322',\n",
              "  'updatedAt': 1612981746219,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27819322',\n",
              "  'uuid': '51131bb9-7c4f-42f9-88e6-0450ea3592e5',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:881',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981746599,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26693073',\n",
              "  'journalName': 'american journal of cancer research',\n",
              "  'name': 'a common variant in mthfr influences response to chemoradiotherapy and recurrence of rectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26693073',\n",
              "  'updatedAt': 1612981746599,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26693073',\n",
              "  'uuid': '951eb918-1070-4398-bd6a-4e17480df7a5',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:883',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981747948,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26108461',\n",
              "  'journalName': 'cancer epidemiology, biomarkers & prevention : a publication of the american association for cancer research, cosponsored by the american society of preventive oncology',\n",
              "  'name': 'the hoxb13 g84e mutation is associated with an increased risk for prostate cancer and other malignancies.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26108461',\n",
              "  'updatedAt': 1612981747948,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26108461',\n",
              "  'uuid': '9a6e321c-b6e0-491b-9326-0592187d4764',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:886',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981749576,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21172893',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii study of the antibody drug conjugate trastuzumab-dm1 for the treatment of human epidermal growth factor receptor 2 (her2)-positive breast cancer after prior her2-directed therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21172893',\n",
              "  'updatedAt': 1612981749576,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21172893',\n",
              "  'uuid': '19a07d63-9f5d-481e-9358-44f5a5bd38c6',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:889',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981751244,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22238366',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'ponatinib (ap24534), a multitargeted pan-fgfr inhibitor with activity in multiple fgfr-amplified or mutated cancer models.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22238366',\n",
              "  'updatedAt': 1612981751244,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22238366',\n",
              "  'uuid': 'af95c943-bac1-47f9-966b-666a6c70a978',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:893',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981753021,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19366796',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'ligand-dependent platelet-derived growth factor receptor (pdgfr)-alpha activation sensitizes rare lung cancer and sarcoma cells to pdgfr kinase inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19366796',\n",
              "  'updatedAt': 1612981753021,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19366796',\n",
              "  'uuid': 'f39cf40d-5ddc-4817-8a7c-cb36cab761f7',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:894',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981753372,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21862407',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21862407',\n",
              "  'updatedAt': 1612981753372,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21862407',\n",
              "  'uuid': 'b6689eec-c9fa-4df1-823c-41b4a1423e69',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:898',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981755703,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26773740',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon egfr mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26773740',\n",
              "  'updatedAt': 1612981755703,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26773740',\n",
              "  'uuid': 'dedebd9e-bf01-4a48-8557-aba2b4b70ad2',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:902',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981759445,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25111426',\n",
              "  'journalName': 'the journal of pathology',\n",
              "  'name': 'somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25111426',\n",
              "  'updatedAt': 1612981759445,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25111426',\n",
              "  'uuid': 'c328c88b-4ad4-462c-bb64-30474a494a33',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:905',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981764042,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26051236',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon egfr mutations: a combined post-hoc analysis of lux-lung 2, lux-lung 3, and lux-lung 6.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26051236',\n",
              "  'updatedAt': 1612981764042,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26051236',\n",
              "  'uuid': '6b26ddfe-6508-478a-a911-52d4f640446f',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:909',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981767895,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27626483',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'association between germline homeobox b13 (hoxb13) g84e allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27626483',\n",
              "  'updatedAt': 1612981767895,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27626483',\n",
              "  'uuid': 'a463c94d-07ef-42b2-9318-70588b8ed1b3',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:912',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981774971,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26689995',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'identification of a novel her3 activating mutation homologous to egfr-l858r in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26689995',\n",
              "  'updatedAt': 1612981774971,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26689995',\n",
              "  'uuid': '79e092f5-b5c6-443e-a5ae-1fe6d2ee7caf',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:915',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981777897,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26629066',\n",
              "  'journalName': 'international journal of clinical and experimental medicine',\n",
              "  'name': 'chek2 mutation and risk of prostate cancer: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26629066',\n",
              "  'updatedAt': 1612981777897,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26629066',\n",
              "  'uuid': 'c77dd9c1-6606-485c-bfd6-0c0ea9869f64',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:919',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981780490,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17224927',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17224927',\n",
              "  'updatedAt': 1612981780490,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17224927',\n",
              "  'uuid': 'e82f84a0-bcd8-4b67-9238-376bb0bfd1f6',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:921',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981782190,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27159395',\n",
              "  'journalName': 'the journal of clinical investigation',\n",
              "  'name': 'immune activation and response to pembrolizumab in pole-mutant endometrial cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27159395',\n",
              "  'updatedAt': 1612981782190,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27159395',\n",
              "  'uuid': '7215c5e3-74da-49c3-97f5-4a722d2c82c2',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:923',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981783043,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27694386',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'acquired metd1228v mutation and resistance to met inhibition in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27694386',\n",
              "  'updatedAt': 1612981783043,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27694386',\n",
              "  'uuid': '67e2c3c2-0876-42c3-ac43-e9d17c62a8b0',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:924',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981783683,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26802149',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'clinical correlation of extensive-stage small-cell lung cancer genomics.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26802149',\n",
              "  'updatedAt': 1612981783683,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26802149',\n",
              "  'uuid': 'daba01d0-78ab-42f5-affb-caed4929a9d3',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:925',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981784081,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27959700',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'osimertinib or platinum-pemetrexed in egfr t790m-positive lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27959700',\n",
              "  'updatedAt': 1612981784081,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27959700',\n",
              "  'uuid': 'a1a2bcea-7113-442e-aeaf-8b41702c01fd',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:926',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981785153,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26565381',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'durable clinical response to entrectinib in ntrk1-rearranged non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26565381',\n",
              "  'updatedAt': 1612981785153,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26565381',\n",
              "  'uuid': '73ce0467-797a-4ed9-a403-c3ea29a6beba',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:935',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981792170,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25899785',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'targeting her2 aberrations as actionable drivers in lung cancers: phase ii trial of the pan-her tyrosine kinase inhibitor dacomitinib in patients with her2-mutant or amplified tumors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25899785',\n",
              "  'updatedAt': 1612981792170,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25899785',\n",
              "  'uuid': '7e97c148-6105-4bc1-ba12-dc3e11321096',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:939',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981794331,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27959684',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 't-cell transfer therapy targeting mutant kras in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27959684',\n",
              "  'updatedAt': 1612981794331,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27959684',\n",
              "  'uuid': 'eaa741ab-0fc7-4af8-b458-61b0d60063e0',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:941',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981795996,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27729313',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'phase ib study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with brafv600e mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27729313',\n",
              "  'updatedAt': 1612981795996,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27729313',\n",
              "  'uuid': 'bb0e4b2b-e280-4e7d-b2d8-19def745a3e6',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:947',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981800340,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27297869',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'upregulation of akt3 confers resistance to the akt inhibitor mk2206 in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27297869',\n",
              "  'updatedAt': 1612981800340,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27297869',\n",
              "  'uuid': 'ed37a73f-9483-4042-bde5-9e4af32d3411',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:948',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981800670,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24335962',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'targeting akt3 signaling in triple-negative breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24335962',\n",
              "  'updatedAt': 1612981800670,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24335962',\n",
              "  'uuid': '15a614d7-4266-4216-b301-c9b4f3fd2795',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:954',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981803354,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20022809',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (wjtog3405): an open label, randomised phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20022809',\n",
              "  'updatedAt': 1612981803354,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20022809',\n",
              "  'uuid': 'ec50ca47-5484-4a7e-86dc-786eefc7128b',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:955',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981803767,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27302369',\n",
              "  'journalName': 'nature communications',\n",
              "  'name': 'a multigene mutation classification of 468 colorectal cancers reveals a prognostic role for apc.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27302369',\n",
              "  'updatedAt': 1612981803767,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27302369',\n",
              "  'uuid': '4ac56e57-42c5-4572-be65-56aa2feb39c7',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:964',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981810941,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23729478',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'amplification of the met receptor drives resistance to anti-egfr therapies in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23729478',\n",
              "  'updatedAt': 1612981810941,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23729478',\n",
              "  'uuid': '603d07de-4ec3-4584-ae53-bb8df0b5388b',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:967',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981813056,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26751376',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'characterization of mtap gene expression in breast cancer patients and cell lines.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26751376',\n",
              "  'updatedAt': 1612981813056,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26751376',\n",
              "  'uuid': '949f4d6c-a1cf-4884-93fe-86b3d1fb20b3',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:968',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981813761,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22016507',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'hvps37a status affects prognosis and cetuximab sensitivity in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22016507',\n",
              "  'updatedAt': 1612981813761,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22016507',\n",
              "  'uuid': '09e6b832-586e-4bba-b47b-7a7a45e285ea',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:974',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981816716,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28223103',\n",
              "  'journalName': 'clinical colorectal cancer',\n",
              "  'name': 'her2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type ras and braf.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28223103',\n",
              "  'updatedAt': 1612981816716,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28223103',\n",
              "  'uuid': '9e16400a-3c6f-4ff9-b72e-cc0d5decd174',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:976',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981817605,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24758907',\n",
              "  'journalName': 'zhongguo fei ai za zhi = chinese journal of lung cancer',\n",
              "  'name': '[association between gnas1 t393c polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown egfr mutation status].',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24758907',\n",
              "  'updatedAt': 1612981817605,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24758907',\n",
              "  'uuid': 'fef1bc32-6a91-4c3b-a0d8-1309e731adea',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:980',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981819679,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18316791',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'wild-type kras is required for panitumumab efficacy in patients with metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18316791',\n",
              "  'updatedAt': 1612981819679,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18316791',\n",
              "  'uuid': '10136286-7f62-45de-91be-504a048186f6',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:981',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981820088,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17409929',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'pten and pik3ca expression is associated with prolonged survival after gefitinib treatment in egfr-mutated lung cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17409929',\n",
              "  'updatedAt': 1612981820088,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17409929',\n",
              "  'uuid': '3de4be62-0d87-48c5-8298-d8557a583a13',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:987',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981822587,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19671852',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pik3ca mutation associates with improved outcome in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19671852',\n",
              "  'updatedAt': 1612981822587,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19671852',\n",
              "  'uuid': '13bbee9c-9a28-40af-9e37-a74ef25856ed',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:988',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981823007,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20453058',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': \"predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor gdc-0941 in breast cancer preclinical models.\",\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20453058',\n",
              "  'updatedAt': 1612981823007,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20453058',\n",
              "  'uuid': '34feeba1-eaf6-4c39-9d06-c8238d9fa0e2',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:989',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981823574,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21594665',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'evaluation of the association of pik3ca mutations and pten loss with efficacy of trastuzumab therapy in metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21594665',\n",
              "  'updatedAt': 1612981823574,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21594665',\n",
              "  'uuid': 'deb22e7b-34e6-4195-bd5e-bcc69276f625',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:990',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981824098,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21258250',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'phosphoinositide-3-kinase catalytic alpha and kras mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21258250',\n",
              "  'updatedAt': 1612981824098,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21258250',\n",
              "  'uuid': 'c1af7cfa-3720-40e8-a3da-a8eb2401dd34',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:991',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981824691,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17202311',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'clinicopathologic analysis of breast cancers with pik3ca mutations in japanese women.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17202311',\n",
              "  'updatedAt': 1612981824691,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17202311',\n",
              "  'uuid': '845862f6-9f1f-4a3e-baf9-772c664fd49c',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:992',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981825167,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17590872',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'pik3ca mutation is predictive of poor survival in patients with colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17590872',\n",
              "  'updatedAt': 1612981825167,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17590872',\n",
              "  'uuid': '5a82be18-9ead-41f0-914f-77a522680ef6',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:993',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981825627,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19903786',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pik3ca mutations predict local recurrences in rectal cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19903786',\n",
              "  'updatedAt': 1612981825627,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19903786',\n",
              "  'uuid': 'c7689791-4791-4f6a-8c6e-ee5ed1bbd967',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:994',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981826071,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19603024',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19603024',\n",
              "  'updatedAt': 1612981826071,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19603024',\n",
              "  'uuid': '2c180973-d45d-4e71-87ae-b5f6cc6becfb',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:995',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981826611,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19571295',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'braf mutation in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19571295',\n",
              "  'updatedAt': 1612981826611,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19571295',\n",
              "  'uuid': '891bfdff-d595-401b-bf8b-59613ec944d0',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:998',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981828215,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22452896',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (lux-lung 1): a phase 2b/3 randomised trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22452896',\n",
              "  'updatedAt': 1612981828215,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22452896',\n",
              "  'uuid': 'e201a0f1-a842-4d03-878b-ab9e56004386',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:999',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981828706,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24755888',\n",
              "  'journalName': 'cancer biology & therapy',\n",
              "  'name': 'a phase ii randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24755888',\n",
              "  'updatedAt': 1612981828706,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24755888',\n",
              "  'uuid': '4dadee9d-e8ba-4cb6-9608-f303402881a3',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1002',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981830229,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17020982',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17020982',\n",
              "  'updatedAt': 1612981830229,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17020982',\n",
              "  'uuid': 'e200d550-f4fc-4541-ba38-06d83bfcf1d5',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1003',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981830637,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18408761',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'bibw2992, an irreversible egfr/her2 inhibitor highly effective in preclinical lung cancer models.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18408761',\n",
              "  'updatedAt': 1612981830637,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18408761',\n",
              "  'uuid': 'd62d0cf9-a076-46c7-89c9-ab017f74d339',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1004',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981831043,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18089823',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'pf00299804, an irreversible pan-erbb inhibitor, is effective in lung cancer models with egfr and erbb2 mutations that are resistant to gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18089823',\n",
              "  'updatedAt': 1612981831043,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18089823',\n",
              "  'uuid': '59006ba8-cdd2-4a07-9388-aa20728fde2f',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1005',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981831513,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16818618',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'non-small-cell lung cancer and ba/f3 transformed cells harboring the erbb2 g776insv_g/c mutation are sensitive to the dual-specific epidermal growth factor receptor and erbb2 inhibitor hki-272.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16818618',\n",
              "  'updatedAt': 1612981831513,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16818618',\n",
              "  'uuid': 'a4d151de-4de7-4186-ab49-40908b9b53e0',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1006',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981832042,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21732342',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'antitumor activity of hm781-36b, a highly effective pan-her inhibitor in erlotinib-resistant nsclc and other egfr-dependent cancer models.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21732342',\n",
              "  'updatedAt': 1612981832042,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21732342',\n",
              "  'uuid': '41f173cf-cda4-4902-872e-42df890ab9c1',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1011',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981836228,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19603018',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'kras codon 61, 146 and braf mutations predict resistance to cetuximab plus irinotecan in kras codon 12 and 13 wild-type metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19603018',\n",
              "  'updatedAt': 1612981836228,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19603018',\n",
              "  'uuid': 'bce1987b-547e-4b8e-a5d2-ea11a03b3818',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1012',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981836784,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22025157',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized phase ii study of erlotinib in combination with placebo or r1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22025157',\n",
              "  'updatedAt': 1612981836784,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22025157',\n",
              "  'uuid': 'aed5ce3e-c140-45fa-97b4-d3b414459e7c',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1013',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981838350,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11595686',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11595686',\n",
              "  'updatedAt': 1612981838350,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11595686',\n",
              "  'uuid': '43ac4c4b-7aef-4236-9d34-e0ab2d26370d',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1014',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981840655,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:14514923',\n",
              "  'journalName': 'molecular pathology : mp',\n",
              "  'name': 'alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '14514923',\n",
              "  'updatedAt': 1612981840655,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/14514923',\n",
              "  'uuid': '13fafa14-1915-41a0-9166-cdcc3911ded4',\n",
              "  'year': 2003},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1017',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981842309,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18955451',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'correlation of kinase genotype and clinical outcome in the north american intergroup phase iii trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: calgb 150105 study by cancer and leukemia group b and southwest oncology group.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18955451',\n",
              "  'updatedAt': 1612981842309,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18955451',\n",
              "  'uuid': '1aecc643-08d8-4ab9-a282-548deee53cdc',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1018',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981843335,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21882184',\n",
              "  'journalName': 'cancer',\n",
              "  'name': 'the association of the braf(v600e) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21882184',\n",
              "  'updatedAt': 1612981843335,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21882184',\n",
              "  'uuid': '65b941d8-bdf1-440b-9b01-48fcf63aed31',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1020',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981844357,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20038723',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase iii interest trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20038723',\n",
              "  'updatedAt': 1612981844357,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20038723',\n",
              "  'uuid': '16e55c0d-097b-4dac-a4df-a62ceeff2a05',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1021',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981844871,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15329413',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'egf receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15329413',\n",
              "  'updatedAt': 1612981844871,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15329413',\n",
              "  'uuid': 'f765c5a9-cf21-45f6-9439-5d06ae3b39c4',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1024',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981849725,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:10786679',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'complete sequencing of tp53 predicts poor response to systemic therapy of advanced breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '10786679',\n",
              "  'updatedAt': 1612981849725,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/10786679',\n",
              "  'uuid': 'efe4f7ad-f2fb-4952-b4f3-7e3935705d71',\n",
              "  'year': 2000},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1028',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981854312,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15824158',\n",
              "  'journalName': 'cancer epidemiology, biomarkers & prevention : a publication of the american association for cancer research, cosponsored by the american society of preventive oncology',\n",
              "  'name': 'the t393c polymorphism of the g alpha s gene (gnas1) is a novel prognostic marker in bladder cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15824158',\n",
              "  'updatedAt': 1612981854312,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15824158',\n",
              "  'uuid': '10212061-2e47-4b9b-a8f5-0392a85af450',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1029',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981854729,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16033819',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'gnas1 t393c polymorphism and survival in patients with sporadic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16033819',\n",
              "  'updatedAt': 1612981854729,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16033819',\n",
              "  'uuid': '049f9fd3-af2e-4162-916e-f886a3d91b2c',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1030',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981855155,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19274060',\n",
              "  'journalName': 'the pharmacogenomics journal',\n",
              "  'name': 'gnas1 t393c polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19274060',\n",
              "  'updatedAt': 1612981855155,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19274060',\n",
              "  'uuid': '8f8d828e-b992-4756-9351-e5504a1da5d8',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1039',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981859017,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24595080',\n",
              "  'journalName': 'cancer biomarkers : section a of disease markers',\n",
              "  'name': 'the tailored chemotherapy based on rrm1 immunohistochemical expression in patients with advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24595080',\n",
              "  'updatedAt': 1612981859017,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24595080',\n",
              "  'uuid': 'e9758404-e327-4758-975b-f982cd4b85ab',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1040',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981859445,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23515407',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'characteristics of lung cancers harboring nras mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23515407',\n",
              "  'updatedAt': 1612981859445,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23515407',\n",
              "  'uuid': '3e1b113e-4120-477c-85ad-a6747b63c3a9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1045',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981862404,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25673644',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'clinical acquired resistance to raf inhibitor combinations in braf-mutant colorectal cancer through mapk pathway alterations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25673644',\n",
              "  'updatedAt': 1612981862404,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25673644',\n",
              "  'uuid': '8a02bfe5-b1b4-4c6e-9770-96de8ac7e8a2',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1052',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981866854,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20570890',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'genomic and biological characterization of exon 4 kras mutations in human cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20570890',\n",
              "  'updatedAt': 1612981866854,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20570890',\n",
              "  'uuid': '78722eca-e373-4f5a-8b81-621b89085f1e',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1056',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981869756,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26546295',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'acquired resistance to the trk inhibitor entrectinib in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26546295',\n",
              "  'updatedAt': 1612981869756,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26546295',\n",
              "  'uuid': 'b1bcaf9c-c486-4a7a-8df9-54506129cd42',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1059',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981871701,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:8929264',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'the dcc protein and prognosis in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '8929264',\n",
              "  'updatedAt': 1612981871701,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/8929264',\n",
              "  'uuid': '0c59b432-9009-465f-81ee-2fb8a62bea03',\n",
              "  'year': 1996},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1062',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981874271,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27489350',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'phosphatidyl inositol-3 kinase (pik3ca) e545k mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27489350',\n",
              "  'updatedAt': 1612981874271,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27489350',\n",
              "  'uuid': '4c70293e-4c29-48f0-bb5d-baff74b5024b',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1064',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981875889,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24868098',\n",
              "  'journalName': 'the oncologist',\n",
              "  'name': 'u.s. food and drug administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (l858r) substitution mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24868098',\n",
              "  'updatedAt': 1612981875889,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24868098',\n",
              "  'uuid': 'b53d929c-cb74-44ee-867c-12d57a40d6ca',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1066',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981878820,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28492898',\n",
              "  'journalName': 'jama',\n",
              "  'name': 'selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with kras-mutant advanced non-small cell lung cancer: the select-1 randomized clinical trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28492898',\n",
              "  'updatedAt': 1612981878820,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28492898',\n",
              "  'uuid': '974121a1-0034-4f9b-9d02-a6498511eb08',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1067',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981879604,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28476872',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'integrative analysis identifies a novel axl-pi3 kinase-pd-l1 signaling axis associated with radiation resistance in head and neck cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28476872',\n",
              "  'updatedAt': 1612981879604,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28476872',\n",
              "  'uuid': 'b0fe57f1-dbf7-4898-a90e-c5a978bdd1d3',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1068',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981880638,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28490518',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'chk1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28490518',\n",
              "  'updatedAt': 1612981880638,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28490518',\n",
              "  'uuid': 'e87c36c0-1d6f-4555-b7fb-2b8d3208704f',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1071',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981882311,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28202511',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'amplification of egfr wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective egfr tyrosine kinase inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28202511',\n",
              "  'updatedAt': 1612981882311,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28202511',\n",
              "  'uuid': 'fa12b908-dbb2-41f3-9383-e34e4f7c953d',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1072',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981882890,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27283860',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'dabrafenib plus trametinib in patients with previously treated braf(v600e)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27283860',\n",
              "  'updatedAt': 1612981882890,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27283860',\n",
              "  'uuid': '139f4cb7-452d-41ad-b852-e0cdcb74fc0a',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1073',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981883311,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27315356',\n",
              "  'journalName': 'cancer',\n",
              "  'name': 'efficacy and safety of dovitinib in pretreated patients with advanced squamous non-small cell lung cancer with fgfr1 amplification: a single-arm, phase 2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27315356',\n",
              "  'updatedAt': 1612981883311,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27315356',\n",
              "  'uuid': '18d9af6e-5346-47d3-8bff-02a75a733c84',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1081',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981887956,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25666295',\n",
              "  'journalName': 'clinical colorectal cancer',\n",
              "  'name': 'folfox4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor ras and braf mutation status: updated analysis of the cecog/core 1.2.002 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25666295',\n",
              "  'updatedAt': 1612981887956,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25666295',\n",
              "  'uuid': 'c97693af-c66e-4e92-8f4b-92e0b6c91a72',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1082',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981888481,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26161928',\n",
              "  'journalName': 'future oncology (london, england)',\n",
              "  'name': 'kras exon 2 mutations influence activity of regorafenib in an sw48-based disease model of colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26161928',\n",
              "  'updatedAt': 1612981888481,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26161928',\n",
              "  'uuid': 'd5dcb310-495f-4581-88cf-c46abfaa60a3',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1083',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981889079,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21969500',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'prospective molecular marker analyses of egfr and kras from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21969500',\n",
              "  'updatedAt': 1612981889079,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21969500',\n",
              "  'uuid': '5bf0ac85-83eb-4298-b5e2-0ebcdb6a4452',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1088',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981891670,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26490654',\n",
              "  'journalName': 'investigational new drugs',\n",
              "  'name': 'sustained response to vemurafenib in a low grade serous ovarian cancer with a braf v600e mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26490654',\n",
              "  'updatedAt': 1612981891670,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26490654',\n",
              "  'uuid': '11c41e46-472d-411c-9288-ca9d0f77e471',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1089',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981892293,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21531810',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21531810',\n",
              "  'updatedAt': 1612981892293,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21531810',\n",
              "  'uuid': '7ccb3ec6-57aa-4629-a898-62842cac45d0',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1094',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981895622,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22722830',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'emergence of kras mutations and acquired resistance to anti-egfr therapy in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22722830',\n",
              "  'updatedAt': 1612981895622,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22722830',\n",
              "  'uuid': '1c45168e-7a8f-4397-9bc2-e8ee6f84f4a4',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1103',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981903435,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17877814',\n",
              "  'journalName': 'molecular cancer',\n",
              "  'name': 'functional analysis of cancer-associated egfr mutants using a cellular assay with yfp-tagged egfr intracellular domain.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17877814',\n",
              "  'updatedAt': 1612981903436,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17877814',\n",
              "  'uuid': '749d2434-fc60-48b1-8e31-a57e5b151f75',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1105',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981904378,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24353160',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'structural, biochemical, and clinical characterization of epidermal growth factor receptor (egfr) exon 20 insertion mutations in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24353160',\n",
              "  'updatedAt': 1612981904378,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24353160',\n",
              "  'uuid': '3e154d22-2cca-4e65-af42-4da98ececd59',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1107',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981905538,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21132006',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of african-american ancestry.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21132006',\n",
              "  'updatedAt': 1612981905538,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21132006',\n",
              "  'uuid': '5c0c297b-f1ca-4b57-8e88-492883d41875',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1109',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981906613,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27032107',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'prospective evaluation of first-line erlotinib in advanced non-small cell lung cancer (nsclc) carrying an activating egfr mutation: a multicenter academic phase ii study in caucasian patients (fielt).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27032107',\n",
              "  'updatedAt': 1612981906613,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27032107',\n",
              "  'uuid': 'c8c1a3ac-681b-41b0-ac65-358be94ec863',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1110',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981907091,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27102076',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'egfr fusions as novel therapeutic targets in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27102076',\n",
              "  'updatedAt': 1612981907091,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27102076',\n",
              "  'uuid': '83677fdf-0976-4837-8d64-9680c2bbc3f7',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1115',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981912165,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26989027',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'mutations of kras/nras/braf predict cetuximab resistance in metastatic colorectal cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26989027',\n",
              "  'updatedAt': 1612981912165,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26989027',\n",
              "  'uuid': '6b3127ee-398a-44b9-8ea8-c7b7446a0f3d',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1124',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981920007,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25765070',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'cancer immunology. mutational landscape determines sensitivity to pd-1 blockade in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25765070',\n",
              "  'updatedAt': 1612981920007,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25765070',\n",
              "  'uuid': '35c7a291-461d-4504-9358-9d476305ab81',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1128',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981923431,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28475456',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase ii trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28475456',\n",
              "  'updatedAt': 1612981923432,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28475456',\n",
              "  'uuid': '33862a2a-ce77-4c29-aa62-4c287ada6c9b',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1129',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981923870,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28242752',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'phase i, dose-escalation, two-part trial of the parp inhibitor talazoparib in patients with advanced germline <i>brca1/2</i> mutations and selected sporadic cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28242752',\n",
              "  'updatedAt': 1612981923870,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28242752',\n",
              "  'uuid': '3e95d21b-d1a9-4f15-af81-476f636afa11',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1130',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981924342,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28526536',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated her2-positive advanced breast cancer (emilia): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28526536',\n",
              "  'updatedAt': 1612981924342,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28526536',\n",
              "  'uuid': '36fee086-06a3-4128-8d1e-d6b284e25094',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1132',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981925238,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27217383',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'efficacy and safety of abemaciclib, an inhibitor of cdk4 and cdk6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27217383',\n",
              "  'updatedAt': 1612981925238,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27217383',\n",
              "  'uuid': '6aea9d53-d28f-4292-9a02-d6aefc04ab26',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1133',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981925573,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28079291',\n",
              "  'journalName': 'the breast journal',\n",
              "  'name': 'prognostic value of pd-l1 in breast cancer: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28079291',\n",
              "  'updatedAt': 1612981925573,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28079291',\n",
              "  'uuid': 'ec045d88-15c5-414c-a751-0f1555aca6d7',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1135',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981927134,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27825636',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'cabozantinib in patients with advanced ret-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27825636',\n",
              "  'updatedAt': 1612981927134,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27825636',\n",
              "  'uuid': '72b2ebf6-97de-4a45-895e-2553b4e42ac6',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1136',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981927595,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27803005',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring ret rearrangement: a phase ii clinical trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27803005',\n",
              "  'updatedAt': 1612981927595,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27803005',\n",
              "  'uuid': '633d3c7e-b145-4fff-8cf7-8f66efe0b6b1',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1137',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981927949,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27825616',\n",
              "  'journalName': 'the lancet. respiratory medicine',\n",
              "  'name': 'vandetanib in patients with previously treated ret-rearranged advanced non-small-cell lung cancer (luret): an open-label, multicentre phase 2 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27825616',\n",
              "  'updatedAt': 1612981927949,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27825616',\n",
              "  'uuid': '18bcf1da-2a59-462a-b710-2a2c5ecdf0c8',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1138',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981928372,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27544060',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'clinical activity of alectinib in advanced ret-rearranged non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27544060',\n",
              "  'updatedAt': 1612981928372,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27544060',\n",
              "  'uuid': 'ebe22b54-764d-40c1-a970-e0b01cf941d8',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1139',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981928818,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28430626',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'expression of pd-l1 and prognosis in breast cancer: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28430626',\n",
              "  'updatedAt': 1612981928818,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28430626',\n",
              "  'uuid': '71e4b65c-7cf9-4449-af3a-fd73ecc46e2a',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1140',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981929173,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28453554',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'prognostic value of pd-l1 expression in tumor infiltrating immune cells in cancers: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28453554',\n",
              "  'updatedAt': 1612981929173,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28453554',\n",
              "  'uuid': '1b637cd6-120c-4068-ab82-23f09826ab31',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1141',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981929637,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28472902',\n",
              "  'journalName': 'immunotherapy',\n",
              "  'name': 'pd-l1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28472902',\n",
              "  'updatedAt': 1612981929637,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28472902',\n",
              "  'uuid': '07573580-b5dc-4b77-a81a-c5e4860cbe52',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1142',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981930219,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28586279',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'alectinib versus crizotinib in untreated alk-positive non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28586279',\n",
              "  'updatedAt': 1612981930219,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28586279',\n",
              "  'uuid': '59fe0d08-146d-4de1-82e4-53c9f1deff93',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1143',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981930693,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26768165',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'dacomitinib versus erlotinib in patients with egfr-mutated advanced nonsmall-cell lung cancer (nsclc): pooled subset analyses from two randomized trials.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26768165',\n",
              "  'updatedAt': 1612981930693,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26768165',\n",
              "  'uuid': 'd6c3b262-ab3e-458e-8948-b19c60941147',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1144',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981931720,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27876675',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'a phase 1/1b study evaluating trametinib plus docetaxel or pemetrexed in patients with advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27876675',\n",
              "  'updatedAt': 1612981931720,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27876675',\n",
              "  'uuid': '09e8a3b2-be32-4840-a636-30e9cfeb8ebf',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1145',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981932122,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28525386',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'prognostic value of kras mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: a meta-analysis and review.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28525386',\n",
              "  'updatedAt': 1612981932122,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28525386',\n",
              "  'uuid': '8d3b2c9b-5b9f-4472-9627-1b20e5158a62',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1147',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981933037,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27167191',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'efficacy of the combination of mek and cdk4/6 inhibitors in vitro and in vivo in kras mutant colorectal cancer models.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27167191',\n",
              "  'updatedAt': 1612981933037,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27167191',\n",
              "  'uuid': '577b13de-5318-4456-a164-ab9cd35a2996',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1149',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981934483,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12748244',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 trial) [corrected].',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12748244',\n",
              "  'updatedAt': 1612981934483,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12748244',\n",
              "  'uuid': '95fd1308-2901-47b0-b74e-67dbdc616708',\n",
              "  'year': 2003},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1154',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981940398,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15118073',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15118073',\n",
              "  'updatedAt': 1612981940398,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15118073',\n",
              "  'uuid': 'a24de93f-8ece-416a-bf71-a950b1d23f49',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1156',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981944902,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28404093',\n",
              "  'journalName': 'the lancet. gastroenterology & hepatology',\n",
              "  'name': 'somatic pole proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28404093',\n",
              "  'updatedAt': 1612981944902,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28404093',\n",
              "  'uuid': '85064351-648b-40ff-bf93-68bb08f8fb9e',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1162',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981957766,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26282658',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized, double-blind phase ii trial with prospective classification by atm protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26282658',\n",
              "  'updatedAt': 1612981957766,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26282658',\n",
              "  'uuid': 'ea641bd5-36d0-404b-b86a-9576d9b717a8',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1169',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981965964,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28679771',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'neratinib efficacy and circulating tumor dna detection of <i>her2</i> mutations in <i>her2</i> nonamplified metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28679771',\n",
              "  'updatedAt': 1612981965964,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28679771',\n",
              "  'uuid': '8535087f-9014-4064-9128-df559eca6537',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1172',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981968153,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28275037',\n",
              "  'journalName': 'journal of the national comprehensive cancer network : jnccn',\n",
              "  'name': 'colon cancer, version 1.2017, nccn clinical practice guidelines in oncology.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28275037',\n",
              "  'updatedAt': 1612981968153,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28275037',\n",
              "  'uuid': 'a849e5e0-9e51-4436-a484-06c7baec6f87',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1181',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981981952,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17131328',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'involvement of ribonucleotide reductase m1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17131328',\n",
              "  'updatedAt': 1612981981952,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17131328',\n",
              "  'uuid': '76d80b10-be0b-4db9-acb2-1db52f75f268',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1182',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981982372,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24647522',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'response to first-line chemotherapy in patients with non-small cell lung cancer according to rrm1 expression.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24647522',\n",
              "  'updatedAt': 1612981982372,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24647522',\n",
              "  'uuid': '1480343c-fc87-4fce-918a-91d1543eb302',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1189',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612981987631,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22808142',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'decreased expression of the arid1a gene is associated with poor prognosis in primary gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22808142',\n",
              "  'updatedAt': 1612981987631,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22808142',\n",
              "  'uuid': '13b3796b-2fc2-4331-8088-2aba2edf1dfb',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1204',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982002252,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25891174',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'pembrolizumab for the treatment of non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25891174',\n",
              "  'updatedAt': 1612982002252,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25891174',\n",
              "  'uuid': '0c536898-95fc-4c69-8eaf-4ae2cbdb8f79',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1206',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982004151,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28578601',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'olaparib for metastatic breast cancer in patients with a germline brca mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28578601',\n",
              "  'updatedAt': 1612982004151,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28578601',\n",
              "  'uuid': 'c09d4ec3-0190-4437-91d1-a8106d944476',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1207',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982005092,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24934408',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'synthetic lethality in atm-deficient rad50-mutant tumors underlies outlier response to cancer therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24934408',\n",
              "  'updatedAt': 1612982005092,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24934408',\n",
              "  'uuid': '93aab82e-1e31-4025-b3ea-c8cda641b27c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1208',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982005531,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28792849',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'olaparib for metastatic breast cancer in patients with a germline brca mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28792849',\n",
              "  'updatedAt': 1612982005531,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28792849',\n",
              "  'uuid': '2788f1eb-6c79-41ab-b198-5bb3cf54b675',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1210',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982007987,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23099803',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'kras gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23099803',\n",
              "  'updatedAt': 1612982007987,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23099803',\n",
              "  'uuid': '0a6c3821-0154-4a8f-8834-b68490800aa3',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1212',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982009804,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28950338',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'successful targeting of the nrg1 pathway indicates novel treatment strategy for metastatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28950338',\n",
              "  'updatedAt': 1612982009804,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28950338',\n",
              "  'uuid': '4a64fc99-8433-47cd-878d-0ea5dc92d3fd',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1214',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982011751,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22187960',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'recurrent somatic dicer1 mutations in nonepithelial ovarian cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22187960',\n",
              "  'updatedAt': 1612982011751,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22187960',\n",
              "  'uuid': 'cab59f54-437d-48b3-85a8-0ef8c2ad63a4',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1221',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982016669,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25366685',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'olaparib monotherapy in patients with advanced cancer and a germline brca1/2 mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25366685',\n",
              "  'updatedAt': 1612982016669,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25366685',\n",
              "  'uuid': 'b716e9d6-e889-44f5-ba94-c45995f15cef',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1222',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982019766,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25072261',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'overall survival and clinical characteristics of pancreatic cancer in brca mutation carriers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25072261',\n",
              "  'updatedAt': 1612982019766,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25072261',\n",
              "  'uuid': 'ca4aaed3-416a-4dff-8b36-d7a05f534282',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1223',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982020644,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27664271',\n",
              "  'journalName': 'journal of investigative medicine : the official publication of the american federation for clinical research',\n",
              "  'name': 'egfr gene copy number as a predictive/biomarker for patients with non-small-cell lung cancer receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27664271',\n",
              "  'updatedAt': 1612982020644,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27664271',\n",
              "  'uuid': '2cd757f9-cc72-4f7b-b58c-690318fa2f38',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1225',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982021854,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21508395',\n",
              "  'journalName': 'anticancer research',\n",
              "  'name': 'evidence for the efficacy of iniparib, a parp-1 inhibitor, in brca2-associated pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21508395',\n",
              "  'updatedAt': 1612982021854,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21508395',\n",
              "  'uuid': '33cc3bb3-2b4f-450d-82ef-8a5a78db270c',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1227',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982024164,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27197561',\n",
              "  'journalName': 'scientific reports',\n",
              "  'name': 'expression of an oncogenic bard1 splice variant impairs homologous recombination and predicts response to parp-1 inhibitor therapy in colon cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27197561',\n",
              "  'updatedAt': 1612982024164,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27197561',\n",
              "  'uuid': '093337ae-bede-4a6b-bf36-d28ced128d5e',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1231',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982028495,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19533750',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19533750',\n",
              "  'updatedAt': 1612982028495,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19533750',\n",
              "  'uuid': '3cec6c25-b989-4394-90bd-febf73c584f7',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1235',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982031787,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:7591282',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'somatic mutations of von hippel-lindau (vhl) tumor-suppressor gene in european kidney cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '7591282',\n",
              "  'updatedAt': 1612982031787,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/7591282',\n",
              "  'uuid': '73a41cd7-e7ba-446f-a770-e1f0a1210786',\n",
              "  'year': 1995},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1240',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982034248,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28363909',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'a phase ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic <i>braf</i>-mutant colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28363909',\n",
              "  'updatedAt': 1612982034248,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28363909',\n",
              "  'uuid': '74ae73be-9f72-45d3-83fb-bdfbc15bfe92',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1245',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982040562,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29431699',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'combined braf, egfr, and mek inhibition in patients with <i>braf</i><sup>v600e</sup>-mutant colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29431699',\n",
              "  'updatedAt': 1612982040562,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29431699',\n",
              "  'uuid': 'b66d3576-4304-479b-9a27-d13763bcb4fc',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1250',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982043649,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17575221',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pik3ca mutations and pten loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17575221',\n",
              "  'updatedAt': 1612982043649,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17575221',\n",
              "  'uuid': '806677e5-4bc6-44fa-97d8-e5f1159ad226',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1255',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982051166,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29802158',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': '<i>nrg1</i> fusions in <i>kras</i> wild-type pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29802158',\n",
              "  'updatedAt': 1612982051166,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29802158',\n",
              "  'uuid': '5b877e5e-e2bc-44f4-89b0-4791e7d40481',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1277',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982070062,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29466156',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'efficacy of larotrectinib in trk fusion-positive cancers in adults and children.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29466156',\n",
              "  'updatedAt': 1612982070062,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29466156',\n",
              "  'uuid': 'b61b46a9-6a81-4fe1-b511-05ef4450f482',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1292',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982082728,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29072975',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'dabrafenib and trametinib treatment in patients with locally advanced or metastatic braf v600-mutant anaplastic thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29072975',\n",
              "  'updatedAt': 1612982082728,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29072975',\n",
              "  'uuid': '7ed1be71-2491-41f4-8c62-69d074820325',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1303',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982094680,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21783417',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'erlotinib versus chemotherapy as first-line treatment for patients with advanced egfr mutation-positive non-small-cell lung cancer (optimal, ctong-0802): a multicentre, open-label, randomised, phase 3 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21783417',\n",
              "  'updatedAt': 1612982094680,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21783417',\n",
              "  'uuid': 'a9a23a55-607d-4dad-9e8c-43a88a54bc2d',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1306',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982097064,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29196463',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'genomic landscape of cell-free dna in patients with colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29196463',\n",
              "  'updatedAt': 1612982097064,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29196463',\n",
              "  'uuid': '8fb2da95-4589-4ac6-9b3f-2465c1693a37',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1310',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982099421,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:30718506',\n",
              "  'journalName': 'nature communications',\n",
              "  'name': 'smarca4 loss is synthetic lethal with cdk4/6 inhibition in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '30718506',\n",
              "  'updatedAt': 1612982099421,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/30718506',\n",
              "  'uuid': '42533e0d-51f0-4219-8d22-83e592188e0a',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1311',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982099893,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20008640',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'prognostic role of kras and braf in stage ii and iii resected colon cancer: results of the translational study on the petacc-3, eortc 40993, sakk 60-00 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20008640',\n",
              "  'updatedAt': 1612982099894,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20008640',\n",
              "  'uuid': 'd2f6f14d-e5d2-46f0-b86e-1accfd64e906',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1312',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982100333,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21502544',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor kras and braf mutation status.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21502544',\n",
              "  'updatedAt': 1612982100333,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21502544',\n",
              "  'uuid': 'f3aaf385-c8d5-468a-b610-099534896aae',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1313',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982100838,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21641636',\n",
              "  'journalName': 'lancet (london, england)',\n",
              "  'name': 'addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 mrc coin trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21641636',\n",
              "  'updatedAt': 1612982100838,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21641636',\n",
              "  'uuid': 'a47cb021-673e-4c81-9e0e-c4a2d50fdf19',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1314',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982101290,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24112392',\n",
              "  'journalName': 'colorectal disease : the official journal of the association of coloproctology of great britain and ireland',\n",
              "  'name': 'braf mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24112392',\n",
              "  'updatedAt': 1612982101290,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24112392',\n",
              "  'uuid': '28779106-2d5d-4cbe-8ef6-5def3984230a',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1316',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982102332,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11051239',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'heterogeneity in the clinical phenotype of tp53 mutations in breast cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11051239',\n",
              "  'updatedAt': 1612982102332,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11051239',\n",
              "  'uuid': '22a370b6-893d-4c37-b789-6f8de72a67ca',\n",
              "  'year': 2000},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1322',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982106615,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21343334',\n",
              "  'journalName': 'molecular cancer research : mcr',\n",
              "  'name': 'dominant-negative features of mutant tp53 in germline carriers have limited impact on cancer outcomes.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21343334',\n",
              "  'updatedAt': 1612982106615,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21343334',\n",
              "  'uuid': 'aae993c9-85c9-4d42-a441-14f65c484b87',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1324',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982108298,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29223982',\n",
              "  'journalName': 'journal of the national comprehensive cancer network : jnccn',\n",
              "  'name': 'pazopanib sensitivity in a patient with breast cancer and <i>fgfr1</i> amplification.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29223982',\n",
              "  'updatedAt': 1612982108298,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29223982',\n",
              "  'uuid': 'd7045dd7-1e1f-4754-a53e-28bb054416b6',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1326',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982112282,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:30980071',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'crizotinib in ros1-rearranged advanced non-small-cell lung cancer (nsclc): updated results, including overall survival, from profile 1001.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '30980071',\n",
              "  'updatedAt': 1612982112282,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/30980071',\n",
              "  'uuid': 'c854d215-0f15-41cc-ba79-4452a8bfda23',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1328',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982113303,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28602779',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'ceritinib versus chemotherapy in patients with alk-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ascend-5): a randomised, controlled, open-label, phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28602779',\n",
              "  'updatedAt': 1612982113303,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28602779',\n",
              "  'uuid': 'c22151fc-bfe0-402b-b49b-ff88fa154715',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1329',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982113732,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:30413378',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'lorlatinib in patients with alk-positive non-small-cell lung cancer: results from a global phase 2 study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '30413378',\n",
              "  'updatedAt': 1612982113732,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/30413378',\n",
              "  'uuid': 'c9f382d0-355a-4b8d-a013-514f55537c2f',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1332',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982115666,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:30857956',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'pertuzumab plus trastuzumab for her2-amplified metastatic colorectal cancer (mypathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '30857956',\n",
              "  'updatedAt': 1612982115666,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/30857956',\n",
              "  'uuid': '7973414c-3204-4b59-911f-8b50d6ffa814',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1333',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982116182,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:31091374',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'alpelisib for <i>pik3ca</i>-mutated, hormone receptor-positive advanced breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '31091374',\n",
              "  'updatedAt': 1612982116182,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/31091374',\n",
              "  'uuid': '34f66ff3-0077-4271-ba70-dd7b28c3e5aa',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1336',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982117705,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28958502',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'dacomitinib versus gefitinib as first-line treatment for patients with egfr-mutation-positive non-small-cell lung cancer (archer 1050): a randomised, open-label, phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28958502',\n",
              "  'updatedAt': 1612982117705,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28958502',\n",
              "  'uuid': '1048ad96-8d8c-46fa-9402-5ad5cc818ae5',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1343',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982123457,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29538669',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'ret fusions in a small subset of advanced colorectal cancers at risk of being neglected.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29538669',\n",
              "  'updatedAt': 1612982123457,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29538669',\n",
              "  'uuid': 'b7df8946-7cfb-4fc6-9dd4-601387d658b7',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1344',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982124554,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26633560',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'novel cad-alk gene rearrangement is drugable by entrectinib in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26633560',\n",
              "  'updatedAt': 1612982124554,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26633560',\n",
              "  'uuid': 'c7a8a348-5f3c-463e-be29-6fbaa89ce81c',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1355',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982132955,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26598747',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: a phase ii global study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26598747',\n",
              "  'updatedAt': 1612982132955,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26598747',\n",
              "  'uuid': '631eec06-0f93-4e17-a749-158c0a2dbe28',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1359',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982135821,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29941343',\n",
              "  'journalName': 'ebiomedicine',\n",
              "  'name': 'somatic fgfr3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29941343',\n",
              "  'updatedAt': 1612982135821,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29941343',\n",
              "  'uuid': '0c50f67d-032e-472f-96ac-c990a3d32a6e',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1361',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982137563,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28947956',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'non-v600 braf mutations recurrently found in lung cancer predict sensitivity to the combination of trametinib and dabrafenib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28947956',\n",
              "  'updatedAt': 1612982137563,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28947956',\n",
              "  'uuid': 'f628f652-3878-47f8-9ee0-08a2932533df',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1362',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982138587,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29650534',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'sequential alk inhibitors can select for lorlatinib-resistant compound <i>alk</i> mutations in alk-positive lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29650534',\n",
              "  'updatedAt': 1612982138587,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29650534',\n",
              "  'uuid': '99e02c6e-a072-488c-8bf7-d6e2ace38e1c',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1363',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982140763,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27432227',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'molecular mechanisms of resistance to first- and second-generation alk inhibitors in alk-rearranged lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27432227',\n",
              "  'updatedAt': 1612982140763,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27432227',\n",
              "  'uuid': '1c10c5b2-44a8-475b-9bc4-cc654bbeb9f0',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1375',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982154110,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17376864',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'rare cancer-specific mutations in pik3ca show gain of function.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17376864',\n",
              "  'updatedAt': 1612982154110,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17376864',\n",
              "  'uuid': '6a08b99b-d54f-4a72-a02a-49465ef12c1c',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1377',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982158513,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27525386',\n",
              "  'journalName': 'cancer',\n",
              "  'name': 'correlative analyses of ret and ras mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27525386',\n",
              "  'updatedAt': 1612982158513,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27525386',\n",
              "  'uuid': 'b479c878-c3ff-442b-8f71-103137bd6853',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1382',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982160922,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29903880',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'real-time genomic characterization of advanced pancreatic cancer to enable precision medicine.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29903880',\n",
              "  'updatedAt': 1612982160922,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29903880',\n",
              "  'uuid': '9781dcce-3781-4289-b5b0-689e17e124ab',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1390',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982168022,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24302556',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified fgfr1 in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24302556',\n",
              "  'updatedAt': 1612982168022,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24302556',\n",
              "  'uuid': '494c0c51-7f6b-465b-bcc5-6004cad56350',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1392',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982171196,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:31932422',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via parp1.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '31932422',\n",
              "  'updatedAt': 1612982171196,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/31932422',\n",
              "  'uuid': '788d34a3-3ef6-4f03-99e8-540ab2a32c62',\n",
              "  'year': 2020},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1395',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982176336,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29596029',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii study of crizotinib in east asian patients with ros1-positive advanced non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29596029',\n",
              "  'updatedAt': 1612982176336,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29596029',\n",
              "  'uuid': '4e08a05c-0854-4110-a688-f504eacd0cd8',\n",
              "  'year': 2018},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1414',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982224114,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16980606',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'ercc1 and rrm1 gene expressions but not egfr are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16980606',\n",
              "  'updatedAt': 1612982224114,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16980606',\n",
              "  'uuid': 'd457d4fb-add1-4b05-a366-01e813343ef7',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1416',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982225639,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28287083',\n",
              "  'journalName': 'nature communications',\n",
              "  'name': 'brigatinib combined with anti-egfr antibody overcomes osimertinib resistance in egfr-mutated non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28287083',\n",
              "  'updatedAt': 1612982225639,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28287083',\n",
              "  'uuid': 'c43f668d-4600-4f68-bbdc-1be18a62a602',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1419',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982227408,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28424201',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': '<i>pik3ca</i> mutations contribute to acquired cetuximab resistance in patients with metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28424201',\n",
              "  'updatedAt': 1612982227408,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28424201',\n",
              "  'uuid': 'b8cc7cf8-9ac3-459e-bab8-3da6f3495615',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1420',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982229087,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:32110058',\n",
              "  'journalName': 'oncotargets and therapy',\n",
              "  'name': 'foxc2 promotes oxaliplatin resistance by inducing epithelial-mesenchymal transition via mapk/erk signaling in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '32110058',\n",
              "  'updatedAt': 1612982229087,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/32110058',\n",
              "  'uuid': '0e1ecf74-7526-44b0-b417-5eb8d8b6fd38',\n",
              "  'year': 2020},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1421',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982229482,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:29151941',\n",
              "  'journalName': 'journal of cancer',\n",
              "  'name': 'zeb1 promotes oxaliplatin resistance through the induction of epithelial - mesenchymal transition in colon cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '29151941',\n",
              "  'updatedAt': 1612982229482,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/29151941',\n",
              "  'uuid': 'd97876ec-87d2-42bf-b50a-af1b4e3727f3',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1427',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982233361,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22237007',\n",
              "  'journalName': 'cancer biology & therapy',\n",
              "  'name': 'mirna-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22237007',\n",
              "  'updatedAt': 1612982233361,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22237007',\n",
              "  'uuid': '24ee5d8a-3c9c-4440-a2e2-088ce597828c',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1435',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982239244,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:32444490',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'metformin selectively inhibits metastatic colorectal cancer with the <i>kras</i> mutation by intracellular accumulation through silencing mate1.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '32444490',\n",
              "  'updatedAt': 1612982239244,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/32444490',\n",
              "  'uuid': '8b442b7b-9028-48f5-93b4-5b53ff4875f6',\n",
              "  'year': 2020},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1439',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982242422,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26920887',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'relationship between tumor biomarkers and efficacy in emilia, a phase iii study of trastuzumab emtansine in her2-positive metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26920887',\n",
              "  'updatedAt': 1612982242422,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26920887',\n",
              "  'uuid': 'a3894f3f-3b13-4fd9-8f5b-ea1ab98317c8',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1440',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982243005,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:31316618',\n",
              "  'journalName': 'experimental and therapeutic medicine',\n",
              "  'name': 'fgfr<sup>3s249c</sup> mutation promotes chemoresistance by activating akt signaling in bladder cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '31316618',\n",
              "  'updatedAt': 1612982243005,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/31316618',\n",
              "  'uuid': '6ac3faef-e954-43e6-9caf-1daf6dfffdaf',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1442',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982244890,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28501140',\n",
              "  'journalName': 'lancet (london, england)',\n",
              "  'name': 'alectinib versus crizotinib in patients with alk-positive non-small-cell lung cancer (j-alex): an open-label, randomised phase 3 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28501140',\n",
              "  'updatedAt': 1612982244890,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28501140',\n",
              "  'uuid': '67f119a7-e825-4dd6-ba4e-f5db67a741de',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1445',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982247637,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:32846060',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'efficacy of selpercatinib in <i>ret</i> fusion-positive non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '32846060',\n",
              "  'updatedAt': 1612982247637,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/32846060',\n",
              "  'uuid': 'b3d2779f-0e80-4b6c-a82b-df279195feb2',\n",
              "  'year': 2020},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1447',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982248525,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:31628085',\n",
              "  'journalName': 'the lancet. respiratory medicine',\n",
              "  'name': 'efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, alk-positive non-small-cell lung cancer: a multicentre, phase 2 trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '31628085',\n",
              "  'updatedAt': 1612982248525,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/31628085',\n",
              "  'uuid': '84d3f0f9-b111-4787-ae83-7d703065c629',\n",
              "  'year': 2020},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1450',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982251236,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:30978502',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'safety and efficacy of crizotinib in patients with advanced or metastatic ros1-rearranged lung cancer (eucross): a european phase ii clinical trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '30978502',\n",
              "  'updatedAt': 1612982251236,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/30978502',\n",
              "  'uuid': '66fdfc25-c952-4d05-a8e1-71cc3d103e44',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1452',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982253381,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:30809568',\n",
              "  'journalName': 'gynecologic oncology reports',\n",
              "  'name': 'response to trametinib in recurrent low-grade serous ovarian cancer with <i>nras</i> mutation: a case report.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '30809568',\n",
              "  'updatedAt': 1612982253381,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/30809568',\n",
              "  'uuid': '40d1d178-246f-48f1-952f-9d229b584487',\n",
              "  'year': 2019},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1454',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612982254868,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:33408251',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'actl6a promotes repair of cisplatin-induced dna damage, a new mechanism of platinum resistance in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '33408251',\n",
              "  'updatedAt': 1612982254868,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/33408251',\n",
              "  'uuid': 'a096bba7-a56b-49e3-8c7d-c695271e13d8',\n",
              "  'year': 2021},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1458',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985128986,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26238431',\n",
              "  'journalName': 'european urology',\n",
              "  'name': 'defects in dna repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26238431',\n",
              "  'updatedAt': 1612985128986,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26238431',\n",
              "  'uuid': '6877a796-6f02-4832-8d7f-a83b91073ba1',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1459',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985130359,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23548269',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'atr inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of brca status.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23548269',\n",
              "  'updatedAt': 1612985130359,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23548269',\n",
              "  'uuid': '388a6e26-95c4-4f7c-b5fd-1f88ebc5f03c',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1461',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985132947,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27397505',\n",
              "  'journalName': 'cell',\n",
              "  'name': 'a landscape of pharmacogenomic interactions in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27397505',\n",
              "  'updatedAt': 1612985132947,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27397505',\n",
              "  'uuid': '109f5f19-89e2-4b59-9e7d-38878433b48f',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1463',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985138965,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26802155',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'selumetinib with and without erlotinib in kras mutant and kras wild-type advanced nonsmall-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26802155',\n",
              "  'updatedAt': 1612985138965,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26802155',\n",
              "  'uuid': 'ca0561d1-9d1b-4f7a-a885-260ba4bc28a8',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1464',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985140642,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24024839',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'panitumumab-folfox4 treatment and ras mutations in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24024839',\n",
              "  'updatedAt': 1612985140642,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24024839',\n",
              "  'uuid': 'eb706ce0-f775-419a-b3c4-2e382371c28b',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1465',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985144371,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25719666',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'whole genomes redefine the mutational landscape of pancreatic cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25719666',\n",
              "  'updatedAt': 1612985144371,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25719666',\n",
              "  'uuid': '2166bc51-8491-4bf9-98f1-ded77415c7cf',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1466',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985144844,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20609467',\n",
              "  'journalName': 'lancet (london, england)',\n",
              "  'name': 'oral poly(adp-ribose) polymerase inhibitor olaparib in patients with brca1 or brca2 mutations and advanced breast cancer: a proof-of-concept trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20609467',\n",
              "  'updatedAt': 1612985144844,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20609467',\n",
              "  'uuid': '06d86830-4ea8-44ee-8cde-6a26147959a7',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1467',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985145638,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26801247',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'phase i study of veliparib (abt-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or brca mutation-associated breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26801247',\n",
              "  'updatedAt': 1612985145638,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26801247',\n",
              "  'uuid': 'e860c872-3b34-4ad9-baac-33e5038a75aa',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1468',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985147580,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19238210',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'alterations in genes of the egfr signaling pathway and their relationship to egfr tyrosine kinase inhibitor sensitivity in lung cancer cell lines.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19238210',\n",
              "  'updatedAt': 1612985147580,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19238210',\n",
              "  'uuid': '4975dcc4-eea3-4071-af03-a4e7b02c5beb',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1473',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985173277,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24045185',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'efficacy of bet bromodomain inhibition in kras-mutant non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24045185',\n",
              "  'updatedAt': 1612985173277,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24045185',\n",
              "  'uuid': '65543236-2f55-4143-a4c6-3fb833055587',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1474',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985182335,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23934192',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'a high-throughput screen identifies parp1/2 inhibitors as a potential therapy for ercc1-deficient non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23934192',\n",
              "  'updatedAt': 1612985182335,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23934192',\n",
              "  'uuid': '3eeb21d6-3df3-4ce2-93ab-32516b7d02af',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1475',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985182809,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23275151',\n",
              "  'journalName': 'carcinogenesis',\n",
              "  'name': 'parp inhibition selectively increases sensitivity to cisplatin in ercc1-low non-small cell lung cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23275151',\n",
              "  'updatedAt': 1612985182809,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23275151',\n",
              "  'uuid': '0c75e6c5-5c86-4ee5-b047-270fbbef2651',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1492',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985210709,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26552009',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'swi/snf-mutant cancers depend on catalytic and non-catalytic activity of ezh2.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26552009',\n",
              "  'updatedAt': 1612985210709,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26552009',\n",
              "  'uuid': 'a741d624-fc08-426a-96eb-9c5bf713dcd5',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1496',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985221554,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23391555',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23391555',\n",
              "  'updatedAt': 1612985221554,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23391555',\n",
              "  'uuid': '702d903e-35db-4edb-83ab-c3e614539dc1',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1497',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985221554,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25722381',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'a randomized phase ii study of the mek1/mek2 inhibitor trametinib (gsk1120212) compared with docetaxel in kras-mutant advanced non-small-cell lung cancer (nsclc)†.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25722381',\n",
              "  'updatedAt': 1612985221554,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25722381',\n",
              "  'uuid': '5f589f8b-0bd7-45b3-97e8-8b32349b16c4',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1498',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985221560,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24947927',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'phase i expansion and pharmacodynamic study of the oral mek inhibitor ro4987655 (ch4987655) in selected patients with advanced cancer with ras-raf mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24947927',\n",
              "  'updatedAt': 1612985221560,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24947927',\n",
              "  'uuid': '3960d577-e092-4a41-a49e-66929ec784ed',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1500',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985222221,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19018267',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'kras or braf mutation status is a useful predictor of sensitivity to mek inhibition in ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19018267',\n",
              "  'updatedAt': 1612985222221,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19018267',\n",
              "  'uuid': '2a433c90-0c1a-4705-a569-2a9af98b359e',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1502',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985222703,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24296828',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'acquired resistance to dasatinib in lung cancer cell lines conferred by ddr2 gatekeeper mutation and nf1 loss.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24296828',\n",
              "  'updatedAt': 1612985222703,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24296828',\n",
              "  'uuid': 'dedb2d5e-db2f-40d1-9c59-e3168e1bedf5',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1504',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985224180,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24535670',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'reduced nf1 expression confers resistance to egfr inhibition in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24535670',\n",
              "  'updatedAt': 1612985224180,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24535670',\n",
              "  'uuid': 'f5334a1f-7c87-43d0-a745-76dc54fbffdd',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1506',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985859966,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24634382',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24634382',\n",
              "  'updatedAt': 1612985859966,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24634382',\n",
              "  'uuid': '153a3a95-60c3-412d-a86e-639d7a0df440',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1507',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985861447,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27269946',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'plasma esr1 mutations and the treatment of estrogen receptor-positive advanced breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27269946',\n",
              "  'updatedAt': 1612985861447,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27269946',\n",
              "  'uuid': 'ddd230ed-7087-4cc2-ae1d-744c98891402',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1508',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985862260,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28644771',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'biomarker-based phase ii trial of savolitinib in patients with advanced papillary renal cell cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28644771',\n",
              "  'updatedAt': 1612985862260,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28644771',\n",
              "  'uuid': '4a5350be-f436-4da9-b10f-d8e1f24ec733',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1509',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985863517,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21166756',\n",
              "  'journalName': 'bju international',\n",
              "  'name': 'the prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21166756',\n",
              "  'updatedAt': 1612985863517,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21166756',\n",
              "  'uuid': '80acebed-efa8-4d80-872e-f77b5e6bc4a4',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1547',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985908857,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24398047',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24398047',\n",
              "  'updatedAt': 1612985908857,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24398047',\n",
              "  'uuid': 'bbc4cadd-34f2-4405-9fa5-8a338706dcf3',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1549',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985910176,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26325560',\n",
              "  'journalName': 'jama',\n",
              "  'name': 'integrative clinical sequencing in the management of refractory or relapsed cancer in youth.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26325560',\n",
              "  'updatedAt': 1612985910176,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26325560',\n",
              "  'uuid': '76991b5d-48c9-44ed-83d0-155ba2b42967',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1553',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985912865,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20065189',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20065189',\n",
              "  'updatedAt': 1612985912865,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20065189',\n",
              "  'uuid': '6b49b5e2-2f24-4815-8dd8-bf31eccbb4fb',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1554',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985912869,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22025146',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase iii trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22025146',\n",
              "  'updatedAt': 1612985912869,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22025146',\n",
              "  'uuid': '08aeac89-81a3-45dc-86e8-887f6743fa8c',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1555',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985915051,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27338794',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'a combinatorial strategy for treating kras-mutant lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27338794',\n",
              "  'updatedAt': 1612985915051,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27338794',\n",
              "  'uuid': 'baa085f9-caf0-42c1-a889-317cbb4a76dd',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1557',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985916558,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19165201',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'lkb1/kras mutant lung cancers constitute a genetic subset of nsclc with increased sensitivity to mapk and mtor signalling inhibition.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19165201',\n",
              "  'updatedAt': 1612985916558,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19165201',\n",
              "  'uuid': '1804a3a0-e0ca-428c-9ec0-ff164c5dab1b',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1558',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985917319,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23352126',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'lkb1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23352126',\n",
              "  'updatedAt': 1612985917319,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23352126',\n",
              "  'uuid': 'b2cca7e2-9129-4abf-aed4-8bcdfc0f2105',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1567',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985932038,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26301689',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'ras-mapk dependence underlies a rational polytherapy strategy in eml4-alk-positive lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26301689',\n",
              "  'updatedAt': 1612985932038,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26301689',\n",
              "  'uuid': '7e0eb4e2-54ee-4866-b7bd-e6f95aaca2ed',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1568',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985932655,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23553849',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'a multicenter phase ii study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23553849',\n",
              "  'updatedAt': 1612985932655,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23553849',\n",
              "  'uuid': '86ffe45b-5702-44fc-ab4c-df91485ffe41',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1571',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985935509,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26951079',\n",
              "  'journalName': 'journal of hematology & oncology',\n",
              "  'name': 'second- and third-generation alk inhibitors for non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26951079',\n",
              "  'updatedAt': 1612985935509,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26951079',\n",
              "  'uuid': '9aac17ca-c1ce-4466-9e41-93d9df483ccc',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1572',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985936149,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22956644',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'her2 amplification: a potential mechanism of acquired resistance to egfr inhibition in egfr-mutant lung cancers that lack the second-site egfrt790m mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22956644',\n",
              "  'updatedAt': 1612985936149,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22956644',\n",
              "  'uuid': 'f92f568e-e1df-4bca-ae89-4d7e37ca2b8f',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1573',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985936761,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24882673',\n",
              "  'journalName': 'european urology',\n",
              "  'name': 'molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24882673',\n",
              "  'updatedAt': 1612985936761,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24882673',\n",
              "  'uuid': '3a4395d6-0a20-4bbc-be24-74cd0de0da6a',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1575',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985939468,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22649144',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'targeting the b-cell lymphoma/leukemia 2 family in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22649144',\n",
              "  'updatedAt': 1612985939468,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22649144',\n",
              "  'uuid': '556df1c1-4bdc-4731-b06e-693e66317ad3',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1577',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985941477,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20526349',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'rearrangements of the raf kinase pathway in prostate cancer, gastric cancer and melanoma.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20526349',\n",
              "  'updatedAt': 1612985941477,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20526349',\n",
              "  'uuid': 'e433b8c9-0388-4cfc-a1ee-a962decf53ca',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1582',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985952251,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22184395',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22184395',\n",
              "  'updatedAt': 1612985952251,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22184395',\n",
              "  'uuid': '180193b7-011d-4177-aaba-3c50ed033acd',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1584',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985956141,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18047674',\n",
              "  'journalName': 'genome biology',\n",
              "  'name': 'identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18047674',\n",
              "  'updatedAt': 1612985956141,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18047674',\n",
              "  'uuid': '0ba4c8b0-8327-4d8c-86e1-54f1dbe386e1',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1586',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985956147,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19861960',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'activity of the multikinase inhibitor dasatinib against ovarian cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19861960',\n",
              "  'updatedAt': 1612985956147,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19861960',\n",
              "  'uuid': 'e6db2182-395d-4205-ad4d-1830d6104594',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1587',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985957003,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23632474',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'combination neratinib (hki-272) and paclitaxel therapy in patients with her2-positive metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23632474',\n",
              "  'updatedAt': 1612985957003,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23632474',\n",
              "  'uuid': '9fa88f8f-0b59-4633-9c4e-f7dc9e234afe',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1588',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985957829,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25694417',\n",
              "  'journalName': 'european journal of cancer (oxford, england : 1990)',\n",
              "  'name': 'lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase ii trial of the arbeitsgemeinschaft internistische onkologie.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25694417',\n",
              "  'updatedAt': 1612985957829,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25694417',\n",
              "  'uuid': '104846e6-595c-45ae-91c6-788ce9a38530',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1589',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985958968,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24960402',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'a phase iia dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with her2-positive advanced gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24960402',\n",
              "  'updatedAt': 1612985958968,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24960402',\n",
              "  'uuid': '2e467847-4174-4215-ac20-9b4187f8a657',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1590',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985960226,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20975068',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase i study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20975068',\n",
              "  'updatedAt': 1612985960226,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20975068',\n",
              "  'uuid': '7c50ab33-e343-427e-a57a-8acb7a66dd32',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1591',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985960231,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21107682',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'phase i trial of oral mtor inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with her2-overexpressing metastatic breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21107682',\n",
              "  'updatedAt': 1612985960231,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21107682',\n",
              "  'uuid': '4c45bc5e-db7c-401a-bf1b-44a10ce60b70',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1592',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985960805,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21558407',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'hsp90 inhibition is effective in breast cancer: a phase ii trial of tanespimycin (17-aag) plus trastuzumab in patients with her2-positive metastatic breast cancer progressing on trastuzumab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21558407',\n",
              "  'updatedAt': 1612985960805,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21558407',\n",
              "  'uuid': '9c0e54a8-b1e2-4f40-b83a-7ab2d63269d8',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1593',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985961827,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23558291',\n",
              "  'journalName': 'biochemical and biophysical research communications',\n",
              "  'name': 'rapamycin inhibits fbxw7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23558291',\n",
              "  'updatedAt': 1612985961827,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23558291',\n",
              "  'uuid': 'a5124859-2064-41cb-a2c7-63896c87ec0c',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1595',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985965090,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26537258',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'plasma ar and abiraterone-resistant prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26537258',\n",
              "  'updatedAt': 1612985965090,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26537258',\n",
              "  'uuid': '34d20015-c973-4314-8af9-9c776961d271',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1599',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985973448,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27075627',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'triple-negative breast cancers with amplification of jak2 at the 9p24 locus demonstrate jak2-specific dependence.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27075627',\n",
              "  'updatedAt': 1612985973448,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27075627',\n",
              "  'uuid': '5a5ba60a-c0bb-41f4-82e5-d4ba58318fd4',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1603',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985974775,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21177407',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21177407',\n",
              "  'updatedAt': 1612985974775,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21177407',\n",
              "  'uuid': '44aabc1b-5c17-4b22-858b-49d68a644dc0',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1604',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985976150,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24458568',\n",
              "  'journalName': 'international journal of cancer',\n",
              "  'name': 'the insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24458568',\n",
              "  'updatedAt': 1612985976150,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24458568',\n",
              "  'uuid': '35ddc041-1d47-4c95-a211-870efc40e30c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1606',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985978297,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22729845',\n",
              "  'journalName': 'molecular cancer therapeutics',\n",
              "  'name': 'antitumor action of the met tyrosine kinase inhibitor crizotinib (pf-02341066) in gastric cancer positive for met amplification.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22729845',\n",
              "  'updatedAt': 1612985978297,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22729845',\n",
              "  'uuid': 'cff861f0-176f-443f-a61a-2486293ab818',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1607',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612985978299,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23327903',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'met amplification as a potential therapeutic target in gastric cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23327903',\n",
              "  'updatedAt': 1612985978299,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23327903',\n",
              "  'uuid': '02f2dd76-0b85-4b0c-8bfd-e730685e5f92',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1621',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986000496,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23708653',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'targeting cell cycle and hormone receptor pathways in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23708653',\n",
              "  'updatedAt': 1612986000496,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23708653',\n",
              "  'uuid': 'e9eac78e-d5dd-4f17-990a-842bee61df4e',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1622',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986000965,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22327622',\n",
              "  'journalName': 'nature medicine',\n",
              "  'name': 'identification of new alk and ret gene fusions from colorectal and lung cancer biopsies.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22327622',\n",
              "  'updatedAt': 1612986000965,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22327622',\n",
              "  'uuid': '5dd52abd-3a02-4115-8296-1debf47f58fe',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1624',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986002249,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:28447912',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'targeting ret in patients with ret-rearranged lung cancers: results from the global, multicenter ret registry.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '28447912',\n",
              "  'updatedAt': 1612986002249,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/28447912',\n",
              "  'uuid': 'b6ebbc5b-6aba-4255-b35f-fc437a980823',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1625',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986002679,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21470995',\n",
              "  'journalName': 'the journal of clinical endocrinology and metabolism',\n",
              "  'name': 'the effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21470995',\n",
              "  'updatedAt': 1612986002679,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21470995',\n",
              "  'uuid': '3acfd9f5-f5d0-4903-9201-bf3ed6240f8d',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1626',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986003604,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23533265',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'targeted inhibition of the molecular chaperone hsp90 overcomes alk inhibitor resistance in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23533265',\n",
              "  'updatedAt': 1612986003604,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23533265',\n",
              "  'uuid': 'eb51f044-8807-4e45-a462-777f6e4a3836',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1627',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986004029,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:27370605',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'identification of existing drugs that effectively target ntrk1 and ros1 rearrangements in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '27370605',\n",
              "  'updatedAt': 1612986004029,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/27370605',\n",
              "  'uuid': 'b61a500e-261a-4d80-96ab-74606a55f6f4',\n",
              "  'year': 2017},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1628',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986006031,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21575865',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'mechanistic rationale for inhibition of poly(adp-ribose) polymerase in ets gene fusion-positive prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21575865',\n",
              "  'updatedAt': 1612986006031,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21575865',\n",
              "  'uuid': '92a60b85-f1e1-466c-90e9-cfc74f9c4506',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1629',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986038384,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22864769',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'top2a amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22864769',\n",
              "  'updatedAt': 1612986038384,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22864769',\n",
              "  'uuid': '36fc3a02-5bcf-429e-9edd-20b7388854e7',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1639',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986235749,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12374230',\n",
              "  'journalName': 'scandinavian journal of gastroenterology',\n",
              "  'name': 'mutations of the apc gene in human sporadic colorectal cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12374230',\n",
              "  'updatedAt': 1612986235749,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12374230',\n",
              "  'uuid': '7adb5ce9-c0ba-49cf-8c4e-a7286f9e5077',\n",
              "  'year': 2002},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1641',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986235749,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15016963',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'high frequency of mutations of the pik3ca gene in human cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15016963',\n",
              "  'updatedAt': 1612986235749,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15016963',\n",
              "  'uuid': 'c7f5cda1-f829-4cb7-85b3-2f9a074e3b54',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1644',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986235909,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15254419',\n",
              "  'journalName': 'cancer biology & therapy',\n",
              "  'name': 'the pik3ca gene is mutated with high frequency in human breast cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15254419',\n",
              "  'updatedAt': 1612986235909,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15254419',\n",
              "  'uuid': 'ff28cf40-c9db-47be-9653-e0abbfe3ba70',\n",
              "  'year': 2004},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1648',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986235966,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16140923',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'somatic mutations of the protein kinase gene family in human lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16140923',\n",
              "  'updatedAt': 1612986235966,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16140923',\n",
              "  'uuid': '5723e4a2-25a4-4f65-8e9e-81dbe6040028',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1649',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986235970,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15930273',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'functional analysis of pik3ca gene mutations in human colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15930273',\n",
              "  'updatedAt': 1612986235970,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15930273',\n",
              "  'uuid': 'e0cb9121-b127-4146-a899-6fb1e135d7df',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1664',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986236390,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16930767',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'pik3ca mutation status in japanese lung cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16930767',\n",
              "  'updatedAt': 1612986236390,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16930767',\n",
              "  'uuid': '12c483c9-f015-4baf-a5a2-3dfffd3ff9e1',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1667',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986236661,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17704924',\n",
              "  'journalName': 'international journal of colorectal disease',\n",
              "  'name': 'genetic alterations of apc, k-ras, p53, msi, and mage in korean colorectal cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17704924',\n",
              "  'updatedAt': 1612986236661,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17704924',\n",
              "  'uuid': '5a3def6c-2158-4936-9432-a01c4df2e98c',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1672',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986236934,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18676830',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'an integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18676830',\n",
              "  'updatedAt': 1612986236934,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18676830',\n",
              "  'uuid': '3f062ec8-a591-4f9d-8d97-11fa4cafb1d5',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1673',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986236936,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25157968',\n",
              "  'journalName': 'the journal of molecular diagnostics : jmd',\n",
              "  'name': 'prospective enterprise-level molecular genotyping of a cohort of cancer patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25157968',\n",
              "  'updatedAt': 1612986236936,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25157968',\n",
              "  'uuid': 'c17b2235-505d-486c-9f59-07d653bd714e',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1679',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986237015,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26619011',\n",
              "  'journalName': 'nature biotechnology',\n",
              "  'name': 'identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26619011',\n",
              "  'updatedAt': 1612986237015,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26619011',\n",
              "  'uuid': '9ebd44a9-634f-435d-a8d5-19fc3a62effa',\n",
              "  'year': 2016},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1687',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986237423,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11569495',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'roots of clinical resistance to sti-571 cancer therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11569495',\n",
              "  'updatedAt': 1612986237423,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11569495',\n",
              "  'uuid': '824095b3-fcd1-4bf0-a18e-755dffb1a036',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1699',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986241047,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24163374',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'mtor inhibition specifically sensitizes colorectal cancers with kras or braf mutations to bcl-2/bcl-xl inhibition by suppressing mcl-1.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24163374',\n",
              "  'updatedAt': 1612986241047,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24163374',\n",
              "  'uuid': 'ca09f1fc-c522-4392-8740-f0bb3afd6aea',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1702',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986241051,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:9598803',\n",
              "  'journalName': 'genes, chromosomes & cancer',\n",
              "  'name': 'inactivation of the pten/mmac1/tep1 gene in human lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '9598803',\n",
              "  'updatedAt': 1612986241051,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/9598803',\n",
              "  'uuid': '728c7f6f-4959-480a-88db-0836a518ee36',\n",
              "  'year': 1998},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1709',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986241646,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24861525',\n",
              "  'journalName': 'revista de gastroenterologia de mexico',\n",
              "  'name': 'genetic analysis in apc, kras, and tp53 in patients with stomach and colon cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24861525',\n",
              "  'updatedAt': 1612986241646,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24861525',\n",
              "  'uuid': '95157149-093a-4dd6-ab94-1ede8c59d2b6',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1713',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986241654,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16011858',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'mutations in the tyrosine kinase domain of the egfr gene associated with gefitinib response in non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16011858',\n",
              "  'updatedAt': 1612986241654,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16011858',\n",
              "  'uuid': '774e5a35-5e8f-4f5a-8d32-fe340c2bb00d',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1718',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986241813,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17653080',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'egfr mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of src: implications in targeting therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17653080',\n",
              "  'updatedAt': 1612986241813,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17653080',\n",
              "  'uuid': '3737c4ee-4db4-4674-bbf4-e668da609dde',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1733',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242355,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21367659',\n",
              "  'journalName': 'trends in molecular medicine',\n",
              "  'name': 'targeting mutant fibroblast growth factor receptors in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21367659',\n",
              "  'updatedAt': 1612986242355,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21367659',\n",
              "  'uuid': '78e91727-72af-4b01-a1f0-f9cdb67a645b',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1734',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242355,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20921465',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized, phase iii trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (folfox4) versus folfox4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the prime study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20921465',\n",
              "  'updatedAt': 1612986242355,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20921465',\n",
              "  'uuid': '952311a9-a9a8-46e7-877d-91f201f82d66',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1736',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242377,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21228335',\n",
              "  'journalName': 'annals of oncology : official journal of the european society for medical oncology',\n",
              "  'name': 'efficacy according to biomarker status of cetuximab plus folfox-4 as first-line treatment for metastatic colorectal cancer: the opus study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21228335',\n",
              "  'updatedAt': 1612986242377,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21228335',\n",
              "  'uuid': 'b12b8fca-79e4-4c05-9bcd-aeacd0c5f3bd',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1738',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242378,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21398618',\n",
              "  'journalName': 'journal of the national cancer institute',\n",
              "  'name': 'effect of simvastatin on cetuximab resistance in human colorectal cancer with kras mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21398618',\n",
              "  'updatedAt': 1612986242378,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21398618',\n",
              "  'uuid': '79329cd9-de24-4c69-82c0-3386057e6d31',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1739',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242378,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20921462',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized phase iii study of panitumumab with fluorouracil, leucovorin, and irinotecan (folfiri) compared with folfiri alone as second-line treatment in patients with metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20921462',\n",
              "  'updatedAt': 1612986242378,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20921462',\n",
              "  'uuid': '6c59d1d1-28bd-4ac5-be86-7757c3e1c768',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1740',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242387,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20881644',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20881644',\n",
              "  'updatedAt': 1612986242387,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20881644',\n",
              "  'uuid': '2c2566ec-3a54-41b6-8a29-554af939ce7d',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1741',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242388,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18392055',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'mutational analysis of oncogenic akt e17k mutation in common solid cancers and acute leukaemias.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18392055',\n",
              "  'updatedAt': 1612986242388,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18392055',\n",
              "  'uuid': '91c0546d-4680-4c8d-9883-0fb53f98ceb5',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1742',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242387,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17676035',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'lkb1 modulates lung cancer differentiation and metastasis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17676035',\n",
              "  'updatedAt': 1612986242387,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17676035',\n",
              "  'uuid': '5b1dbe7a-38ac-4d68-879c-0e652ff0178d',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1745',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242436,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18611285',\n",
              "  'journalName': 'bmc research notes',\n",
              "  'name': 'detection of the transforming akt1 mutation e17k in non-small cell lung cancer by high resolution melting.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18611285',\n",
              "  'updatedAt': 1612986242436,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18611285',\n",
              "  'uuid': 'ec0f117e-06bd-46b0-a12b-b735697a0149',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1746',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242530,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17611497',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'a transforming mutation in the pleckstrin homology domain of akt1 in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17611497',\n",
              "  'updatedAt': 1612986242530,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17611497',\n",
              "  'uuid': '073f488a-27a3-4f3d-8abb-882841133d7c',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1757',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242746,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18339846',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'prediction of cancer driver mutations in protein kinases.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18339846',\n",
              "  'updatedAt': 1612986242746,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18339846',\n",
              "  'uuid': '83dcb053-f266-4b5b-974e-782b8edf0373',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1764',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986242976,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19692684',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'screening for epidermal growth factor receptor mutations in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19692684',\n",
              "  'updatedAt': 1612986242976,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19692684',\n",
              "  'uuid': '173d9db5-71e1-4b1b-aaf1-c9905fc188ea',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1765',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243033,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19922469',\n",
              "  'journalName': 'the febs journal',\n",
              "  'name': 'epidermal growth factor receptor in relation to tumor development: egfr gene and cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19922469',\n",
              "  'updatedAt': 1612986243033,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19922469',\n",
              "  'uuid': '2b709035-2cab-4b04-bb04-c1fd9493428f',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1766',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243033,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20068085',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'analysis of genetic variants in never-smokers with lung cancer facilitated by an internet-based blood collection protocol: a preliminary report.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20068085',\n",
              "  'updatedAt': 1612986243033,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20068085',\n",
              "  'uuid': '010bda10-5ae3-49e3-9190-8af898b10eca',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1767',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243038,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18594010',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'eml4-alk fusion gene and efficacy of an alk kinase inhibitor in lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18594010',\n",
              "  'updatedAt': 1612986243038,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18594010',\n",
              "  'uuid': '19fc6c0e-2b32-4fad-80fd-82e6d14672e5',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1770',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243045,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20479403',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'neratinib, an irreversible pan-erbb receptor tyrosine kinase inhibitor: results of a phase ii trial in patients with advanced non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20479403',\n",
              "  'updatedAt': 1612986243045,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20479403',\n",
              "  'uuid': 'cc8901bf-34a3-4dbf-809c-dfcdd5ea7022',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1771',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243046,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20573926',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'gefitinib or chemotherapy for non-small-cell lung cancer with mutated egfr.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20573926',\n",
              "  'updatedAt': 1612986243046,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20573926',\n",
              "  'uuid': '74995d13-485d-4fb4-920b-c93e9fb1342a',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1774',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243580,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25656898',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25656898',\n",
              "  'updatedAt': 1612986243580,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25656898',\n",
              "  'uuid': '3fbee80e-cdc9-4786-b507-18e508220f86',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1777',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243596,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18559588',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'somatic mutations of jak1 and jak3 in acute leukemias and solid cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18559588',\n",
              "  'updatedAt': 1612986243596,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18559588',\n",
              "  'uuid': '90dad96a-4d3d-4931-a769-2fd9fafcd346',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1782',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243845,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19351834',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'pten loss contributes to erlotinib resistance in egfr-mutant lung cancer by activation of akt and egfr.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19351834',\n",
              "  'updatedAt': 1612986243845,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19351834',\n",
              "  'uuid': '0054c7ff-cc6c-449d-a9f5-8971672ae537',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1783',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243845,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19679400',\n",
              "  'journalName': 'pathology, research and practice',\n",
              "  'name': 'frequency and type of kras mutations in routine diagnostic analysis of metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19679400',\n",
              "  'updatedAt': 1612986243845,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19679400',\n",
              "  'uuid': '1bc8937c-f098-443a-a36c-cbdde6ac06b4',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1786',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243879,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12068308',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'mutations of the braf gene in human cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12068308',\n",
              "  'updatedAt': 1612986243879,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12068308',\n",
              "  'uuid': '74823cc9-7a64-488a-a096-cba8d8aef802',\n",
              "  'year': 2002},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1794',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243960,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17603485',\n",
              "  'journalName': 'nature genetics',\n",
              "  'name': 'two variants on chromosome 17 confer prostate cancer risk, and the one in tcf2 protects against type 2 diabetes.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17603485',\n",
              "  'updatedAt': 1612986243960,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17603485',\n",
              "  'uuid': '5c19e9c7-72b6-4d7e-bab3-36486020af66',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1795',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243966,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12460918',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'braf and ras mutations in human lung cancer and melanoma.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12460918',\n",
              "  'updatedAt': 1612986243966,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12460918',\n",
              "  'uuid': 'b8c68d8f-04e0-4ba4-8c88-9cf1c9b67d47',\n",
              "  'year': 2002},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1796',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243966,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17384584',\n",
              "  'journalName': 'nature reviews. cancer',\n",
              "  'name': 'hyperactive ras in developmental disorders and cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17384584',\n",
              "  'updatedAt': 1612986243966,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17384584',\n",
              "  'uuid': '060afa10-43c5-43b3-a9de-3018c215e59b',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1806',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243976,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18628075',\n",
              "  'journalName': 'clinical & translational oncology : official publication of the federation of spanish oncology societies and of the national cancer institute of mexico',\n",
              "  'name': 'a novel egfr nonsense mutation in a non-small-cell lung cancer (nsclc) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18628075',\n",
              "  'updatedAt': 1612986243976,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18628075',\n",
              "  'uuid': '39e45409-f723-4319-8c0e-4d71e277291e',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1807',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243976,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20018398',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'pten mutations and relationship to egfr, erbb2, kras, and tp53 mutations in non-small cell lung cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20018398',\n",
              "  'updatedAt': 1612986243976,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20018398',\n",
              "  'uuid': 'b3d4f987-a0ae-49f1-bbb9-7dca41ba4696',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1808',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986243990,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18458038',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'first-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic egfr mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18458038',\n",
              "  'updatedAt': 1612986243990,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18458038',\n",
              "  'uuid': '6c272d83-db99-4ae0-b2f7-09807a032016',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1812',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244311,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22753918',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'randomized phase ii study of dacomitinib (pf-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22753918',\n",
              "  'updatedAt': 1612986244311,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22753918',\n",
              "  'uuid': '4c04f667-e120-4a14-9168-376bfaed023c',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1824',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244325,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20847059',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'phase ii study of daily sunitinib in fdg-pet-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20847059',\n",
              "  'updatedAt': 1612986244325,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20847059',\n",
              "  'uuid': '36af1157-0cdd-435a-9c90-3276cdc0764a',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1825',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244326,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18682749',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'germline ephb2 receptor variants in familial colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18682749',\n",
              "  'updatedAt': 1612986244326,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18682749',\n",
              "  'uuid': '63e5883c-0ef6-4749-9a98-9eaac8b2469e',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1838',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244675,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:10479724',\n",
              "  'journalName': 'mutation research',\n",
              "  'name': 'inactivation of both alleles of the dpc4/smad4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from japanese patients.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '10479724',\n",
              "  'updatedAt': 1612986244675,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/10479724',\n",
              "  'uuid': '56f27f84-0a90-4b83-a15b-feeddbadb078',\n",
              "  'year': 1999},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1840',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244677,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23578570',\n",
              "  'journalName': 'european journal of cancer (oxford, england : 1990)',\n",
              "  'name': 'a patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23578570',\n",
              "  'updatedAt': 1612986244677,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23578570',\n",
              "  'uuid': 'e4efcdf9-3f88-4515-8d28-4326dd3ce525',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1843',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244680,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23549875',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'concomitant braf and pi3k/mtor blockade is required for effective treatment of braf(v600e) colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23549875',\n",
              "  'updatedAt': 1612986244680,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23549875',\n",
              "  'uuid': '78546942-e3e8-45bd-991d-0a00835c9bab',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1845',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244682,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11535556',\n",
              "  'journalName': 'cancer epidemiology, biomarkers & prevention : a publication of the american association for cancer research, cosponsored by the american society of preventive oncology',\n",
              "  'name': 'tp53 polymorphism, hpv infection, and risk of cervical cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11535556',\n",
              "  'updatedAt': 1612986244682,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11535556',\n",
              "  'uuid': '0d8d201a-bc55-4d13-9185-65427cd64692',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1847',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244684,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24217577',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'd538g mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24217577',\n",
              "  'updatedAt': 1612986244684,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24217577',\n",
              "  'uuid': '4d38d2a9-09f8-4b47-9013-12b65f495df6',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1849',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244695,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12840112',\n",
              "  'journalName': 'mutagenesis',\n",
              "  'name': 'tp53 polymorphisms and lung cancer risk: a systematic review and meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12840112',\n",
              "  'updatedAt': 1612986244695,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12840112',\n",
              "  'uuid': '3d7bfaf5-2771-4ada-b6d6-d745ecaf750c',\n",
              "  'year': 2003},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1850',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244695,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23816963',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'lux-lung 4: a phase ii trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23816963',\n",
              "  'updatedAt': 1612986244695,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23816963',\n",
              "  'uuid': '62087b0b-4151-4f3a-a172-0eed92b05c4d',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1851',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244696,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23800712',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'revisiting clinical trials using egfr inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an md anderson cancer center phase i population.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23800712',\n",
              "  'updatedAt': 1612986244696,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23800712',\n",
              "  'uuid': 'ba93c225-c94c-4ba4-aa08-686656468166',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1857',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244864,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18767981',\n",
              "  'journalName': 'annual review of pathology',\n",
              "  'name': 'pten and the pi3-kinase pathway in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18767981',\n",
              "  'updatedAt': 1612986244864,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18767981',\n",
              "  'uuid': '194e729a-175f-4657-b259-5d6295a84aad',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1858',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244967,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22114986',\n",
              "  'journalName': 'breast cancer research : bcr',\n",
              "  'name': 'chek2 contribution to hereditary breast cancer in non-brca families.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22114986',\n",
              "  'updatedAt': 1612986244967,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22114986',\n",
              "  'uuid': 'c2c8e51e-602d-4419-9ebe-6ed3b232fb85',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1865',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986244993,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18541894',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii trial of sorafenib in advanced thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18541894',\n",
              "  'updatedAt': 1612986244993,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18541894',\n",
              "  'uuid': '221e77fb-9455-492a-8f28-3bcef5bce1d9',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1885',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247048,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23934607',\n",
              "  'journalName': 'virchows archiv : an international journal of pathology',\n",
              "  'name': 'alterations in the egfr pathway coincide in colorectal cancer and impact on prognosis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23934607',\n",
              "  'updatedAt': 1612986247048,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23934607',\n",
              "  'uuid': '6a76bc74-df0b-4a4c-9e14-3a115a34f700',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1887',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247048,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:25989278',\n",
              "  'journalName': 'british journal of cancer',\n",
              "  'name': 'meta-analysis of braf mutation as a predictive biomarker of benefit from anti-egfr monoclonal antibody therapy for ras wild-type metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '25989278',\n",
              "  'updatedAt': 1612986247048,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/25989278',\n",
              "  'uuid': 'e2c63c1b-7f32-468b-91fc-8a7af7808e25',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1888',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247128,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17909070',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'do mdm2 snp309 and tp53 r72p interact in breast cancer susceptibility? a large pooled series from the breast cancer association consortium.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17909070',\n",
              "  'updatedAt': 1612986247128,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17909070',\n",
              "  'uuid': 'fdd77035-86ba-40b1-8f2b-770e02da68b1',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1908',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247715,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20350999',\n",
              "  'journalName': 'the oncologist',\n",
              "  'name': 'prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20350999',\n",
              "  'updatedAt': 1612986247715,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20350999',\n",
              "  'uuid': '47fa5a37-7dd0-4bd7-9b9c-897f0d680c2a',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1909',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247716,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20233444',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'a rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20233444',\n",
              "  'updatedAt': 1612986247716,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20233444',\n",
              "  'uuid': '48b287ad-b91e-47e8-81c0-1771bd864537',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1917',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247740,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23237847',\n",
              "  'journalName': 'oncotarget',\n",
              "  'name': 'functional analysis of non-hotspot akt1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23237847',\n",
              "  'updatedAt': 1612986247740,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23237847',\n",
              "  'uuid': '38e87533-fac7-4695-9942-c4513a22bb86',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1920',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247758,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19537845',\n",
              "  'journalName': 'molecular diagnosis & therapy',\n",
              "  'name': 'clinical biomarkers in oncology: focus on colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19537845',\n",
              "  'updatedAt': 1612986247758,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19537845',\n",
              "  'uuid': 'a7a1c459-5783-47de-bb59-879bb0204d21',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1923',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247759,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21129611',\n",
              "  'journalName': 'cancer treatment reviews',\n",
              "  'name': 'prognostic vs predictive molecular biomarkers in colorectal cancer: is kras and braf wild type status required for anti-egfr therapy?',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21129611',\n",
              "  'updatedAt': 1612986247759,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21129611',\n",
              "  'uuid': '54472d8a-cc15-4316-80f4-5ee25c744bb6',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1929',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986247873,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20857202',\n",
              "  'journalName': 'molecular biology reports',\n",
              "  'name': 'braf v600e mutation and resistance to anti-egfr monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20857202',\n",
              "  'updatedAt': 1612986247873,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20857202',\n",
              "  'uuid': 'ac480312-d8b1-484f-9792-4e897d4c7b72',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1934',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248111,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20413299',\n",
              "  'journalName': 'european journal of cancer (oxford, england : 1990)',\n",
              "  'name': 'markers for egfr pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20413299',\n",
              "  'updatedAt': 1612986248111,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20413299',\n",
              "  'uuid': '6ce91d83-1a23-493c-9343-6a2827daa7dd',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1937',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248120,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21426297',\n",
              "  'journalName': 'anti-cancer agents in medicinal chemistry',\n",
              "  'name': 'braf as a target for cancer therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21426297',\n",
              "  'updatedAt': 1612986248120,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21426297',\n",
              "  'uuid': 'f2c19ea2-477f-446f-b98e-ca7603078db8',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1939',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248120,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22734028',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'association of kras g13d tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22734028',\n",
              "  'updatedAt': 1612986248120,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22734028',\n",
              "  'uuid': '43e3d1c3-0e7c-41a4-8458-8cd81a981cbb',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1951',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248147,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21975775',\n",
              "  'journalName': 'the cochrane database of systematic reviews',\n",
              "  'name': 'epidermal growth factor receptor blockers for the treatment of ovarian cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21975775',\n",
              "  'updatedAt': 1612986248147,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21975775',\n",
              "  'uuid': '526d0da5-7e63-4552-ad9f-25c07f989d98',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1953',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248149,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22448344',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'egfr-mediated re-activation of mapk signaling contributes to insensitivity of braf mutant colorectal cancers to raf inhibition with vemurafenib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22448344',\n",
              "  'updatedAt': 1612986248149,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22448344',\n",
              "  'uuid': 'fa16543f-13af-4bfc-94f5-ea0eee561d57',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1958',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248373,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16094359',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'colorectal cancer: mutations in a signalling pathway.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16094359',\n",
              "  'updatedAt': 1612986248373,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16094359',\n",
              "  'uuid': '28a4c0bb-16ff-4afe-89d4-5229e23dd5de',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1967',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248457,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22538770',\n",
              "  'journalName': 'breast cancer research and treatment',\n",
              "  'name': 'mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22538770',\n",
              "  'updatedAt': 1612986248457,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22538770',\n",
              "  'uuid': '2aefebef-3623-4918-9ce8-dcdbc545d6ec',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1981',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248815,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23833300',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'clinical, pathologic, and biologic features associated with braf mutations in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23833300',\n",
              "  'updatedAt': 1612986248815,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23833300',\n",
              "  'uuid': '87bcda7f-5b6b-4b45-8a69-4c7bc3a2e38c',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1983',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248819,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23251002',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'resistance to braf inhibition in braf-mutant colon cancer can be overcome with pi3k inhibition or demethylating agents.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23251002',\n",
              "  'updatedAt': 1612986248819,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23251002',\n",
              "  'uuid': '72cb2d3f-b7cb-46f8-b487-fa09876c54c4',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1985',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248825,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23489023',\n",
              "  'journalName': 'thyroid : official journal of the american thyroid association',\n",
              "  'name': 'clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring braf(v600e) mutation.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23489023',\n",
              "  'updatedAt': 1612986248825,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23489023',\n",
              "  'uuid': 'ce7da6b1-c743-49cc-8ce9-f31203d688e4',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1989',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248830,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23182985',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'mutant kras codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23182985',\n",
              "  'updatedAt': 1612986248830,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23182985',\n",
              "  'uuid': '95051c7c-6539-444c-8da2-7cb68b259b18',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:1998',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248852,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23680147',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'oncogenic erbb3 mutations in human cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23680147',\n",
              "  'updatedAt': 1612986248852,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23680147',\n",
              "  'uuid': 'c07a507c-dd7f-4c10-ae4e-bb533fadec2b',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2004',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248934,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22908275',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of erbb2.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22908275',\n",
              "  'updatedAt': 1612986248934,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22908275',\n",
              "  'uuid': '804d7727-c923-4db2-bcef-e87e22927620',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2005',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248943,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22722201',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'the landscape of cancer genes and mutational processes in breast cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22722201',\n",
              "  'updatedAt': 1612986248943,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22722201',\n",
              "  'uuid': '585992d5-bc19-4d59-83ce-b13723e60e08',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2006',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986248992,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24558511',\n",
              "  'journalName': 'gastrointestinal cancer research : gcr',\n",
              "  'name': 'kras g13d mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24558511',\n",
              "  'updatedAt': 1612986248992,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24558511',\n",
              "  'uuid': 'da032e4d-e5ac-484f-90fe-893e47e6b4e1',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2007',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986249051,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:26623049',\n",
              "  'journalName': 'molecular and clinical oncology',\n",
              "  'name': 'cetuximab treatment for metastatic colorectal cancer with kras p.g13d mutations improves progression-free survival.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '26623049',\n",
              "  'updatedAt': 1612986249051,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/26623049',\n",
              "  'uuid': '0071ede0-bc33-4f85-a307-f2e33c8053cd',\n",
              "  'year': 2015},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2011',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986249085,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22610119',\n",
              "  'journalName': 'nature genetics',\n",
              "  'name': 'exome sequencing identifies recurrent spop, foxa1 and med12 mutations in prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22610119',\n",
              "  'updatedAt': 1612986249085,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22610119',\n",
              "  'uuid': 'e856aa7f-e094-44dd-975e-443750dd8907',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2016',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986249130,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22722839',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'the mutational landscape of lethal castration-resistant prostate cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22722839',\n",
              "  'updatedAt': 1612986249130,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22722839',\n",
              "  'uuid': 'dcf82289-9722-4140-b8b5-ad7593e50d48',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2021',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986249306,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20140017',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'activating rock1 somatic mutations in human cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20140017',\n",
              "  'updatedAt': 1612986249306,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20140017',\n",
              "  'uuid': 'd4ea29a3-d5e6-4300-b6f2-859136f2ca65',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2024',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986249876,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:9679244',\n",
              "  'journalName': 'molecular medicine today',\n",
              "  'name': 'tgf-beta signaling and cancer: structural and functional consequences of mutations in smads.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '9679244',\n",
              "  'updatedAt': 1612986249876,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/9679244',\n",
              "  'uuid': '370898b8-94de-45ed-9256-ff329e24a0d1',\n",
              "  'year': 1998},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2025',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986249876,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:8898652',\n",
              "  'journalName': 'gastroenterology',\n",
              "  'name': 'somatic alterations of the dpc4 gene in human colorectal cancers in vivo.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '8898652',\n",
              "  'updatedAt': 1612986249876,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/8898652',\n",
              "  'uuid': '744f41c3-05bd-47b0-a3fa-12b15b6de80c',\n",
              "  'year': 1996},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2032',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250153,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19114683',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19114683',\n",
              "  'updatedAt': 1612986250153,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19114683',\n",
              "  'uuid': 'ebe9824d-105e-4596-8ac2-2404c61f123e',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2034',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250166,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19881948',\n",
              "  'journalName': 'neoplasia (new york, n.y.)',\n",
              "  'name': 'braf(v600e) efficient transformation and induction of microsatellite instability versus kras(g12v) induction of senescence markers in human colon cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19881948',\n",
              "  'updatedAt': 1612986250166,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19881948',\n",
              "  'uuid': 'bdd9ae66-7699-4998-8100-0e2509b50de3',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2037',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250171,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:15710947',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '15710947',\n",
              "  'updatedAt': 1612986250171,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/15710947',\n",
              "  'uuid': 'b28c4a7d-447c-460d-bbbc-4c6681cff1f1',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2040',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250563,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16730855',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'double mutation and gene copy number of egfr in gefitinib refractory non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16730855',\n",
              "  'updatedAt': 1612986250563,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16730855',\n",
              "  'uuid': 'fc7539bd-43a2-41d2-a79a-1cd86ad252ad',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2042',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250573,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18829470',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/met signaling in cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18829470',\n",
              "  'updatedAt': 1612986250573,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18829470',\n",
              "  'uuid': 'dacb5fba-c3d3-402f-8507-b3e182d7b967',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2045',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250580,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:17332364',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '17332364',\n",
              "  'updatedAt': 1612986250580,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/17332364',\n",
              "  'uuid': '12884789-f1cd-4034-ac65-70b26b17afa4',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2046',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250587,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16912157',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'presence of epidermal growth factor receptor gene t790m mutation as a minor clone in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16912157',\n",
              "  'updatedAt': 1612986250587,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16912157',\n",
              "  'uuid': '2fdb2597-1d0b-4edb-8380-8a4f137c6604',\n",
              "  'year': 2006},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2047',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250587,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16258541',\n",
              "  'journalName': 'nature genetics',\n",
              "  'name': 'inherited susceptibility to lung cancer may be associated with the t790m drug resistance mutation in egfr.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16258541',\n",
              "  'updatedAt': 1612986250587,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16258541',\n",
              "  'uuid': '2411929c-fd83-4f5a-9682-965f514754db',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2048',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250599,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21194487',\n",
              "  'journalName': 'bmc cancer',\n",
              "  'name': 'clinical responses to egfr-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21194487',\n",
              "  'updatedAt': 1612986250599,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21194487',\n",
              "  'uuid': '8cbbae89-92e3-4343-ab8a-f4e6ab739d6e',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2050',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250604,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21233402',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pretreatment egfr t790m mutation and brca1 mrna expression in erlotinib-treated advanced non-small-cell lung cancer patients with egfr mutations.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21233402',\n",
              "  'updatedAt': 1612986250604,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21233402',\n",
              "  'uuid': '14cff8c0-e1d5-43bb-af0a-6f62bfe05ea3',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2051',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250604,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20581473',\n",
              "  'journalName': 'cancer biology & therapy',\n",
              "  'name': 'prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (chasm).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20581473',\n",
              "  'updatedAt': 1612986250604,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20581473',\n",
              "  'uuid': 'e6f67316-88b7-4c24-b733-d5c19295d570',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2053',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250622,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21683865',\n",
              "  'journalName': 'human pathology',\n",
              "  'name': 'molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21683865',\n",
              "  'updatedAt': 1612986250622,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21683865',\n",
              "  'uuid': '6073f0ef-cf56-4bfe-a2c4-a370c0bb4e35',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2055',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250655,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21274259',\n",
              "  'journalName': 'journal of oncology',\n",
              "  'name': 'screening for egfr mutations in patients with head and neck cancer treated with gefitinib on a compassionate-use program: a hellenic cooperative oncology group study.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21274259',\n",
              "  'updatedAt': 1612986250655,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21274259',\n",
              "  'uuid': '0e43218e-2ebc-4aab-bc9e-d1a9c5b3e12a',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2056',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250728,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22215752',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'pretreatment epidermal growth factor receptor (egfr) t790m mutation predicts shorter egfr tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22215752',\n",
              "  'updatedAt': 1612986250728,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22215752',\n",
              "  'uuid': 'aed9af48-6e89-400f-84ce-96cb3b222f39',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2057',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250728,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22588155',\n",
              "  'journalName': 'journal of thoracic oncology : official publication of the international association for the study of lung cancer',\n",
              "  'name': 'screening for germline egfr t790m mutations through lung cancer genotyping.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22588155',\n",
              "  'updatedAt': 1612986250728,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22588155',\n",
              "  'uuid': '4cc1602c-2494-4906-b3a9-1d3bc01812d2',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2058',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250730,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21670455',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'biomarker analyses and final overall survival results from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in asia (ipass).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21670455',\n",
              "  'updatedAt': 1612986250730,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21670455',\n",
              "  'uuid': '4a387e8f-56ca-471a-bc0d-226fd9623016',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2063',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250936,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22649091',\n",
              "  'journalName': 'science translational medicine',\n",
              "  'name': 'kinase-impaired braf mutations in lung cancer confer sensitivity to dasatinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22649091',\n",
              "  'updatedAt': 1612986250936,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22649091',\n",
              "  'uuid': 'fc0ff2ce-efa8-4a9b-8d88-61d93cff0b8c',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2066',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250948,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23102728',\n",
              "  'journalName': 'molecular oncology',\n",
              "  'name': 'mek inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23102728',\n",
              "  'updatedAt': 1612986250948,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23102728',\n",
              "  'uuid': '17439246-c443-47f9-94ed-984e33291209',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2069',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250963,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22773810',\n",
              "  'journalName': 'proceedings of the national academy of sciences of the united states of america',\n",
              "  'name': 'lung cancers with acquired resistance to egfr inhibitors occasionally harbor braf gene mutations but lack mutations in kras, nras, or mek1.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22773810',\n",
              "  'updatedAt': 1612986250963,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22773810',\n",
              "  'uuid': '92e28073-50c0-4660-9332-4111311f99b4',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2072',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986250987,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23485129',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of egfr tyrosine kinase inhibitors sensitivity and resistance.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23485129',\n",
              "  'updatedAt': 1612986250987,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23485129',\n",
              "  'uuid': 'd5c22ce3-531b-4701-bbe8-dc15174682a9',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2077',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251034,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23948351',\n",
              "  'journalName': 'the lancet. oncology',\n",
              "  'name': 'icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (icogen): a randomised, double-blind phase 3 non-inferiority trial.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23948351',\n",
              "  'updatedAt': 1612986251034,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23948351',\n",
              "  'uuid': 'c37d1593-9a4d-40c0-b403-cd103759ec56',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2079',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251040,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22885469',\n",
              "  'journalName': 'gynecologic oncology',\n",
              "  'name': 'lapatinib and potential prognostic value of egfr mutations in a gynecologic oncology group phase ii trial of persistent or recurrent endometrial cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22885469',\n",
              "  'updatedAt': 1612986251040,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22885469',\n",
              "  'uuid': 'cf1a6ab1-32af-4198-b163-239c54750587',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2083',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251053,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19010912',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'genetic predictors of mek dependence in non-small cell lung cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19010912',\n",
              "  'updatedAt': 1612986251053,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19010912',\n",
              "  'uuid': '68d12f5e-9ecf-4e7c-a87e-532380c42f26',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2086',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251082,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19255327',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'phase ii trial of sorafenib in metastatic thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19255327',\n",
              "  'updatedAt': 1612986251082,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19255327',\n",
              "  'uuid': 'e28d5fec-7409-42a3-9763-997d3b718bfe',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2088',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251095,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19366826',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'pik3ca mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19366826',\n",
              "  'updatedAt': 1612986251095,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19366826',\n",
              "  'uuid': '6722c637-34a1-4b5b-b3bc-0e7921432315',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2097',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251297,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21305640',\n",
              "  'journalName': 'genes, chromosomes & cancer',\n",
              "  'name': 'frequency of kras, braf, and nras mutations in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21305640',\n",
              "  'updatedAt': 1612986251297,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21305640',\n",
              "  'uuid': '4abaebd1-049c-40c6-b86a-708c44724755',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2112',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251364,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24327273',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'co-clinical trials demonstrate superiority of crizotinib to chemotherapy in alk-rearranged non-small cell lung cancer and predict strategies to overcome resistance.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24327273',\n",
              "  'updatedAt': 1612986251364,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24327273',\n",
              "  'uuid': 'c1a8cc63-e747-4250-a06c-2d414600fa0c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2114',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251439,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21729679',\n",
              "  'journalName': 'clinical colorectal cancer',\n",
              "  'name': 'development of molecular biomarkers in individualized treatment of colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21729679',\n",
              "  'updatedAt': 1612986251439,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21729679',\n",
              "  'uuid': '70ba5e8a-8d5d-4101-9079-bebf93eb1004',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2118',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251478,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:20736745',\n",
              "  'journalName': 'diagnostic molecular pathology : the american journal of surgical pathology, part b',\n",
              "  'name': 'nras mutations are rare in colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '20736745',\n",
              "  'updatedAt': 1612986251478,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/20736745',\n",
              "  'uuid': '9af1e23b-59e4-40cf-80f5-4a981ffd590a',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2123',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251522,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18060073',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'mutation analysis of braf, mek1 and mek2 in 15 ovarian cancer cell lines: implications for therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18060073',\n",
              "  'updatedAt': 1612986251522,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18060073',\n",
              "  'uuid': '047112a2-17aa-4477-a538-5fe785151e0d',\n",
              "  'year': 2007},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2125',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251651,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21829508',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'pik3ca mutations frequently coexist with ras and braf mutations in patients with advanced cancers.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21829508',\n",
              "  'updatedAt': 1612986251651,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21829508',\n",
              "  'uuid': '3c25b874-2792-45c4-a2a6-2b3f5861384e',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2131',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251719,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21479466',\n",
              "  'journalName': 'molecular medicine reports',\n",
              "  'name': 'akt1 and akt2 mutations in lung cancer in a japanese population.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21479466',\n",
              "  'updatedAt': 1612986251719,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21479466',\n",
              "  'uuid': '2637ad9f-dca8-4025-88da-de3fee991dd6',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2132',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251740,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:21984976',\n",
              "  'journalName': 'cancer discovery',\n",
              "  'name': 'high frequency of pik3r1 and pik3r2 mutations in endometrial cancer elucidates a novel mechanism for regulation of pten protein stability.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '21984976',\n",
              "  'updatedAt': 1612986251740,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/21984976',\n",
              "  'uuid': '987b40cd-1e80-45c6-8dc0-bb204a8fb48b',\n",
              "  'year': 2011},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2136',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251747,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22898540',\n",
              "  'journalName': 'nature reviews. cancer',\n",
              "  'name': 'cancer stem cells: tracing clones.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22898540',\n",
              "  'updatedAt': 1612986251747,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22898540',\n",
              "  'uuid': '698d3f98-6c91-46a2-b2a8-9d03b0fb4712',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2137',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251747,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24657128',\n",
              "  'journalName': 'lung cancer (amsterdam, netherlands)',\n",
              "  'name': 'molecular profiling of small cell lung cancer in a japanese cohort.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24657128',\n",
              "  'updatedAt': 1612986251747,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24657128',\n",
              "  'uuid': '5c73dbf7-ad05-4029-93ff-41cc8db8f750',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2143',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251766,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23406027',\n",
              "  'journalName': 'the new england journal of medicine',\n",
              "  'name': 'selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23406027',\n",
              "  'updatedAt': 1612986251766,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23406027',\n",
              "  'uuid': 'dfd8532d-c521-427b-b115-2e3ac2a8aaf8',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2146',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251810,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24370118',\n",
              "  'journalName': 'clinical lung cancer',\n",
              "  'name': 'genetic mutation screen in early non--small-cell lung cancer (nsclc) specimens.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24370118',\n",
              "  'updatedAt': 1612986251810,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24370118',\n",
              "  'uuid': '7f90634e-87ae-47f9-adb2-8aafed22073c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2147',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251772,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24651012',\n",
              "  'journalName': 'cancer cell',\n",
              "  'name': 'mutant p53 in cancer: new functions and therapeutic opportunities.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24651012',\n",
              "  'updatedAt': 1612986251772,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24651012',\n",
              "  'uuid': 'd5fa11b6-55a2-4852-8eee-a227f4717c23',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2150',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251863,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19946327',\n",
              "  'journalName': 'oncogene',\n",
              "  'name': 'the fgfr4 y367c mutant is a dominant oncogene in mda-mb453 breast cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19946327',\n",
              "  'updatedAt': 1612986251863,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19946327',\n",
              "  'uuid': 'fefe724e-6e16-4767-ae5c-593836d706fa',\n",
              "  'year': 2010},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2151',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251870,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16043828',\n",
              "  'journalName': 'journal of clinical oncology : official journal of the american society of clinical oncology',\n",
              "  'name': 'mutations in the epidermal growth factor receptor and in kras are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16043828',\n",
              "  'updatedAt': 1612986251870,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16043828',\n",
              "  'uuid': 'fd77aadc-98d6-49c9-a464-a80b093e4e2c',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2153',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251874,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:16204070',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'epidermal growth factor-independent transformation of ba/f3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '16204070',\n",
              "  'updatedAt': 1612986251874,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/16204070',\n",
              "  'uuid': '4b84ae26-07e6-4bf2-af00-c4a62fcd7b4b',\n",
              "  'year': 2005},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2163',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251895,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22357840',\n",
              "  'journalName': 'clinical cancer research : an official journal of the american association for cancer research',\n",
              "  'name': 'prognostic role of pik3ca mutation in colorectal cancer: cohort study and literature review.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22357840',\n",
              "  'updatedAt': 1612986251895,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22357840',\n",
              "  'uuid': 'e9c69c9b-e831-4c88-a4fe-e69710a65772',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2164',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251895,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18992635',\n",
              "  'journalName': 'cancer genetics and cytogenetics',\n",
              "  'name': 'prevalence of mutations in apc, ctnnb1, and braf in tunisian patients with sporadic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18992635',\n",
              "  'updatedAt': 1612986251895,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18992635',\n",
              "  'uuid': 'f91c6b9a-4587-40a8-b39e-f456761be331',\n",
              "  'year': 2008},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2166',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251903,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:22810696',\n",
              "  'journalName': 'nature',\n",
              "  'name': 'comprehensive molecular characterization of human colon and rectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '22810696',\n",
              "  'updatedAt': 1612986251903,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/22810696',\n",
              "  'uuid': 'dde17cbc-201b-48bf-a2fa-ad57707bdcbc',\n",
              "  'year': 2012},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2172',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251919,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24459181',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'the structural basis of pi3k cancer mutations: from mechanism to therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24459181',\n",
              "  'updatedAt': 1612986251919,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24459181',\n",
              "  'uuid': 'd5e13503-b469-490e-a350-9e86f801fd4c',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2174',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251928,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19513541',\n",
              "  'journalName': 'international journal of molecular medicine',\n",
              "  'name': 'a novel dual pi3kalpha/mtor inhibitor pi-103 with high antitumor activity in non-small cell lung cancer cells.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19513541',\n",
              "  'updatedAt': 1612986251928,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19513541',\n",
              "  'uuid': 'f7da7eaf-0ae7-49a8-947e-7ad7bde7a8b4',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2175',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251923,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23408298',\n",
              "  'journalName': 'cancer',\n",
              "  'name': 'a phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23408298',\n",
              "  'updatedAt': 1612986251923,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23408298',\n",
              "  'uuid': '64279d84-b3e8-440e-a4ea-338097167b2a',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2177',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251937,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11567109',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'roots of clinical resistance to sti-571 cancer therapy.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11567109',\n",
              "  'updatedAt': 1612986251937,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11567109',\n",
              "  'uuid': '56071d78-edbe-40ae-8207-874e55a1dade',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2182',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986251975,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:11423618',\n",
              "  'journalName': 'science (new york, n.y.)',\n",
              "  'name': 'clinical resistance to sti-571 cancer therapy caused by bcr-abl gene mutation or amplification.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '11423618',\n",
              "  'updatedAt': 1612986251975,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/11423618',\n",
              "  'uuid': '3122e51c-e56f-447c-9e27-af989770b24f',\n",
              "  'year': 2001},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2191',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986252053,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23700467',\n",
              "  'journalName': 'plos one',\n",
              "  'name': 'targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23700467',\n",
              "  'updatedAt': 1612986252053,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23700467',\n",
              "  'uuid': '5a4f0b20-9a03-4377-8611-ccf95c75b72b',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2194',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986253121,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24628546',\n",
              "  'journalName': 'the journal of clinical endocrinology and metabolism',\n",
              "  'name': 'development and characterization of a differentiated thyroid cancer cell line resistant to vegfr-targeted kinase inhibitors.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24628546',\n",
              "  'updatedAt': 1612986253121,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24628546',\n",
              "  'uuid': 'bd0b2572-3c8a-4864-8abf-688d2d9e0944',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2200',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986253203,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:12821112',\n",
              "  'journalName': 'biochemical and biophysical research communications',\n",
              "  'name': 'role of smad4 (dpc4) inactivation in human cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '12821112',\n",
              "  'updatedAt': 1612986253203,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/12821112',\n",
              "  'uuid': 'ac929622-239e-4a99-9ca4-4307d4b91e40',\n",
              "  'year': 2003},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2206',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986257155,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:19487299',\n",
              "  'journalName': 'cancer research',\n",
              "  'name': 'mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for braf, pik3ca, and akt1.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '19487299',\n",
              "  'updatedAt': 1612986257155,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/19487299',\n",
              "  'uuid': '25eb6654-6192-4435-9b09-1c9fc15f0db0',\n",
              "  'year': 2009},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2211',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986257215,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:23728071',\n",
              "  'journalName': 'oncology reports',\n",
              "  'name': 'a detailed immunohistochemical analysis of the pi3k/akt/mtor pathway in lung cancer: correlation with pik3ca, akt1, k-ras or pten mutational status and clinicopathological features.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '23728071',\n",
              "  'updatedAt': 1612986257215,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/23728071',\n",
              "  'uuid': '5570aabb-2b96-4dec-994a-8528889576e3',\n",
              "  'year': 2013},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2220',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986265895,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24559322',\n",
              "  'journalName': 'expert review of anticancer therapy',\n",
              "  'name': 'regorafenib in metastatic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24559322',\n",
              "  'updatedAt': 1612986265895,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24559322',\n",
              "  'uuid': '323a69a1-fab7-4eea-bb83-c36f1594e130',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2221',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986265900,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:24518971',\n",
              "  'journalName': 'cell journal',\n",
              "  'name': 'a unique profile of adenomatous polyposis coli gene mutations in iranian patients suffering sporadic colorectal cancer.',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '24518971',\n",
              "  'updatedAt': 1612986265900,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/24518971',\n",
              "  'uuid': '334eae3a-862c-4472-85de-b82e308736b8',\n",
              "  'year': 2014},\n",
              " {'@class': 'Publication',\n",
              "  '@rid': '#38:2227',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612986265967,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pmid:18186519',\n",
              "  'journalName': 'human mutation',\n",
              "  'name': 'rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (mrd).',\n",
              "  'source': '#17:21',\n",
              "  'sourceId': '18186519',\n",
              "  'updatedAt': 1612986265967,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'https://pubmed.ncbi.nlm.nih.gov/18186519',\n",
              "  'uuid': '1fc4e897-b235-4c02-b8bc-bc872697432d',\n",
              "  'year': 2008}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 5
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "7A-ROancYJaJ"
      },
      "source": [
        "You can also filter on multiple conditions. To do this we nest filters in an object which uses a single AND/OR property with a list of regular conditions. For example if we want to find diseases with the name \"cancer\" or \"carcinoma\"  "
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "bKS77ev-YKyp",
        "outputId": "2dd75647-e312-44d4-890d-13e69e0578d5"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Disease',\n",
        "    'filters': {\n",
        "        'OR': [\n",
        "            {'name': 'cancer'},\n",
        "            {'name': 'carcinoma'},\n",
        "        ]\n",
        "    },\n",
        "})"
      ],
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'@class': 'Disease',\n",
              "  '@rid': '#43:99077',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926192944,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'carcinoma',\n",
              "  'name': 'carcinoma',\n",
              "  'out_DeprecatedBy': ['#29:1400'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:2428',\n",
              "  'updatedAt': 1612926192944,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '2c61fd80-43fb-4cd2-941c-889a020cbbde'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:99076',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926192912,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'carcinoma',\n",
              "  'name': 'carcinoma',\n",
              "  'out_DeprecatedBy': ['#29:1399'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:6570',\n",
              "  'updatedAt': 1612926192912,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'baedee00-47a8-4d78-8ff5-7d9d8fadc03f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:99072',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926192816,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'A cell type cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.',\n",
              "  'displayName': 'carcinoma',\n",
              "  'history': '#43:107676',\n",
              "  'in_AliasOf': ['#26:160594', '#26:160595', '#26:160596'],\n",
              "  'in_DeprecatedBy': ['#29:1399', '#29:1400'],\n",
              "  'in_SubClassOf': [],\n",
              "  'name': 'carcinoma',\n",
              "  'out_CrossReferenceOf': ['#28:37788'],\n",
              "  'out_SubClassOf': ['#33:13951'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:305',\n",
              "  'subsets': ['doid#do_flybase_slim',\n",
              "   'doid#ncithesaurus',\n",
              "   'doid#do_cancer_slim'],\n",
              "  'updatedAt': 1612980618003,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '1775c2a3-b923-49f4-9e28-d5ccfcb32bc3'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:68962',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612863235878,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'cancer [c9305]',\n",
              "  'name': 'cancer',\n",
              "  'out_AliasOf': ['#26:137530'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c9305',\n",
              "  'updatedAt': 1612863235878,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'ed0fffc2-31ef-435b-ae11-6efd6b193dd3'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:100548',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926228848,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis.',\n",
              "  'displayName': 'cancer',\n",
              "  'history': '#43:107678',\n",
              "  'in_AliasOf': ['#26:161531', '#26:161532', '#26:161533'],\n",
              "  'in_SubClassOf': ['#33:5210', '#33:5268'],\n",
              "  'name': 'cancer',\n",
              "  'out_CrossReferenceOf': ['#28:37957'],\n",
              "  'out_ElementOf': ['#30:82543'],\n",
              "  'out_SubClassOf': ['#33:7594'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:162',\n",
              "  'subsets': ['doid#do_flybase_slim',\n",
              "   'doid#ncithesaurus',\n",
              "   'doid#do_cancer_slim',\n",
              "   'doid#do_agr_slim',\n",
              "   'doid#do_gxd_slim'],\n",
              "  'updatedAt': 1612980640268,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '6a051270-4611-4af2-a5ff-1b31a872b4e0'}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 6
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "ujSilBcJYUjV"
      },
      "source": [
        "The operator can be omitted here since `=` is the default operator. We can also combined conditions with `AND`\n"
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-zj5u2AIYWQt",
        "outputId": "0489da48-caf8-4e7f-8df0-ca8ce1d1c874"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Disease',\n",
        "    'filters': {\n",
        "        'AND': [\n",
        "            {'name': 'cancer', 'operator': 'CONTAINSTEXT'},\n",
        "            {'name': 'pancreatic', 'operator': 'CONTAINSTEXT'},\n",
        "        ]\n",
        "    },\n",
        "})"
      ],
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'@class': 'Disease',\n",
              "  '@rid': '#43:1683',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612854000193,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'recurrent pancreatic neuroendocrine cancer [c115433]',\n",
              "  'name': 'recurrent pancreatic neuroendocrine cancer',\n",
              "  'out_AliasOf': ['#26:5496'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c115433',\n",
              "  'updatedAt': 1612854000193,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'a0831763-7bcb-4c68-a9dc-7aee6b3795c3'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8254',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453528,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer by ajcc v6 and v7 stage [c134902]',\n",
              "  'name': 'pancreatic cancer by ajcc v6 and v7 stage',\n",
              "  'out_AliasOf': ['#26:18191'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134902',\n",
              "  'updatedAt': 1612855453528,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '21e9a523-1982-4bf0-824d-c50bbe9b11b9'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8255',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453548,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'exocrine and endocrine pancreatic cancer by ajcc v6 and v7 stage [c134902]',\n",
              "  'name': 'exocrine and endocrine pancreatic cancer by ajcc v6 and v7 stage',\n",
              "  'out_AliasOf': ['#26:18192'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134902',\n",
              "  'updatedAt': 1612855453548,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'd66fdfc2-578c-49cf-b3d7-cfe693fae104'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8259',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453624,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer by ajcc v8 stage [c134909]',\n",
              "  'name': 'pancreatic cancer by ajcc v8 stage',\n",
              "  'out_AliasOf': ['#26:18195'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134909',\n",
              "  'updatedAt': 1612855453624,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'b8317e89-a42e-44cf-9ab6-7f6f1d58b615'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8260',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453645,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'exocrine pancreatic cancer by ajcc v8 stage [c134909]',\n",
              "  'name': 'exocrine pancreatic cancer by ajcc v8 stage',\n",
              "  'out_AliasOf': ['#26:18196'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134909',\n",
              "  'updatedAt': 1612855453645,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '3224e5c3-df93-4f6f-b1ff-623f5da9a0fe'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8263',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855453705,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage 0 Pancreatic Cancer AJCC v8 [c134914]',\n",
              "  'in_AliasOf': ['#26:18199', '#26:18200', '#26:18201'],\n",
              "  'name': 'stage 0 pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134914',\n",
              "  'updatedAt': 1612855453705,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134914',\n",
              "  'uuid': '773197a4-bd68-40f8-836f-83aefb204f42'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8264',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453718,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage 0 exocrine pancreatic cancer ajcc v8 [c134914]',\n",
              "  'name': 'stage 0 exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18199'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134914',\n",
              "  'updatedAt': 1612855453718,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'a3c22592-d13b-43f2-ad95-b37ff2e06d64'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8266',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453758,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage 0 pancreatic cancer [c134914]',\n",
              "  'name': 'stage 0 pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18201'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134914',\n",
              "  'updatedAt': 1612855453758,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'aa9f0df4-2709-40ec-b668-ec197b8b4263'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8267',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855453777,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage I includes: IA: (T1, N0, M0); IB: (T2, N0, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage I Pancreatic Cancer AJCC v8 [c134915]',\n",
              "  'in_AliasOf': ['#26:18202', '#26:18203', '#26:18204'],\n",
              "  'name': 'stage i pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134915',\n",
              "  'updatedAt': 1612855453777,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134915',\n",
              "  'uuid': 'a9cb43c5-dc34-4417-aa19-86f94e572a20'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8268',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453793,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage i exocrine pancreatic cancer ajcc v8 [c134915]',\n",
              "  'name': 'stage i exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18202'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134915',\n",
              "  'updatedAt': 1612855453793,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '36684e51-e96b-447c-959d-b5ad865e264a'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8270',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453837,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage i pancreatic cancer [c134915]',\n",
              "  'name': 'stage i pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18204'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134915',\n",
              "  'updatedAt': 1612855453837,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '4817728a-82e7-4f87-aacf-9a5ba4efa732'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8271',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855453864,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IA includes: T1, N0, M0. T1: Tumor measuring 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage IA Pancreatic Cancer AJCC v8 [c134917]',\n",
              "  'in_AliasOf': ['#26:18205', '#26:18206', '#26:18207', '#26:18208'],\n",
              "  'name': 'stage ia pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134917',\n",
              "  'updatedAt': 1612855453864,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134917',\n",
              "  'uuid': 'a17fbd1b-af7e-4d97-96cb-8d9577bbac6d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8273',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453896,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ia exocrine pancreatic cancer ajcc v8 [c134917]',\n",
              "  'name': 'stage ia exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18206'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134917',\n",
              "  'updatedAt': 1612855453896,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '77760383-9581-4e5e-993d-ba79bf190de1'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8275',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453937,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ia pancreatic cancer [c134917]',\n",
              "  'name': 'stage ia pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18208'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134917',\n",
              "  'updatedAt': 1612855453937,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '3f6b9f4e-5e27-40ea-9c9f-779075045210'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8276',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855453957,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IB includes: T2, N0, M0. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage IB Pancreatic Cancer AJCC v8 [c134920]',\n",
              "  'in_AliasOf': ['#26:18209', '#26:18210', '#26:18211', '#26:18212'],\n",
              "  'name': 'stage ib pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134920',\n",
              "  'updatedAt': 1612855453957,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134920',\n",
              "  'uuid': '31803ce6-c88a-402d-b1b7-94b960c77abb'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8278',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855453990,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ib exocrine pancreatic cancer ajcc v8 [c134920]',\n",
              "  'name': 'stage ib exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18210'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134920',\n",
              "  'updatedAt': 1612855453990,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'c9d8a5f7-a313-414f-be13-1fa8ebbd6f6f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8280',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454030,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ib pancreatic cancer [c134920]',\n",
              "  'name': 'stage ib pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18212'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134920',\n",
              "  'updatedAt': 1612855454030,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'b2835313-872f-425c-9b63-dc1caf933fea'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8281',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855454049,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage II includes: IIA: (T3, N0, M0); IIB: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage II Pancreatic Cancer AJCC v8 [c134921]',\n",
              "  'in_AliasOf': ['#26:18213', '#26:18214', '#26:18215'],\n",
              "  'name': 'stage ii pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134921',\n",
              "  'updatedAt': 1612855454049,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134921',\n",
              "  'uuid': '6c353bdf-3054-4623-897d-32805a1de01f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8282',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454062,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ii exocrine pancreatic cancer ajcc v8 [c134921]',\n",
              "  'name': 'stage ii exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18213'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134921',\n",
              "  'updatedAt': 1612855454062,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'baf82288-696b-45b7-ab75-00d414b8db60'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8284',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454100,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ii pancreatic cancer [c134921]',\n",
              "  'name': 'stage ii pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18215'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134921',\n",
              "  'updatedAt': 1612855454100,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '9038bd0d-876c-4e17-95bc-0fbab9f9c355'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8285',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855454119,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IIA includes: T3, N0, M0. T3: Tumor measuring more than 4 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage IIA Pancreatic Cancer AJCC v8 [c134925]',\n",
              "  'in_AliasOf': ['#26:18216', '#26:18217', '#26:18218', '#26:18219'],\n",
              "  'name': 'stage iia pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134925',\n",
              "  'updatedAt': 1612855454119,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134925',\n",
              "  'uuid': 'ad5a6175-d855-472c-bf9d-8264de012115'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8287',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454209,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iia exocrine pancreatic cancer ajcc v8 [c134925]',\n",
              "  'name': 'stage iia exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18217'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134925',\n",
              "  'updatedAt': 1612855454209,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '844e8684-bc91-4960-9391-ec097cd69f01'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8289',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454250,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iia pancreatic cancer [c134925]',\n",
              "  'name': 'stage iia pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18219'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134925',\n",
              "  'updatedAt': 1612855454250,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '056b447e-a282-452a-9c8a-25a120629aa1'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8290',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855454271,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. N1: Metastasis in one to three regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage IIB Pancreatic Cancer AJCC v8 [c134927]',\n",
              "  'in_AliasOf': ['#26:18220', '#26:18221', '#26:18222', '#26:18223'],\n",
              "  'name': 'stage iib pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134927',\n",
              "  'updatedAt': 1612855454271,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134927',\n",
              "  'uuid': '1030ebb7-6f5f-40a7-9eb1-82f2a078ce62'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8292',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454303,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iib exocrine pancreatic cancer ajcc v8 [c134927]',\n",
              "  'name': 'stage iib exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18221'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134927',\n",
              "  'updatedAt': 1612855454303,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '14fa922b-a7d8-4998-bd3c-5d6ddbdcaeb6'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8294',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454342,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iib pancreatic cancer [c134927]',\n",
              "  'name': 'stage iib pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18223'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134927',\n",
              "  'updatedAt': 1612855454342,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '9ed3103a-f9d7-4495-ac45-140b1041340c'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8295',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855454362,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N2, M0); (T4, Any N, M0). T1: Tumor measuring 2 cm or less in greatest dimension. T2: Tumor measuring more than 2 cm and 4 cm or less in greatest dimension. T3: Tumor measuring more than 4 cm in greatest dimension. T4: Tumor involving the celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size. N2: Metastasis in four or more regional lymph nodes. M0: No distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage III Pancreatic Cancer AJCC v8 [c134928]',\n",
              "  'in_AliasOf': ['#26:18224', '#26:18225', '#26:18226', '#26:18227'],\n",
              "  'name': 'stage iii pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134928',\n",
              "  'updatedAt': 1612855454362,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134928',\n",
              "  'uuid': '5134adf4-1168-449b-aee0-3efe03b6a3b3'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8297',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454402,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iii exocrine pancreatic cancer ajcc v8 [c134928]',\n",
              "  'name': 'stage iii exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18225'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134928',\n",
              "  'updatedAt': 1612855454402,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'a0236a5a-4e40-4292-97db-40a83c00df5b'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8299',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454449,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iii pancreatic cancer [c134928]',\n",
              "  'name': 'stage iii pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18227'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134928',\n",
              "  'updatedAt': 1612855454449,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'cf52c186-d5c1-4b50-a347-6238ca4c5200'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8300',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612855454469,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 8th ed.)',\n",
              "  'displayName': 'Stage IV Pancreatic Cancer AJCC v8 [c134930]',\n",
              "  'in_AliasOf': ['#26:18228', '#26:18229', '#26:18230', '#26:18231'],\n",
              "  'name': 'stage iv pancreatic cancer ajcc v8',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134930',\n",
              "  'updatedAt': 1612855454469,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c134930',\n",
              "  'uuid': 'd11016c8-8f41-40dc-9c56-b8e24882ca92'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8302',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454552,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iv exocrine pancreatic cancer ajcc v8 [c134930]',\n",
              "  'name': 'stage iv exocrine pancreatic cancer ajcc v8',\n",
              "  'out_AliasOf': ['#26:18229'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134930',\n",
              "  'updatedAt': 1612855454552,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '1dd34b7a-fcb3-4ff3-9d46-5f7e8d323826'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:8304',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855454597,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iv pancreatic cancer [c134930]',\n",
              "  'name': 'stage iv pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:18231'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c134930',\n",
              "  'updatedAt': 1612855454597,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '0318ee85-d9d0-4d01-9d64-19ff07ef11bf'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:9072',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612855490364,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'refractory pancreatic neuroendocrine cancer [c137862]',\n",
              "  'name': 'refractory pancreatic neuroendocrine cancer',\n",
              "  'out_AliasOf': ['#26:19541'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c137862',\n",
              "  'updatedAt': 1612855490364,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '021268d2-84b6-4110-92d8-c4adfc483aef'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:11384',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612856094960,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'metastatic pancreatic neuroendocrine cancer [c153075]',\n",
              "  'name': 'metastatic pancreatic neuroendocrine cancer',\n",
              "  'out_AliasOf': ['#26:26884'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c153075',\n",
              "  'updatedAt': 1612856094960,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'c3253b23-24c4-4af5-ae0a-3b3dd9a5da15'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:11386',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612856095076,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'unresectable pancreatic neuroendocrine cancer [c153079]',\n",
              "  'name': 'unresectable pancreatic neuroendocrine cancer',\n",
              "  'out_AliasOf': ['#26:26889'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c153079',\n",
              "  'updatedAt': 1612856095076,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '94604925-8027-40c6-ae69-e117b788d18f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:14127',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612856623570,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreaticobiliary cancer [c166418]',\n",
              "  'name': 'pancreaticobiliary cancer',\n",
              "  'out_AliasOf': ['#26:37042'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c166418',\n",
              "  'updatedAt': 1612856623570,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '4367deae-82c1-4b67-9be5-c89513c3798f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:17122',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612857298580,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'melanoma-pancreatic cancer syndrome [c176904]',\n",
              "  'name': 'melanoma-pancreatic cancer syndrome',\n",
              "  'out_AliasOf': ['#26:46184'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c176904',\n",
              "  'updatedAt': 1612857298580,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'e2910a6f-4dfb-4ebf-9ef5-28e24c0606e7'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:30363',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612858805999,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic neuroendocrine cancer [c3770]',\n",
              "  'name': 'pancreatic neuroendocrine cancer',\n",
              "  'out_AliasOf': ['#26:68856'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c3770',\n",
              "  'updatedAt': 1612858805999,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '5233d0a4-4722-42ca-b45a-a5c57a7b9eb9'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:30366',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612858806075,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic endocrine cancer [c3770]',\n",
              "  'name': 'pancreatic endocrine cancer',\n",
              "  'out_AliasOf': ['#26:68859'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c3770',\n",
              "  'updatedAt': 1612858806076,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '2edd7d5d-dd05-4138-89f6-28f44689877e'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:30862',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612858821838,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer [c3850]',\n",
              "  'name': 'pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:69449'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c3850',\n",
              "  'updatedAt': 1612858821838,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '243866b9-4b7c-4b4d-ae42-083e5ec0f02c'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:30863',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612858821858,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer (excluding islets), nos [c3850]',\n",
              "  'name': 'pancreatic cancer (excluding islets), nos',\n",
              "  'out_AliasOf': ['#26:69450'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c3850',\n",
              "  'updatedAt': 1612858821858,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'dfb8ee5e-5f77-49d2-bc76-663adf1ec67b'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:30864',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612858821877,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer (not islets) [c3850]',\n",
              "  'name': 'pancreatic cancer (not islets)',\n",
              "  'out_AliasOf': ['#26:69451'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c3850',\n",
              "  'updatedAt': 1612858821877,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '98d9ccdc-b871-4c23-9664-bef4eacdfa6d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:34642',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859074428,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'familial pancreatic cancer [c43298]',\n",
              "  'name': 'familial pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:73901'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c43298',\n",
              "  'updatedAt': 1612859074428,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '2bb6cfc5-0ad8-4b23-9764-8d0964e9666d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:34644',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859074465,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'familial pancreatic cancer syndrome [c43298]',\n",
              "  'name': 'familial pancreatic cancer syndrome',\n",
              "  'out_AliasOf': ['#26:73903'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c43298',\n",
              "  'updatedAt': 1612859074465,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '488074fb-f911-42d3-b079-3d0ce773adf0'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:34645',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859074483,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'hereditary pancreatic cancer [c43298]',\n",
              "  'name': 'hereditary pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:73904'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c43298',\n",
              "  'updatedAt': 1612859074483,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '85021b92-f1d1-479f-bb1b-e73c44c33f12'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:39620',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859550528,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'unresectable pancreatic cancer [c5018]',\n",
              "  'name': 'unresectable pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:82391'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5018',\n",
              "  'updatedAt': 1612859550528,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'e5dea52f-71c1-42bf-9bed-6af9c945fdb7'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:40379',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859568876,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'resectable pancreatic cancer [c5099]',\n",
              "  'name': 'resectable pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:83100'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5099',\n",
              "  'updatedAt': 1612859568876,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '88df17b4-86ac-43a4-b12c-ef3a7b8a0646'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44334',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612859943996,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IV includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 6th and 7th Eds.)',\n",
              "  'displayName': 'Stage IV Pancreatic Cancer AJCC v6 and v7 [c5711]',\n",
              "  'in_AliasOf': ['#26:87803',\n",
              "   '#26:87804',\n",
              "   '#26:87805',\n",
              "   '#26:87806',\n",
              "   '#26:87807',\n",
              "   '#26:87808',\n",
              "   '#26:87809',\n",
              "   '#26:87810'],\n",
              "  'name': 'stage iv pancreatic cancer ajcc v6 and v7',\n",
              "  'out_ElementOf': ['#30:82531'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5711',\n",
              "  'updatedAt': 1612859943996,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c5711',\n",
              "  'uuid': 'ce0260c1-c507-4031-b68f-2ba94efaecf2'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44335',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859944010,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer stage iv [c5711]',\n",
              "  'name': 'pancreatic cancer stage iv',\n",
              "  'out_AliasOf': ['#26:87803'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5711',\n",
              "  'updatedAt': 1612859944010,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '2594e69a-8d4c-4b35-a71b-69b43072fd67'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44338',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859944145,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iv exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c5711]',\n",
              "  'name': 'stage iv exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:87806'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5711',\n",
              "  'updatedAt': 1612859944145,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '0b61644c-2e8b-4c12-b878-d2440e83d9ec'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44339',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859944166,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iv pancreatic cancer [c5711]',\n",
              "  'name': 'stage iv pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:87807'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5711',\n",
              "  'updatedAt': 1612859944166,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '91e78658-2dc3-4dee-a25c-96da6e25bf2b'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44340',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859944186,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iv pancreatic cancer ajcc v6 [c5711]',\n",
              "  'name': 'stage iv pancreatic cancer ajcc v6',\n",
              "  'out_AliasOf': ['#26:87808'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5711',\n",
              "  'updatedAt': 1612859944186,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '9ddc2bda-1e37-4e53-9666-961dadcf40e9'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44341',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859944206,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iv pancreatic cancer ajcc v7 [c5711]',\n",
              "  'name': 'stage iv pancreatic cancer ajcc v7',\n",
              "  'out_AliasOf': ['#26:87809'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5711',\n",
              "  'updatedAt': 1612859944206,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '89f75c9a-4b09-42b0-9838-34e677302311'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44384',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859945137,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic adenosquamous cancer [c5721]',\n",
              "  'name': 'pancreatic adenosquamous cancer',\n",
              "  'out_AliasOf': ['#26:87845'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5721',\n",
              "  'updatedAt': 1612859945137,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '172e9873-46bf-44b8-817c-d9296f687056'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44420',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612859945857,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)',\n",
              "  'displayName': 'Stage 0 Pancreatic Cancer AJCC v6 and v7 [c5729]',\n",
              "  'in_AliasOf': ['#26:87876',\n",
              "   '#26:87877',\n",
              "   '#26:87878',\n",
              "   '#26:87879',\n",
              "   '#26:87880',\n",
              "   '#26:87881',\n",
              "   '#26:87882',\n",
              "   '#26:87883',\n",
              "   '#26:87884',\n",
              "   '#26:87885'],\n",
              "  'name': 'stage 0 pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5729',\n",
              "  'updatedAt': 1612859945857,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c5729',\n",
              "  'uuid': '95092c66-6c89-43ea-a90c-4e1b0ffc947b'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44421',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859945907,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer stage 0 [c5729]',\n",
              "  'name': 'pancreatic cancer stage 0',\n",
              "  'out_AliasOf': ['#26:87876'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5729',\n",
              "  'updatedAt': 1612859945907,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'd2e5099a-223c-4927-89c8-54633226d192'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44425',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859945992,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage 0 exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c5729]',\n",
              "  'name': 'stage 0 exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:87880'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5729',\n",
              "  'updatedAt': 1612859945992,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '279f1263-b333-4626-b923-0fce6c21ebe0'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44426',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859946014,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage 0 pancreatic cancer [c5729]',\n",
              "  'name': 'stage 0 pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:87881'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5729',\n",
              "  'updatedAt': 1612859946014,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '1bf73f81-23fc-41ef-a8d5-d5eeca3686f8'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44427',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859946034,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage 0 pancreatic cancer ajcc v6 [c5729]',\n",
              "  'name': 'stage 0 pancreatic cancer ajcc v6',\n",
              "  'out_AliasOf': ['#26:87882'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5729',\n",
              "  'updatedAt': 1612859946034,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'cf1e1291-3471-44bd-a967-b007f46b6138'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:44428',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612859946053,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage 0 pancreatic cancer ajcc v7 [c5729]',\n",
              "  'name': 'stage 0 pancreatic cancer ajcc v7',\n",
              "  'out_AliasOf': ['#26:87883'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c5729',\n",
              "  'updatedAt': 1612859946053,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '6c198324-4c96-4f62-b4d9-9b5d28534112'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:56372',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861597316,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'recurrent pancreatic cancer [c7626]',\n",
              "  'name': 'recurrent pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:113659'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7626',\n",
              "  'updatedAt': 1612861597316,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '9239d11e-4756-4e1e-a900-68db24e72c17'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:56377',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861597411,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'relapsed pancreatic cancer [c7626]',\n",
              "  'name': 'relapsed pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:113664'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7626',\n",
              "  'updatedAt': 1612861597411,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'f5b9557b-bcd2-49ed-b953-1cb201cd4d79'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57138',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612861827869,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage I includes: IA (T1, N0, M0); IB (T2, N0, M0). T1: Tumor limited to the pancreas 2 cm or less in greatest dimension. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)',\n",
              "  'displayName': 'Stage I Pancreatic Cancer AJCC v6 and v7 [c7785]',\n",
              "  'in_AliasOf': ['#26:116742',\n",
              "   '#26:116743',\n",
              "   '#26:116744',\n",
              "   '#26:116745',\n",
              "   '#26:116746',\n",
              "   '#26:116747',\n",
              "   '#26:116748',\n",
              "   '#26:116749'],\n",
              "  'name': 'stage i pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7785',\n",
              "  'updatedAt': 1612861827869,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c7785',\n",
              "  'uuid': '89ec72ac-6a95-4879-838f-a2cae0213205'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57139',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861827881,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer stage i [c7785]',\n",
              "  'name': 'pancreatic cancer stage i',\n",
              "  'out_AliasOf': ['#26:116742'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7785',\n",
              "  'updatedAt': 1612861827881,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '6c0dbde2-6d06-4b5a-8894-39175ee990b1'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57142',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861827938,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage i exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c7785]',\n",
              "  'name': 'stage i exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:116745'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7785',\n",
              "  'updatedAt': 1612861827938,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '93007b66-4f7f-45b8-b0dd-915f32cec8fa'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57143',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861827960,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage i pancreatic cancer [c7785]',\n",
              "  'name': 'stage i pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:116746'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7785',\n",
              "  'updatedAt': 1612861827960,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '347f769d-6b46-4abb-90df-0887fb032e81'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57144',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861827980,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage i pancreatic cancer ajcc v6 [c7785]',\n",
              "  'name': 'stage i pancreatic cancer ajcc v6',\n",
              "  'out_AliasOf': ['#26:116747'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7785',\n",
              "  'updatedAt': 1612861827980,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '226e6a14-b8de-4cce-bef5-d2ed2cd889c7'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57145',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861827999,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage i pancreatic cancer ajcc v7 [c7785]',\n",
              "  'name': 'stage i pancreatic cancer ajcc v7',\n",
              "  'out_AliasOf': ['#26:116748'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7785',\n",
              "  'updatedAt': 1612861827999,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '14d97e5f-a141-4b09-98d0-4146f0fd0703'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57147',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612861828749,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage II includes: IIA (T3, N0, M0); IIB (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor limited to the pancreas 2 cm or less in greatest dimension. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. N0: No regional lymph node metastasis. N1: Regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th Eds.)',\n",
              "  'displayName': 'Stage II Pancreatic Cancer AJCC v6 and v7 [c7786]',\n",
              "  'in_AliasOf': ['#26:116771',\n",
              "   '#26:116772',\n",
              "   '#26:116773',\n",
              "   '#26:116774',\n",
              "   '#26:116775',\n",
              "   '#26:116776',\n",
              "   '#26:116777',\n",
              "   '#26:116778'],\n",
              "  'name': 'stage ii pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7786',\n",
              "  'updatedAt': 1612861828749,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c7786',\n",
              "  'uuid': '98007027-7e36-4e15-99f4-944805ea1034'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57148',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861828763,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer stage ii [c7786]',\n",
              "  'name': 'pancreatic cancer stage ii',\n",
              "  'out_AliasOf': ['#26:116771'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7786',\n",
              "  'updatedAt': 1612861828763,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'ec0c5416-dd72-4acb-9f2c-de7661fe756e'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57151',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861828819,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ii exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c7786]',\n",
              "  'name': 'stage ii exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:116774'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7786',\n",
              "  'updatedAt': 1612861828819,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'abe73ca6-125e-432e-8b9a-1ec08701a81a'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57152',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861828838,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ii pancreatic cancer [c7786]',\n",
              "  'name': 'stage ii pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:116775'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7786',\n",
              "  'updatedAt': 1612861828838,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'aaab8221-2294-4ba3-b4db-6d84968e8dea'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57153',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861828857,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ii pancreatic cancer ajcc v6 [c7786]',\n",
              "  'name': 'stage ii pancreatic cancer ajcc v6',\n",
              "  'out_AliasOf': ['#26:116776'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7786',\n",
              "  'updatedAt': 1612861828857,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '0e565e1a-09fd-49b0-8848-5e340b28f8c7'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57154',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861828882,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ii pancreatic cancer ajcc v7 [c7786]',\n",
              "  'name': 'stage ii pancreatic cancer ajcc v7',\n",
              "  'out_AliasOf': ['#26:116777'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7786',\n",
              "  'updatedAt': 1612861828882,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '1251ee13-bcc4-487a-a909-4d171239920d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57156',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612861829539,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage III includes: T4, Any N, M0. T4: Tumor involves the celiac axis or the superior mesenteric artery. M0: No distant metastasis. (AJCC 6th and 7th Eds.)',\n",
              "  'displayName': 'Stage III Pancreatic Cancer AJCC v6 and v7 [c7787]',\n",
              "  'in_AliasOf': ['#26:116798',\n",
              "   '#26:116799',\n",
              "   '#26:116800',\n",
              "   '#26:116801',\n",
              "   '#26:116802',\n",
              "   '#26:116803',\n",
              "   '#26:116804',\n",
              "   '#26:116805'],\n",
              "  'name': 'stage iii pancreatic cancer ajcc v6 and v7',\n",
              "  'out_ElementOf': ['#30:82530'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7787',\n",
              "  'updatedAt': 1612861829539,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c7787',\n",
              "  'uuid': '47e257a9-7973-40ba-b680-8260db62fb52'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57157',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861829552,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic cancer stage iii [c7787]',\n",
              "  'name': 'pancreatic cancer stage iii',\n",
              "  'out_AliasOf': ['#26:116798'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7787',\n",
              "  'updatedAt': 1612861829552,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '3d33b3dd-a216-4134-ad54-b052f430ef85'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57160',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861829608,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iii exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c7787]',\n",
              "  'name': 'stage iii exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:116801'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7787',\n",
              "  'updatedAt': 1612861829608,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'de6545ce-d5ee-4e2a-a1e9-258a39416ea4'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57161',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861829628,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iii pancreatic cancer [c7787]',\n",
              "  'name': 'stage iii pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:116802'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7787',\n",
              "  'updatedAt': 1612861829628,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '7ac18fe5-8bc8-4879-9520-7b5270596943'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57162',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861829648,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iii pancreatic cancer ajcc v6 [c7787]',\n",
              "  'name': 'stage iii pancreatic cancer ajcc v6',\n",
              "  'out_AliasOf': ['#26:116803'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7787',\n",
              "  'updatedAt': 1612861829648,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '1b68697a-eedd-4af4-961b-ae8ac2892266'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:57163',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612861829667,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iii pancreatic cancer ajcc v7 [c7787]',\n",
              "  'name': 'stage iii pancreatic cancer ajcc v7',\n",
              "  'out_AliasOf': ['#26:116804'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7787',\n",
              "  'updatedAt': 1612861829667,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'e08bef2c-b527-4eaa-82de-b3167f4c377f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:59042',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612862042241,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'An adenocarcinoma arising from the pancreas. It is characterized by the presence of relatively uniform malignant cells which form acinar patterns. It usually occurs during adulthood. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It may metastasize to regional lymph nodes and the liver. A minority of patients develop lipase hypersecretion syndrome. This syndrome may be seen in patients with liver metastases and it is characterized by excessive secretion of lipase in the serum, polyarthralgia, and subcutaneous fat necrosis.',\n",
              "  'displayName': 'Pancreatic Acinar Cell Cancer [c7977]',\n",
              "  'in_AliasOf': ['#26:119651',\n",
              "   '#26:119652',\n",
              "   '#26:119653',\n",
              "   '#26:119654',\n",
              "   '#26:119655',\n",
              "   '#26:119656',\n",
              "   '#26:119657'],\n",
              "  'in_CrossReferenceOf': ['#28:35899'],\n",
              "  'name': 'pancreatic acinar cell cancer',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c7977',\n",
              "  'updatedAt': 1612862042241,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c7977',\n",
              "  'uuid': '4e298567-6ad8-423f-92b1-553f059688e8'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65597',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612862963694,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IA includes: T1, N0, M0. T1: Tumor limited to the pancreas, 2 cm or less in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 7th Ed.)',\n",
              "  'displayName': 'Stage IA Pancreatic Cancer AJCC v6 and v7 [c88100]',\n",
              "  'in_AliasOf': ['#26:132642', '#26:132643'],\n",
              "  'name': 'stage ia pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88100',\n",
              "  'updatedAt': 1612862963694,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c88100',\n",
              "  'uuid': '3ab4ce65-31ca-4127-a7d7-6ae129344e53'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65598',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963706,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ia exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c88100]',\n",
              "  'name': 'stage ia exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:132642'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88100',\n",
              "  'updatedAt': 1612862963706,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'a0041521-b9fd-462b-8fac-085aa451c2dc'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65599',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963725,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ia pancreatic cancer [c88100]',\n",
              "  'name': 'stage ia pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:132643'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88100',\n",
              "  'updatedAt': 1612862963725,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '8e91be49-2f2e-4938-bd2f-15499ed1797d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65600',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612862963745,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IB includes: T2, N0, M0. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 7th Ed.)',\n",
              "  'displayName': 'Stage IB Pancreatic Cancer AJCC v6 and v7 [c88101]',\n",
              "  'in_AliasOf': ['#26:132644', '#26:132645'],\n",
              "  'name': 'stage ib pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88101',\n",
              "  'updatedAt': 1612862963745,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c88101',\n",
              "  'uuid': '73945d38-6abc-4fd2-8d74-b05e519067e4'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65601',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963770,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ib exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c88101]',\n",
              "  'name': 'stage ib exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:132644'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88101',\n",
              "  'updatedAt': 1612862963770,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'ec8b7145-3c16-4c50-84b4-0627f02b5c2f'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65602',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963789,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage ib pancreatic cancer [c88101]',\n",
              "  'name': 'stage ib pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:132645'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88101',\n",
              "  'updatedAt': 1612862963789,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'b76cfb64-d82e-4eed-9113-7c214b3b6b5d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65603',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612862963809,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IIA includes: T3, N0, M0. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. N0: No regional lymph node metastasis. M0: No distant metastasis. (from AJCC 7th Ed.)',\n",
              "  'displayName': 'Stage IIA Pancreatic Cancer AJCC v6 and v7 [c88102]',\n",
              "  'in_AliasOf': ['#26:132646', '#26:132647'],\n",
              "  'name': 'stage iia pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88102',\n",
              "  'updatedAt': 1612862963809,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c88102',\n",
              "  'uuid': 'a6255a39-ecb3-4826-b706-d2dd70a6d2ae'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65604',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963822,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iia exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c88102]',\n",
              "  'name': 'stage iia exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:132646'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88102',\n",
              "  'updatedAt': 1612862963822,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '5d558430-ade8-4b32-8e43-bb4eb43bf091'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65605',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963840,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iia pancreatic cancer [c88102]',\n",
              "  'name': 'stage iia pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:132647'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88102',\n",
              "  'updatedAt': 1612862963840,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'e5284dfd-a357-4502-8891-8061562b0c0e'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65606',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612862963859,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'Stage IIB includes: (T1, N1, M0); (T2, N1, M0); (T3, N1, M0). T1: Tumor limited to the pancreas, 2 cm or less in greatest dimension. T2: Tumor limited to the pancreas, more than 2 cm in greatest dimension. T3: Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery. N1: Regional lymph node metastasis. M0: No distant metastasis. (from AJCC 7th Ed.)',\n",
              "  'displayName': 'Stage IIB Pancreatic Cancer AJCC v6 and v7 [c88103]',\n",
              "  'in_AliasOf': ['#26:132648', '#26:132649'],\n",
              "  'name': 'stage iib pancreatic cancer ajcc v6 and v7',\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88103',\n",
              "  'updatedAt': 1612862963859,\n",
              "  'updatedBy': '#14:0',\n",
              "  'url': 'http://ncicb.nci.nih.gov/xml/owl/evs/thesaurus.owl#c88103',\n",
              "  'uuid': '29886648-8fc6-4f84-993a-84325e91b5d4'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65607',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963871,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iib exocrine and endocrine pancreatic cancer ajcc v6 and v7 [c88103]',\n",
              "  'name': 'stage iib exocrine and endocrine pancreatic cancer ajcc v6 and v7',\n",
              "  'out_AliasOf': ['#26:132648'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88103',\n",
              "  'updatedAt': 1612862963871,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'f267e294-0951-4a70-8158-059e1df34ee7'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:65608',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612862963890,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'stage iib pancreatic cancer [c88103]',\n",
              "  'name': 'stage iib pancreatic cancer',\n",
              "  'out_AliasOf': ['#26:132649'],\n",
              "  'source': '#17:0',\n",
              "  'sourceId': 'c88103',\n",
              "  'updatedAt': 1612862963890,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'd5868188-f4d2-4a63-8ba2-c66c7007c305'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:87371',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612925655691,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'pancreatic duct cancer',\n",
              "  'name': 'pancreatic duct cancer',\n",
              "  'out_AliasOf': ['#26:153647'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:3587',\n",
              "  'updatedAt': 1612925655691,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '75c2a7f3-31ea-4f01-912b-f0daad46e3f0'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:100463',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926226527,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'An endocrine gland cancer located_in the pancreas.',\n",
              "  'displayName': 'pancreatic cancer',\n",
              "  'in_AliasOf': ['#26:161479',\n",
              "   '#26:161480',\n",
              "   '#26:161481',\n",
              "   '#26:161482',\n",
              "   '#26:161483',\n",
              "   '#26:161484',\n",
              "   '#26:161485',\n",
              "   '#26:161486',\n",
              "   '#26:161487'],\n",
              "  'in_DeprecatedBy': ['#29:1479', '#29:1480', '#29:1481', '#29:1482'],\n",
              "  'in_SubClassOf': ['#33:1655',\n",
              "   '#33:6724',\n",
              "   '#33:6979',\n",
              "   '#33:9875',\n",
              "   '#33:10043',\n",
              "   '#33:10074',\n",
              "   '#33:10299'],\n",
              "  'name': 'pancreatic cancer',\n",
              "  'out_SubClassOf': ['#33:2894', '#33:2997'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:1793',\n",
              "  'subsets': ['doid#topnodes_docancerslim',\n",
              "   'doid#do_rare_slim',\n",
              "   'doid#ncithesaurus',\n",
              "   'doid#do_cancer_slim'],\n",
              "  'updatedAt': 1612926226527,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '76d148ff-0e81-4b1a-a3f9-43b9c01f30e7'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:100473',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926226713,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'pancreatic cancer',\n",
              "  'name': 'pancreatic cancer',\n",
              "  'out_DeprecatedBy': ['#29:1479'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:1797',\n",
              "  'updatedAt': 1612926226713,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '4e04d9d3-b223-46cc-8aa5-5fad7db1e31b'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:100474',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926226733,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'pancreatic cancer',\n",
              "  'name': 'pancreatic cancer',\n",
              "  'out_DeprecatedBy': ['#29:1480'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:9859',\n",
              "  'updatedAt': 1612926226733,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'da651673-c465-42a2-9106-62f5d7865704'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:100475',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926226753,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'pancreatic cancer',\n",
              "  'name': 'pancreatic cancer',\n",
              "  'out_DeprecatedBy': ['#29:1481'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:3588',\n",
              "  'updatedAt': 1612926226753,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'eb20af96-5947-4186-9296-521e093c0cc8'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:100476',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926226774,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'pancreatic cancer',\n",
              "  'name': 'pancreatic cancer',\n",
              "  'out_DeprecatedBy': ['#29:1482'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:14356',\n",
              "  'updatedAt': 1612926226774,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'da4e4b84-146a-44b0-bd26-9fe4f8da7aaa'}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 7
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "8z9yDbdQYdgB"
      },
      "source": [
        "The above will look for diseases that have both 'cancer' and 'pancreatic' in the name."
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "NejsnEyCYhFQ"
      },
      "source": [
        "#### Subquery Filters\n",
        "\n",
        "Sometimes we would like to filter records on a linked field (essentially a foreign key). We can do this with subquery filters."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "uE_D-HtiYhxs",
        "outputId": "b3b7b8be-8931-4b1a-b6ee-88d13fed25dc"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Disease',\n",
        "    'filters': {\n",
        "        'source': {'target': 'Source', 'filters': {'name': 'disease ontology'}}\n",
        "    },\n",
        "}, paginate=False, limit=10)"
      ],
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'@class': 'Disease',\n",
              "  '@rid': '#43:72269',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612924874193,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'von reklinghausen disease',\n",
              "  'name': 'von reklinghausen disease',\n",
              "  'out_AliasOf': ['#26:145059'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8712',\n",
              "  'updatedAt': 1612924874193,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '5647ae2d-8837-48fd-8b46-7669ec046e8e'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72251',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612924873047,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'other named variants of lymphosarcoma and reticulosarcoma involving lymph nodes of axilla and upper limb',\n",
              "  'name': 'other named variants of lymphosarcoma and reticulosarcoma involving lymph nodes of axilla and upper limb',\n",
              "  'out_AliasOf': ['#26:145052'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8716',\n",
              "  'updatedAt': 1612924873047,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '9586920c-fc10-4c5d-9cdb-f92d234d7cb3'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72256',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612924873474,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'other named variants of lymphosarcoma and reticulosarcoma involving intrapelvic lymph nodes',\n",
              "  'name': 'other named variants of lymphosarcoma and reticulosarcoma involving intrapelvic lymph nodes',\n",
              "  'out_AliasOf': ['#26:145057'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8716',\n",
              "  'updatedAt': 1612924873474,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'e8cf5e88-9624-4900-8986-177e607fd95a'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72233',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612924871520,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'obsolete carcinoma in situ of respiratory system',\n",
              "  'name': 'obsolete carcinoma in situ of respiratory system',\n",
              "  'out_DeprecatedBy': ['#29:84'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8965',\n",
              "  'updatedAt': 1612924871520,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '96b23041-6351-44ab-ae86-378f0bbe05c4'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72238',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612924871901,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'decubitus (pressure) ulcer',\n",
              "  'name': 'decubitus (pressure) ulcer',\n",
              "  'out_AliasOf': ['#26:145044'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8717',\n",
              "  'updatedAt': 1612924871901,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '7be15c9b-9d9e-43cd-9256-2ed14b52aa4d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72261',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612924873816,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'obsolete lymphosarcoma and reticulosarcoma',\n",
              "  'name': 'obsolete lymphosarcoma and reticulosarcoma',\n",
              "  'out_DeprecatedBy': ['#29:93'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8890',\n",
              "  'updatedAt': 1612924873816,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': 'cbbe1575-2256-4dee-9386-a137a0e34137'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72266',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612924874015,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'obsolete lymphosarcoma and reticulosarcoma',\n",
              "  'name': 'obsolete lymphosarcoma and reticulosarcoma',\n",
              "  'out_DeprecatedBy': ['#29:98'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8764',\n",
              "  'updatedAt': 1612924874015,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '0b4ebc45-dacf-4326-bd2b-c08d4d3c7d8d'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72243',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612924872105,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': True,\n",
              "  'displayName': 'decubitus ulcer',\n",
              "  'name': 'decubitus ulcer',\n",
              "  'out_DeprecatedBy': ['#29:88'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:9002',\n",
              "  'updatedAt': 1612924872105,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '4f370f02-3f82-4031-84a6-52596ce369b5'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72248',\n",
              "  'alias': True,\n",
              "  'createdAt': 1612924872811,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'other named variants of lymphosarcoma and reticulosarcoma involving intra-abdominal lymph nodes',\n",
              "  'name': 'other named variants of lymphosarcoma and reticulosarcoma involving intra-abdominal lymph nodes',\n",
              "  'out_AliasOf': ['#26:145049'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8716',\n",
              "  'updatedAt': 1612924872811,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '4eff8478-f029-4481-926d-6d3ad53550ea'},\n",
              " {'@class': 'Disease',\n",
              "  '@rid': '#43:72244',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612924872155,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'displayName': 'obsolete lymphosarcoma and reticulosarcoma',\n",
              "  'in_AliasOf': ['#26:145046',\n",
              "   '#26:145047',\n",
              "   '#26:145048',\n",
              "   '#26:145049',\n",
              "   '#26:145050',\n",
              "   '#26:145051',\n",
              "   '#26:145052',\n",
              "   '#26:145053',\n",
              "   '#26:145054',\n",
              "   '#26:145055',\n",
              "   '#26:145056',\n",
              "   '#26:145057'],\n",
              "  'in_DeprecatedBy': ['#29:89',\n",
              "   '#29:90',\n",
              "   '#29:91',\n",
              "   '#29:92',\n",
              "   '#29:93',\n",
              "   '#29:94',\n",
              "   '#29:95',\n",
              "   '#29:96',\n",
              "   '#29:97',\n",
              "   '#29:98'],\n",
              "  'name': 'obsolete lymphosarcoma and reticulosarcoma',\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:8716',\n",
              "  'subsets': [],\n",
              "  'updatedAt': 1612924872155,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '9af84b66-edc3-4a86-8e90-e81abade2693'}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 8
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "O5LsApF2Yrsy"
      },
      "source": [
        "Above we are only returning disease records that have been imported from the disease ontology.\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "j3X_F8DhYwv4"
      },
      "source": [
        "### Return Properties (Fields)\n",
        "\n",
        "The return fields property allows the user to specify what they would like to return. This can mean returning a subset of fields for a large query to improve the speed of the client digesting the data, or it can be used to de-nest fields. By default the query will return only the immediate properties of the class being queries. This means that linked fields will be listed as their record ID. De-nesting these fields allows you to return them without additional queries."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "KZQ4X2tcYx2Q",
        "outputId": "4530d34e-9a5c-4463-edc1-426d1e7d4ae2"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Disease',\n",
        "    'filters': {\n",
        "        'AND': [\n",
        "            {'source': {'target': 'Source', 'filters': {'name': 'disease ontology'}}},\n",
        "            {'name': 'cancer'}\n",
        "        ],\n",
        "    },\n",
        "})"
      ],
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'@class': 'Disease',\n",
              "  '@rid': '#43:100548',\n",
              "  'alias': False,\n",
              "  'createdAt': 1612926228848,\n",
              "  'createdBy': '#14:0',\n",
              "  'deprecated': False,\n",
              "  'description': 'A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis.',\n",
              "  'displayName': 'cancer',\n",
              "  'history': '#43:107678',\n",
              "  'in_AliasOf': ['#26:161531', '#26:161532', '#26:161533'],\n",
              "  'in_SubClassOf': ['#33:5210', '#33:5268'],\n",
              "  'name': 'cancer',\n",
              "  'out_CrossReferenceOf': ['#28:37957'],\n",
              "  'out_ElementOf': ['#30:82543'],\n",
              "  'out_SubClassOf': ['#33:7594'],\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:162',\n",
              "  'subsets': ['doid#do_flybase_slim',\n",
              "   'doid#ncithesaurus',\n",
              "   'doid#do_cancer_slim',\n",
              "   'doid#do_agr_slim',\n",
              "   'doid#do_gxd_slim'],\n",
              "  'updatedAt': 1612980640268,\n",
              "  'updatedBy': '#14:0',\n",
              "  'uuid': '6a051270-4611-4af2-a5ff-1b31a872b4e0'}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 9
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "cu7DWgNUZGUp"
      },
      "source": [
        "We probably are not interested in all of these fields so let's pick a few to return."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2YBrKdukZHVJ",
        "outputId": "9e2659a6-ece7-46e3-8ac9-b0e40cf0751a"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Disease',\n",
        "    'filters': {\n",
        "        'AND': [\n",
        "            {'source': {'target': 'Source', 'filters': {'name': 'disease ontology'}}},\n",
        "            {'name': 'cancer'}\n",
        "        ],\n",
        "    },\n",
        "    'returnProperties': ['name', 'source', 'sourceId', 'alias', 'deprecated']\n",
        "})"
      ],
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'alias': False,\n",
              "  'deprecated': False,\n",
              "  'name': 'cancer',\n",
              "  'source': '#17:19',\n",
              "  'sourceId': 'doid:162'}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 10
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "IyF0AuBsZNs9"
      },
      "source": [
        "The new return looks much more reasonable. However the source field right now is a seperate record ID. This means with the current query we would have to fetch that record separately if we want to see details about it. This can be done in a single query with the nested return properties. Simply delimite properties and sub-properties with a period."
      ]
    },
    {
      "cell_type": "code",
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LJwmeZqoZSEZ",
        "outputId": "a0d06e2c-cacc-4e35-9536-65dd301774ec"
      },
      "source": [
        "graphkb_conn.query({\n",
        "    'target': 'Disease',\n",
        "    'filters': {\n",
        "        'AND': [\n",
        "            {'source': {'target': 'Source', 'filters': {'name': 'disease ontology'}}},\n",
        "            {'name': 'cancer'}\n",
        "        ],\n",
        "    },\n",
        "    'returnProperties': ['name', 'source.name', 'sourceId', 'alias', 'deprecated']\n",
        "})"
      ],
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "execute_result",
          "data": {
            "text/plain": [
              "[{'alias': False,\n",
              "  'deprecated': False,\n",
              "  'name': 'cancer',\n",
              "  'source': {'name': 'disease ontology'},\n",
              "  'sourceId': 'doid:162'}]"
            ]
          },
          "metadata": {
            "tags": []
          },
          "execution_count": 11
        }
      ]
    }
  ]
}